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Abstract
TheMAP 3-kinase TPL-2 is required for activation of ERK1/2MAP kinases in mac-
rophages after stimulation of Toll-like receptors and the receptors for TNF and IL-
1β. TPL-2 drives inflammation in a number of autoimmune and inflammatory dis-
ease models, and consequently is considered a potential anti-inflammatory drug
target. Recent evidence from the Ley laboratory has indicated that TPL-2 regu-
lates the production of the critical pro-inflammatory cytokine TNFα in an ERK1/2-
independent manner. The aim of this study was to use mass spectrometry-based
phosphoproteomics to investigate the signalling pathways regulated by TPL-2 in
an unbiased manner to more fully understand how TPL-2 regulates innate im-
munity. A method for SILAC labelling of bone marrow-derived macrophages was
developed and used to quantify phosphorylation changes after genetic and phar-
macological perturbation of TPL-2 signalling. Across 11 pair-wise comparisons,
31,457 unique phosphosites were identified, fromwhich a shortlist of 37 potentially
TPL-2-dependent, ERK1/2-independent phosphorylations was generated. The
biological consequences of the majority of these TPL-2 regulated sites remain to
be determined, although bioinformatic analysis suggest that they may have roles
in regulation of gene expression and the cytoskeleton. The activating residues
of the MAP 2-kinases, MKK3 and MKK6 were validated as novel TPL-2 targets
in LPS-stimulated macrophages and MKK6 was shown to be a direct substrate
by in vitro kinase assays using recombinant proteins. It was also demonstrated
that TPL-2 controlled the phosphorylation of the activation loop of the MAP kinase
p38γ, which is a direct target of MKK3/6. These data identified a novel signalling
pathway downstream of TPL-2, increasing our understanding of how TPL-2 con-
trols inflammatory responses.
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1 General Introduction
14
1.1 The immune response
This project focused on signalling in macrophages in response to stimulation
through innate immune receptors, and these will be introduced in the following
sections.
1.1.1 Innate and adaptive immunity
An invading pathogen is initially recognised through the presence of pathogen-
specific molecules as well as “danger” signals, mediators released by infected
or damaged cells (Iwasaki and Medzhitov, 2015). These signals are detected
by tissue-resident cells of the innate immune system, the first line of defence,
which react quickly and in a non-pathogen specific manner. Following pathogen
recognition, these innate immune cells, which include mast cells, macrophages
and innate lymphoid cells, rapidly transcribe genes, the products of which trig-
ger an inflammatory response (Murphy et al., 2008). The responding cells also
produce inflammatory factors, such as prostaglandins and histamine, which act
on nearby capillaries to weaken endothelial cell contacts and induce integrin ex-
pression. This promotes fluid entry to the tissue and allows immune cells from
the blood to extravasate and enter the tissue. The tissue resident innate cells
release chemokines, short peptides which attract other cell types to the site. The
first cell type to enter the tissue from the blood are neutrophils, innate immune
cells which can kill a range of pathogens by phagocytosis, production of antimi-
crobial peptides/reactive oxygen species and release of neutrophil extracellular
traps (Kolaczkowska and Kubes, 2013). In most cases, the neutrophil response
is sufficient to eliminate the pathogen and the influx of macrophages that follows
removes any debris and promotes healing of the tissue (Gilroy and De Maeyer,
2015).
In infections where the innate response is not able to clear the pathogen, a
more specific adaptive immune response is induced. For this to happen, the in-
vading pathogen must be ingested at the site of infection by professional antigen
presenting cells (APCs) called dendritic cells, which degrade pathogen proteins
15
into short peptides (Murphy et al., 2008; Roche and Furuta, 2015). These cells
then traffic to a secondary lymphoid organ, such as the lymph nodes, where they
present pathogen-derived peptide antigens on their surface in association with
major histocompatibility complexes (MHCs) for T cells to recognise via their an-
tigen receptors. When a T cell encounters an APC presenting an antigen-MHC
complex to which its TCR is specific, the APC provides three signals to the T cell,
which help determine the subsequent fate of that T cell (Murphy et al., 2008).
These are signalling through the engaged TCR itself, co-stimulation through
CD80/CD86 on the APC binding to T cell CD28, and cytokines that drive the
CD4+ T cell lineage decision. IFNγ and IL-12 will cause CD4+ T cells to become
T helper type 1 (Th1) cells, IL-4 induces T helper type 2 (Th2) cells, IL-1β and
IL-6 together with TGF-β induce differentiation into T helper type 17 (Th17) cells
and TGF-β leads to differentiation of inducible regulatory T cells (iTreg) (Locks-
ley, 2009). The T cells return to the site of infection where each T helper cell
subset has a specific set of functions associated with clearance of different types
of pathogen.
Like T cells, B cells are adaptive cells with hyper-variable antigen receptors.
Once B cells encounter their specific antigen in peripheral lymphoid organs, they
undergo a process of rapid expansion during which the affinity of the BCR for an-
tigen is improved stochastically to create a BCR with a higher affinity for the same
antigen (Wabl and Steinberg, 1996). In addition to this, antigen-stimulated B cells
also rearrange their BCR constant region locus in response to T cell help through
ligation of CD40 and cytokines. The use of different immunoglobulin heavy chain
genes leads to production of antibodies of alternate isotypes that confer different
properties. (Murphy et al., 2008). B cells then become plasma cells and produce
large amount of soluble antibody which optimises pathogen killing, for example
through phagocytosis by macrophages.
The immune response can become deregulated at many of these stages.
Over-production of cytokines, particularly TNFα, can trigger cytokine storm as in
septic shock (Apostolaki et al., 2010). In an allergic reaction, the immune sys-
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tem responds aggressively to innocuous antigens. This is associated with over-
activation of Th2 responses, high levels of IgE antibodies and excessive release
of histamine (Licona-Limón et al., 2013). In recent years, immune responses
have also been linked to seemingly unrelated diseases such as cancer. In or-
der for a tumour to grow it must evade detection by the immune system and, to
this end, some tumours induce an anti-inflammatory microenvironment around
them. Furthermore, excessive inflammation over a pro-longed period can induce
cancer (Wagner and Nebreda, 2009). For example, the chronic liver inflammation
caused by hepatitis infection can contribute to the development of hepatocellular
carcinoma by increasing levels of mutagenic free radicals in the liver, amongst
other things (Aravalli, 2013). Thus whilst the immune system performs an essen-
tial role in protection from infectious diseases, if it is not tightly controlled it can
cause pathology.
1.1.2 Macrophages
Macrophages are innate immune cells which specialise in sensing microorgan-
isms and tissue damage through a wide range of receptors. Their main effector
functions are to phagocytose and degrade pathogens and other particles, and to
produce cytokines like TNFα to promote appropriate immune responses (Epelman
et al., 2014).
Development
Macrophages are found in all tissues but vary widely in their origin, phenotype
and function (Pollard, 2009). Certain macrophage populations, such as central
nervous system microglia, develop from the foetal yolk sac prior to birth (Schulz
et al., 2012). These populations are not commonly replenished from the peri-
phery, but instead are largely self-renewing. Specialised tissue macrophages dis-
play many diverse phenotypes and take on particular characteristics depending
on the tissue environment in which they reside. For example, liver resident mac-
rophages, known as Kupffer cells, are highly specialised in lipid metabolism and
17
clearance of noxious substances (Wynn et al., 2013).
During subsequent in utero development, definitive haematopoiesis, which
produces circulatingmonocytes, begins in the foetal liver (Wynn et al., 2013). After
birth, foetal liver haematopoiesis declines and haematopoiesis in the bonemarrow
takes over generation of leukocytes. Common haematopoietic stem cells develop
through myeloid committed and monocyte committed stages, and then become
monoblasts under the control of monocyte colony-stimulating factor (Mosser and
Edwards, 2008). Monoblasts differentiate into pro-monocytes and finally mono-
cytes, which are released into the blood. This population replenishes certain tis-
sue resident macrophages such as those in the skin, which are derived from both
yolk sac and haematopoietic precursors (Epelman et al., 2014). In an inflam-
matory setting, monocytes are recruited to tissues from the blood by appropriate
cytokine cues, where they differentiate into macrophages.
Function
Monocyte-derived macrophages have been sub-classified based on their func-
tional status as classically activated, regulatory or wound-healing (figure 1.1;
Mosser and Edwards, 2008). However, macrophages show a large degree of
plasticity and individual cells can move between the different phenotypic classi-
fications depending on the local tissue microenvironment. Classically activated
macrophages are induced by IFN-γ and TNFα. This phenotype is associated with
microbicidal functions and production of pro-inflammatory mediators. Regulatory
macrophages, on the other hand, are anti-inflammatory and function to regulate
the immune response through production of large amounts of IL-10. They are
induced by IL-10 plus a second trigger from a diverse range of stimuli, including
apoptotic cells and glucocorticoids, which may all induce slightly different subpop-
ulations (Mosser and Edwards, 2008). Regulatory macrophages are competent
in phagocytosis but may be defective in presenting antigen to T cells or specific-
ally induce Treg or Th2 differentiation. Due to these functions, some pathogens
induce regulatory macrophages to enable them to evade the immune system.
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Macrophages with an alternative wound-healing phenotype are induced by the
presence of IL-4 and IL-13. These macrophages are involved in tissue repair
and express factors that promote remodelling of the extracellular matrix such as
arginase and chitinase. In certain circumstances, such as airway remodelling in
asthma, wound-healingmacrophages can contribute to tissue fibrosis and disease
progression (Murray and Wynn, 2011).
Figure 1.1: Macrophage Heterogeneity.
Macrophages fall broadly into either tissue resident or recruited inflammatory cat-
egories. The tissue resident macrophages can be derived either from the em-
bryonic yolk sac or from circulating monocytes. Once in a tissue they take on
highly specialised functions associated with the character of the tissue such as the
bone remodelling processes of osteoclasts. Tissue resident macrophage popula-
tions are self-renewing to a greater or lesser extent. On the other hand circulating
monocytes are recruited to sites of injury or infection. Depending on the signals
available in the microenvironment, these macrophages can take on character-
istics from one of three extremes; classically activated, alternatively activated or
regulatory. The classically activated macrophages show more pro-inflammatory
functions and are associated with host defence, the alternatively activated macro-
phages display functions which aid the wound healing process and the regulatory
macrophages dampen the local immune response and protect against immuno-
pathology.
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Studies of ex vivo macrophage populations have supported this spectrum of
activation states at the transcriptional level (Xue et al., 2014). However, this ex-
tensive heterogeneity also complicates such studies, as subpopulations may re-
spond differently to a stimulus, leading to no clear overall phenotype for the pop-
ulation (Ostuni and Natoli, 2011). For this reason, macrophages derived in vitro
from bone marrow stem cells (bone marrow-derived macrophages, BMDM) are
commonly used in model studies and have the advantage of a homogeneous
population that is likely to show less variability (Weischenfeldt and Porse, 2008).
Recent studies using BMDMs have employed multiple “omics” approaches (e.g.
transcriptomics and phosphoproteomics) and bioinformatics to investigate the bio-
chemistry and molecular biology of macrophage responses on a systems level
(Weintz et al., 2010; Dinasarapu et al., 2013).
1.1.3 Tumour necrosis factor-α
Biological functions and relevance in disease
TNFα is a key pro-inflammatory cytokine in the early immune response produced
by immune cells, particularly macrophages, but also by tissue cells like keratino-
cytes (Papadakis and Targan, 2000). In an inflammatory setting, its release is
triggered by pathogen-derived molecules and endogenous stress signals. TNFα
has paracrine and autocrine actions and both the cell surface-bound and soluble
forms of TNFα are biologically active.
There are two receptors for TNFα, TNFR1 and TNFR2, at least one of which
is expressed on all nucleated cells, although TNFR2 is mostly limited to haema-
topoietic cells (Wajant et al., 2003). A further layer of complexity is added to TNFα
signalling through cleavage of both receptors into soluble forms, which antagon-
ise TNFα signalling by competing with cell surface receptors for ligand binding
(Apostolaki et al., 2010). TNFR1 can be ligated by either soluble or membrane-
bound TNFα. TNFR2, on the other hand, is activated more efficiently by surface-
bound than soluble TNFα (Grell et al., 1995). TNFα binding to either receptor can
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trigger primarily (but not exclusively) pro-inflammatory responses, inducing ex-
pression of other immune mediators, including cytokines and chemokines, as well
as adhesion molecules and pro-apoptotic effectors (Bluml et al., 2012). However,
these receptors have different biological functions, due to differences in their intra-
cellular domains (MacEwan, 2002). For example, deletion of TNFR1 attenuates
the inflammatory response in a model of polymicrobial septic shock, whilst TNFR2
deletion exaggerates the symptoms (Ebach et al., 2005). Therefore, TNFR1 is
predominantly thought of as pro-inflammatory and TNFR2 as anti-inflammatory,
although this distinction is far from absolute. As well as functions in inflamma-
tion, TNFα signalling through TNFR1 has homeostatic functions in formation of
secondary lymphoid organs (Ruuls et al., 2001; Bluml et al., 2012).
TNFα is a central mediator of multiple immune disorders, including inflammat-
ory bowel disease (IBD), rheumatoid arthritis (RA) and psoriatic arthritis (Sfikakis,
2010). Genetic over-expression of TNFα in mice leads to spontaneous devel-
opment of symptoms similar to rheumatoid arthritis including joint inflammation
and bone destruction (Alexopoulou et al., 1997). Rheumatoid arthritis models
in rodents suggest disease development and progression can be mediated by
membrane bound and soluble forms of TNFα (Palladino et al., 2003). However,
in an endotoxic shock model, mice which express only the cell surface form of
TNFα are resistant to immunopathology, suggesting there are functional differ-
ences between the two forms (Nowak et al., 2000).
Therapeutically targeting TNFα
In light of the role of TNFα in immunopathology, anti-TNFα biologics have be-
come the gold standard for treatment of patients whose disease is refractory to
first line therapy using disease-modifying anti-rheumatic drugs. These treatments,
which include etanercept (soluble TNFR2), infliximab and adalimumab (anti-TNFα
antibodies), prevent TNFα from interacting with its receptors and, in the case
of the antibodies, by inducing complement-dependent and antibody-dependent
cytotoxicity of cells expressing transmembrane TNFα (Sfikakis, 2010). They are
effective in about 60 % of patients who did not benefit from non-biologic drugs.
21
However, although treatment with TNFα-blocking biologics revolutionised therapy
for autoimmune diseases, less than half of those who respond achieve complete
remission, so there remains a need for alternative treatments. Biologics also suf-
fer from several important drawbacks, since they cannot be administered orally
and must be injected at regular intervals. There is also strict regulation around
the production of antibodies due to their batch-to-batch variation, making them
expensive. For this reason, it would be advantageous if a small molecule inhibitor
could be developed to target the production of TNFα, making treatment cheaper
and more convenient (Palladino et al., 2003).
Synthesis and release
Deregulated TNFα expression can have many detrimental effects including septic
shock following systemic bacterial infection and joint inflammation in rheumatoid
arthritis. Therefore, its production is tightly controlled at every stage of its produc-
tion through a range of different mechanisms (figure 1.2).
Protein expression
TNFα gene transcription is minimal in unstimulated macrophages, but is sig-
nificantly enhanced by stress stimuli, such as the bacterial cell wall component
lipopolysaccharide (LPS) that increases TNFα transcription 3-fold (Papadakis and
Targan, 2000; Murray and Stow, 2014). The same stimulus, however, increases
levels of TNFα messenger RNA (mRNA) by 50 - 100-fold indicating that further
regulation is occurring at the post-transcriptional level. Indeed, the TNFα tran-
script is subjected to controls which alter its stability, and its half life in human
monocytes is as low as 12 minutes (Papadakis and Targan, 2000). A sequence
known as the AU-rich element (ARE) is present in the 3’-untranslated region of
the mature TNFα mRNA. This sequence can be bound by proteins which regulate
mRNA stability and inhibit translation, such as tristetraproline (TTP) (Arthur and
Ley, 2013). Upon TTP binding to the TNFα message the mRNA gets targeted
for degradation by RNases. TTP is phosphorylated by signalling through the p38
MAP kinase pathway, decreasing its affinity for the ARE motif and allowing HUR
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to bind instead; HUR then initiates the translation of TNFmRNA. Mice in which the
TNFα ARE sequence has been deleted display elevated levels of TNFα produc-
tion and develop spontaneous inflammatory conditions in their joints and bowel
(Kontoyiannis et al., 1999).
Figure 1.2: Production, processing and secretion of TNFα
TNFα production is regulated at multiple levels to ensure tight control of its levels.
TNFαmRNA is unstable due to recognition by proteins which promote its degrada-
tion in the absence of activating signals. Once TNFα is translated to its pre-protein
form, it is trafficked through the cell towards recycling endosomes, during which
time its production can be regulated at many points. TNFα is finally brought to the
cell surface, where eventual release of soluble TNFα is dependent on the pres-
ence of the metalloprotease TACE, whose levels of the surface of the cell can also
be altered to tune soluble TNFα levels.
Trafficking
TNFα is translated as a 26 kDa, transmembrane precursor. This pro-TNFα
protein is trafficked through the endoplasmic reticulum and Golgi network, where
it is packaged into vesicles along with the Q-SNARE components Stx6, Stx7 and
Vti1b (Murray and Stow, 2014). Vesicle exit from the Golgi is regulated by PI3Kδ
and dynamin II, as well as changes in the lipid composition of the membrane
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mediated by CCTα (Tian et al., 2008). After leaving the Golgi, the vesicles fuse
with recycling endosomes through Q-SNARE pairing with VAMP3, the R-SNARE
on the recycling endosome. TNFα reaches the plasma membrane by fusion of
recycling endosomes at specific sites, determined by the location of cell sur-
face Stx4/SNAP23 Q-SNARE complexes in cholesterol-rich lipid rafts (Kay et al.,
2006). The proteins mentioned here as regulators of TNFα trafficking are all up-
regulated in response to LPS stimulation to enhance TNFα production (Murray
and Stow, 2014). Other proteins which have been shown to be involved in TNFα
trafficking to the cell surface include the small GTPases, Rac1, Cdc42, Rab11
and Rab37. In the absence of Rac1, pro-TNFα remains sequestered in recycling
endosomes rather than being delivered to the cell surface (Stanley et al., 2014).
Release
The final stage of TNFα maturation is cleavage of a 17 kDa portion from the
cell surface by the metalloprotease, TNFα-converting enzyme (TACE/ADAM17)
(Black et al., 1997; Moss et al., 1997). Production of soluble TNFα in response to
LPS was strongly reduced in TACE-deficient macrophages compared to TACE-
sufficient cells (Horiuchi et al., 2007). In order for cleavage to happen, TNFα
and TACE must come into close proximity, a process which has been proposed
to be regulated by partitioning into cholesterol-rich lipid rafts (Kay et al., 2006;
Levine, 2008). Cholesterol depletion, which disrupts lipid rafts, leads to increased
shedding of TACE substrates, implying an import role of lipid rafts in regulating
TACE interaction with its substrates (Tellier et al., 2006).
TACE is itself expressed as an inactive form and requires proteolytic pro-
cessing to become active (Levine, 2008). Its level on the cell surface is also
augmented in response to LPS stimulation, mediated partly through ERK1/2 phos-
phorylation of threonine 735, which promotes TACE translocation to the plasma
membrane (Soond et al., 2005; Murray and Stow, 2014). TACE activity on the cell
surface is regulated by the metalloprotease inhibitor TIMP3, and, in the absence
of TIMP3, levels of soluble TNFα are constitutively increased (Levine, 2008). Nu-
merous other proteins interact with the cytoplasmic tail of TACE, including SAP97
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and Eve-1, and may regulate its protease activity.
Both the membrane bound and cleaved forms of TNFα then aggregate into tri-
mers in which conformation they can ligate their receptors (Palladino et al., 2003).
The final outcome of all these levels of regulation is an increase in protein secretion
of approximately 10,000-fold from macrophages in response to ligation of pattern
recognition receptors (Papadakis and Targan, 2000).
1.1.4 Pattern recognition receptors
Pattern recognition receptors (PRRs) are innate immune receptors used to recog-
nise pathogen-associated molecular patterns (PAMPs), highly conserved features
of micro-organisms like components of the bacterial cell wall or the viral genome
(Takeuchi and Akira, 2010). They also recognise host-derived molecules, such as
heat shock proteins and crystalline uric acid, called damage-associated molecular
patterns (DAMPs), which indicate injury or infection. PRRs are germline encoded
and all cells express at least some of these to detect cell-intrinsic infection (Iwasaki
and Medzhitov, 2015). Immune cells like macrophages and dendritic cells also
detect cell-extrinsic infections and receive their initial activation stimulus through
PRRs. Activation of these receptors leads to expression of genes which promote
an immune response, such as cytokines like TNFα, or trigger effector mechan-
isms that directly target the micro-organism, like inducible nitric oxide synthase
which produces nitrous oxide (Arthur and Ley, 2013).
PRRs include membrane bound Toll-like receptors (TLRs) and C-type lectin
receptors (CLRs), cytosolic NOD-like receptors (NLRs) and RIG-I-like recept-
ors, and miscellaneous others including DAI and cGAS (Unterholzner, 2013).
TLRs recognise a diverse range of ligands like lipids and nucleic acids. CLRs,
which contain a carbohydrate-binding domain, include Dectin-1. They recog-
nise carbohydrates, such as fungal-derived β-glucan, and induce transcription of
proinflammatory cytokines (Takeuchi and Akira, 2010). NLRs, such as NALP1,
have a central nucleotide binding/oligomerisation domain and C-terminal leucine-
rich repeats (LRRs) through which they respond to bacterial peptidoglycans, like
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muramyl dipeptide. Upon ligand binding, NLRs oligomerize and induce release
of pro-inflammatory cytokines through several mechanisms, including activation
of caspase-1, which cleaves inactive pro-IL-1β into active IL-1β (Meylan et al.,
2006). RLRs, such as MDA5, have a central helicase/ATPase domain, a regu-
latory C-terminus and two N-terminal CARD domains through which they interact
with their downstream adaptor, MAVS. They recognise viral double stranded RNA
and induce type I interferons through NFκB and IRF3 and IRF7.
Thus many cells will have both extracellular and intracellular sensors for the
same common pathogen features, allowing the immune system to determine the
location of the micro-organism. For example, LPS is recognised by TLR4 on
the cell surface and by the caspase 4 (murine caspase 11) inflammasome in
the cytosol (Shi et al., 2014). The micro-environment induced by PRR signalling
provides context to antigen-recognition by adaptive immune cells, as well as in-
formation on micro-organism viability and pathogenicity, leading to an appropriate
immune response (Iwasaki and Medzhitov, 2015).
This study focused on signalling pathways initiated via TLRs, particularly
TLR4, which will be described in detail in the next section.
Toll-like receptor signalling
The TLRs are the most intensively studied of the PRRs (table 1.1). There are 10
in human and 12 in mice, present either on the surface of the cell or inside endo-
somes (Takeuchi and Akira, 2010). They play vital roles in immune responses and
immunopathology in instances where the innate immune system is over-activated.
For example, TLR4 is essential for protection in Salmonella Typhimurium infec-
tion (Talbot et al., 2009) but also for LPS-induced endotoxic shock. Wild type mice
injected with LPS succumb to endotoxic shock in 18 - 48 hours whereas in the ab-
sence of TLR4, LPS injection is not lethal in the absence of priming stimuli (Hagar
et al., 2013).
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Table 1.1: Toll-like receptors and their ligands.
Receptor Subcellular
location
Physiological ligands Species
TLR1/2 Cell
surface
Triacylated lipopeptides Mouse/human
TLR2 Cell
surface
Peptidoglycan, phospholipomannan,
tGPI-mucins, haemagglutinin, porins,
lipoarabinomannan,
glucuronoxylomannan, HMGB1
Mouse/human
TLR2/6 Cell
surface
Diacylated lipopeptides, lipoteichoic
acid, zymosan
Mouse/human
TLR3 Endosome Double stranded RNA Mouse/human
TLR4 Cell
surface
LPS, VSV glycoprotein G, RSV fusion
protein, MMTV envelope protein,
mannan, glucuronoxylomannan,
glycosylinositolphospholipids, HSP60,
HSP70, fibrinogen, nickel, HMGB1
Mouse/human
TLR4/6 Cell
surface
Oxidised low density lipoprotein,
amyloid-β fibrils
Mouse/human
TLR5 Cell
surface
Flagellin Mouse/human
TLR6 Cell
surface
Diacyl lipoprotein Mouse/human
TLR7 Cell
surface
Single stranded RNA Mouse/human
TLR8 Endosome Single stranded RNA Mouse/human
TLR9 Endosome DNA, haemozoin Mouse/human
TLR10 Endosome Unknown Human
TLR11 Cell
surface
Profilin Mouse
TLR12 Unknown Profilin Mouse
TLR13 Endosome Bacterial ribosomal RNA Mouse
HMGB1 = high-mobility group box 1 protein; VSV, vesicular stomatitis virus; RSV
= respiratory syncytial virus; MMTV, mouse mammary tumour virus; HSP = heat-
shock protein; tGPI-mucin = Trypanosoma cruzi glycosylphosphatidylinositol-
anchored mucin-like glycoprotein. [Table adapted from Takeuchi and Akira (2010)
and Kawai and Akira (2010)]
TLRs are type I transmembrane proteins. The extracellular portion has a
number of LRRs through which they engage their ligands (Takeuchi and Akira,
2010). Their intracellular portion contains a Toll-IL-1 receptor (TIR) domain, which
is necessary for transducing downstream signals. All TLRs signal via one of
two adaptor proteins upon ligand binding; most use MyD88 (myeloid differenti-
ation primary response gene 88) except for TLR3 which uses TRIF (TIR domain-
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containing adapter protein inducing IFN-β, or TICAM-1). TLR4 is exceptional in
that it can transduce signals via both of the adaptors, MyD88 and TRIF.
Figure 1.3: Signalling pathways activated following TLR4 ligation with LPS.
Extracellular LPS is sensed by TLR4 on the cell surface leading to formation of
TLR4 dimers. These dimers transduce signals into the cell through two pathways,
MyD88 and TRIF. Signalling through the MyD88 adaptor leads to activation of
the canonical IKK complex and MAP kinase pathways. TRIF mediated signalling
leads to activation of the non-canonical IKKs, IKKε and TBK1. Through these
three pathways TLR4 ligation leads to activation of three groups of transcription
factors, NFκB, AP-1 and IRF3.
TLR4 on the cell surface is bound to the co-receptor, MD2, and as a com-
plex they function as the main LPS-binding receptor (Kawai and Akira, 2010). In
vivo the plasma protein, LPS-binding protein (LBP), is also important for capturing
LPS in the blood. LBP bound to LPS is delivered to the TLR4-MD2 complex by
a LRR-containing, glycosylphosphatidylinositol-linked co-receptor called CD14.
LPS binding induces dimerisation of two TLR4-MD2-LPS complexes (figure 1.3;
Takeuchi and Akira, 2010).
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MyD88 activated pathways
TLR4 is somewhat unusual in that it uses another adaptor, TIRAP, to re-
cruit MyD88 and trigger intracellular signalling. MyD88 interacts with the ser-
ine/threonine kinase IRAK4, that then activates IRAKs 1 and 2 (Wesche et al.,
1997; Kawagoe et al., 2008). At this stage, the IRAKs dissociate from MyD88
and subsequently interact with TRAF6. TRAF6 is an E3 ubiquitin ligase, which,
together with the E2 ubiquitin-conjugating complex of Uev1A and Ubc13, syn-
thesises K63-linked polyubiquitin chains anchored on TRAF6 (Lamothe et al.,
2006). The poly-ubiquitin chains enable TAB1, TAB2 and TAB3 to recruit the
kinase TAK1, which becomes active, phosphorylates MAP 2-kinases and initiates
MAP kinase cascades (Wang et al., 2001). IRAK1 also phosphorylates another
E3 ligase, Pellino1, which catalyses formation of K63-linked polyubiquitin chains
on IRAK1 (Goh et al., 2012). NEMO, the regulatory subunit of the canonical IKK
complex, is also brought into close proximity with TAK1 by binding to these ubi-
quitin chains (Conze et al., 2008). This enables TAK1 to phosphorylate IKK2,
which then phosphorylates IκB proteins, inducing their proteolysis by the protea-
some. This releases NFκB transcription factors to translocate to the nucleus, as
well as activating the kinase TPL-2 and subsequently the ERK1/2 MAP kinase
pathway (see below).
TRIF activated pathways
After ligand binding, TLR4 becomes internalised to endosomes, and it is from
this location that the TRIF pathway is activated (Kawai and Akira, 2010). Un-
like TLR3, TLR4 requires the adaptor TRAM to interact with TRIF (Yamamoto
et al., 2002). TRIF recruits TRAF3, which undergoes auto-ubiquitination and activ-
ates the non-canonical inhibitor of NFκB kinases (IKKs), IKKε and TBK1 (Häcker
et al., 2006; Oganesyan et al., 2006). IKKε and TBK1 phosphorylate IRF3 and
IRF7 leading to induction of type I interferons. TRIF also uses another adaptor,
TRADD, to recruit RIP1 and TRAF6 (Cusson-Hermance, 2005; Ermolaeva et al.,
2008; Pobezinskaya et al., 2008). TRAF6 catalyses synthesis of polyubiquitin
chains which bring TAB1/2/3 and TAK1 together, enabling activation of the canon-
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ical IKK complex of NEMO, IKK1 and IKK2. Activation of IKK1 and IKK2 leads to
a second wave of activation of NFκB transcription factors and the ERK1/2 MAP
kinase pathway.
The major downstream outputs of TLR4 signalling pathways are activation of
NFκB and IRF transcription factors and MAP kinase pathways (discussed in detail
below).
1.2 Mitogen-activated protein kinase pathways
Mitogen-activated protein (MAP) kinases are protein kinases. These are enzymes
that catalyse the addition of a phosphate group on serine, threonine or tyrosine
residues. This modification can lead to functional changes in the ability of the
target to interact with other proteins or catalyse other reactions, amongst other
things. Protein kinases have a highly conserved active site (Cohen, 2002). Key
residues within the active site, such as the DFG (aspartate-phenylalanine-glycine)
motif, bind ATP, the phosphate donor, in complex with a metal ion cofactor, com-
monly Mg2+. Such residues orientate the ATP-metal ion complex towards the
substrate to allow the phosphate transfer (Adams, 2001).
TheMAP kinase subgroup of protein kinases are activated whenmacrophages
sense changes in the extracellular environment, such as pathogen infection, cy-
tokine stimulation and osmotic stress, and initiate cellular programmes that en-
able the cell to respond in an appropriate manner (e.g. through proliferation
or growth). MAP kinase signalling pathways consist of conserved three-tiered
kinase cascades. At the top of these cascades, a serine/threonine MAP 3-
kinase phosphorylates the activation loop of the downstream dual-specificity pro-
tein kinase (MAP 2-kinase). The activated MAP 2-kinase, in turn, phosphorylates
the threonine-X-tyrosine (T-X-Y, where X is any amino acid) motif in the activa-
tion loop of a MAP kinase, which then phosphorylates a number of target proteins
(figure 1.4). Recognition of a specific MAP kinase by MAP 2-kinases, mediated
via MAP kinase-docking domains, ensures specificity of signal transmission via
a particular MAP kinase pathway (Arthur and Ley, 2013). Specificity, amplitude
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and duration of MAP kinase cascade interactions is also regulated through scaf-
fold proteins (e.g. JNK-interacting protein 1, JIP1) that link the different members
of the cascade into complexes (Langeberg and Scott, 2015).
MAP kinases are proline directed kinases, preferentially phosphorylating ser-
ine/threonine residues to the N-terminal side of a proline residue. Many MAP
kinase substrates also contain D-domains and DEF-domains, which allow them
to be recognised by the MAP kinase (Roux and Blenis, 2004). Activated MAP
kinases ultimately phosphorylate a range of effectors directly. These include cyto-
skeletal proteins and transcription factors, particularly NFκB and AP-1 transcrip-
tion factors (e.g. c-Fos, c-Jun, ATF) through which they induce the transcription
of “immediate-early” genes, the products of which trigger a programme of cellular
changes in response to stimulation (O’Donnell et al., 2012). Many of the effects
of MAP kinases are mediated by phosphorylation of downstream MAP kinase-
activated protein kinases (MAPKAPKs). These include RSKs (1, 2, 3 and 4), MKs
(2, 3 and 5), MSKs (1 and 2) and MNKs (1 and 2) which can be activated by
ERK1/2 and/or p38 MAP kinases (Roux and Blenis, 2004). Through the phos-
phorylation of these substrates, MAP kinases regulate multiple cellular processes
involved in innate immunity including phagocytosis, cell migration and production
of cytokines.
Termination of MAP kinase signalling is largely controlled by dual-specificity
phosphatases (DUSPs, also known as MAP kinase phosphatases). These en-
zymes can dephosphorylate both the threonine and tyrosine residues of the MAP
kinase activation loop and inactivate them (Caunt and Keyse, 2013). DUSP
mRNA expression is induced by MAP kinases signalling downstream of PRR ac-
tivation, creating a negative feedback loop. Signalling through MAP kinase path-
ways is also terminated by ubiquitin-mediated degradation of components of the
MAP kinase pathways, including MAP 2-kinases and MAP 3-kinases (Chen and
Thorner, 2007). Furthermore, post-translational modifications or protein interac-
tions can disrupt associations between pathway components and prevent contin-
ued signalling.
31
Figure 1.4: Mitogen-activated protein kinase pathways.
Changes in the extracellular environment, including the presence of microorgan-
isms and other stresses, trigger activation of the MAP kinase pathways. These
three tiered kinase cascades consist of upstreamMAP 3-kinases (MAP3K), which
phosphorylate and activate a MAP 2-kinase (MAP2K), which then phosphorylates
and activates theMAP kinase (MAPK). Active MAPKs phosphorylate multiple sub-
strate proteins with a variety of functions, resulting in altered gene expression
as well as a host of other intracellular changes in response to the extracellular
change.
Due to the important role of MAP kinase pathways in triggering immune re-
sponses downstream of PRR ligation, pathogens have developed ways to disrupt
them, thereby avoiding elimination by the immune response. For example, Vibrio
parahaemolyticus VopA protein acetylates lysine in the ATP-binding site of MAP
kinases, blocking its signalling by preventing ATP binding (Trosky et al., 2007).
Similarly Yersinia pestis YopJ protein acetylates MAP kinase activation loop ser-
ine and threonine residues blocking their phosphorylation and kinase activation
(Mukherjee et al., 2006).
1.2.1 The atypical MAP kinases
Very little is known about the atypical MAP kinases ERK3/4, ERK7 and NLK in
immune responses, owing partly to the absence of chemical inhibitors of these
kinases (Arthur and Ley, 2013). Their classification as “atypical” is based on two
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characteristics (Coulombe and Meloche, 2007). ERK3/4 has a different activa-
tion loop sequence to the canonical MAP kinase T-X-Y, consisting instead of a
serine-glutamate-glycine motif. NLK also has only a single phosphorylation site
in its activation loop motif of threonine-glutamine-glutamate, as well as unusual
extensions on both the N- and C-terminals. ERK7 is also atypical because of its
extended C-terminal that is not present in the canonical MAP kinases.
NLK can be activated by cytokines, such as IL-6 and TGF-β, and Wnts, like
Wnt-1 and Wnt-5a (Kanei-Ishii et al., 2004; Ohkawara et al., 2004). It has been
shown that the MAP 3-kinase TAK1 can activate NLK but the identity of any inter-
mediate MAP 2-kinases are not known. Several transcription factor substrates of
NLK have been identified, including STAT3 (Kojima et al., 2005). For ERK7, the
MAP 2-kinase involved in its activation is currently not known in spite of it having
the canonical activation loop sequence, T-X-Y. ERK7 is known to phosphorylate
some of the same substrates as classical MAP kinases, namely myelin basic pro-
tein, c-Fos and c-Myc (Abe et al., 1999) and to regulate cell proliferation, as well
as the response to glucocorticoids and oestrogens (Cargnello and Roux, 2011).
Although it is not known what stimuli activate the ERK3/4 pathway, Deleris
et al. (2011) showed that the MAP 2-kinase family responsible are the PAKs. The
only known substrate of ERK3/4 is MK5, although ERK3 has been shown to be
important in immunity through a role in T cell activation. Marquis et al. (2014)
showed that ERK3-deficient T cells secreted decreased amounts of cytokines and
showed impaired proliferation in response to TCR-stimulation in vitro.
1.2.2 Canonical MAP kinase pathways
The p38 and JNK pathways
The p38 and JNKMAP kinases are also known as stress-activated protein kinases
due to their predominant role in transduction of danger signals after PRR engage-
ment. These pathways can also be activated by diverse environmental stimuli
such as osmotic stress and ultraviolet light (Rosette and Karin, 1996; Aggeli et al.,
2002). Based largely on experiments with knockout fibroblasts, multiple MAP 3-
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kinases have been shown to activate p38 pathways including TAK1, ASK1, DLK1
and TAO1 (Matsuzawa et al., 2005; Cuadrado and Nebreda, 2010; Sakurai, 2012).
Similarly, the MAP 3-kinases TAK1, MLK1, and MEKK1 have been implicated in
JNK activation (Davis, 2000; Sakurai, 2012). However, the MAP 3-kinase used
by TLR4 for activation of p38 and JNK pathways in innate immune cells has yet
to be determined (Arthur and Ley, 2013).
TheMAP 2-kinases responsible for activation of p38 and JNKMAP kinases are
much better defined as they have a more restricted substrate specificity and show
less context dependence. The canonical p38α pathway is activated by the MAP 2-
kinases MKK3 and MKK6 and current knowledge suggests these MAP 2-kinases
exclusively activate p38 isoforms (Remy et al., 2010). JNK MAP kinases are ac-
tivated by the MAP 2-kinases MKK4 and MKK7 (Lawler et al., 1998). MKK4 and
MKK7 appear to show a preference for the activation loop tyrosine and threonine,
respectively, and co-operate to induce maximal JNK activation following stress
stimulation (Fleming et al., 2000). However, inflammatory stimuli like IL-1β and
TNFα have been shown to activate JNK through MKK7 alone (Tournier et al.,
2001).
Some of the downstream targets of p38 and JNK pathways regulate transcrip-
tional changes. In addition, JNK can control many other targets in a variety of
cellular pathways. For example, adaptor proteins like IRS-1, that can alter how
other signalling pathways are integrated, Bcl2 family members, that promote cell
survival, and paxillin, a protein involved in focal adhesions through which JNK is
thought to regulate cell movement (Bogoyevitch and Kobe, 2006). JNK signalling
has been linked to development of insulin resistance in mice fed a high-fat diet
(Han et al., 2013). JNK deletion in myeloid cells correlates with reduced numbers
of macrophages in adipose tissue and impaired polarisation of macrophages to
an inflammatory phenotype.
p38α also regulates gene expression at the post-transcriptional level, regu-
lating mRNA stability through control of the RNA binding protein tristetraprolin
(TTP). A key target for TTP is the mRNA of cytokines, such as TNFα, which are
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targeted for degradation by TTP binding. p38α activates its substrate, MK2, which
phosphorylates TTP, decreasing TTP affinity for the mRNA ARE motif. This al-
lows HUR to bind the mRNA instead and initiate translation (Tiedje et al., 2012).
Through control of this pathway, p38α promotes production of cytokines and has
been associated with inflammatory diseases. In support of this, p38α/β inhibitors
have been shown to be protective in animal models of inflammatory and autoim-
mune diseases like rheumatoid arthritis (Cohen, 2009). Clinical trials of p38α/β
inhibitors in immune diseases have suffered from problems of toxicity and an ab-
sence of long-term efficacy (Zhang et al., 2007; Arthur and Ley, 2013). A possible
explanation for these problems comes from the fact that p38α inhibition blocks
negative feedback pathways and results in increased inflammation. For example,
p38α phosphorylation of TAB1 and/or TAB3 leads to inhibition of TAK1. In the ab-
sence of p38α activity, this feedback loop is inactive, resulting in elevated TAK1
activation and greater activation of NFκB, JNK and ERK1/2 pathways (Cheung
et al., 2003).
The ERK5 pathway
Although its kinase domain shares 51 % amino acid identity with ERK2 (Cargnello
and Roux, 2011), ERK5 has a unique structure amongst the canonical MAP
kinases due to its large C-terminal domain. ERK5 is activated by extracellular
stimuli, including growth factors like VEGF, cytokines like IL-6 and environmental
stresses like hypoxia (Nithianandarajah-Jones et al., 2012). These stimuli in-
duce the activation of the MAP 3-kinases MEKK2/3, which then activate the only
MAP 2-kinase for ERK5, MEK5 (Cargnello and Roux, 2011). ERK5 activation in-
duces phosphorylation of a number of proteins, the best characterised of which
are MEF2A, MEF2C and MEF2D transcription factors that are positively regulated
by ERK5.
In the immune system, ERK5 negatively regulates expression of the macro-
phage colony stimulating factor receptor (M-CSFR) in human acute myeloid leuk-
emia cells, preventing their differentiation into macrophages (Wang et al., 2015).
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ERK5 also promotes B cell survival in response to BAFF stimulation and therefore
maintenance of mature B cell numbers (Jacque et al., 2015).
The MEK1/2/ERK1/2 pathway
One of the key MAP kinase pathways is the MEK1/2/ERK1/2 pathway, which can
be activated by a variety of exogenous and endogenous stimuli, such as growth
factor signalling via tyrosine kinase receptors, and PAMP signalling via TLRs.
ERK1/2 signalling controls cellular function at transcriptional and post-
transcriptional levels. Its role at the transcriptional level is fairly well understood
(O’Donnell et al., 2012). However, the functions of other ERK1/2 substrates have
not been fully elucidated. This was illustrated by a recent study in which use of
an “analog-sensitive” ERK2 kinase identified 80 ERK2 substrates, of which only
13 were previously known (Carlson et al., 2011). The majority of these were not
directly related to transcriptional control and suggested functions for ERK1/2 sig-
nalling in mRNA processing, cytoskeletal organisation and protein transport.
ERK1/2 has a role in many cancers (e.g. melanoma, ovarian and colon can-
cer) through promotion of cell growth and survival (Davies et al., 2002). In this
instance, ERK1/2 activation is often the result of activating mutations in Raf iso-
forms, the MAP 3-kinases which activate ERK1/2 in response to growth factor
stimulation, or Ras, the small GTPase upstream of Raf. Fortunately, it is possible
to inhibit Raf without blocking the important immune functions of ERK1/2 because
immune stimuli use the alternative MAP 3-kinase, TPL-2, which is the main focus
of this study. Similarly, this could eventually allow selective blockade of immunolo-
gical ERK1/2 activation through TPL-2 inhibition, meaning inflammatory diseases
could be treated without the side effects of MEK1/2 or ERK1/2 inhibition on growth
factor signalling.
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1.3 Tumour progression locus-2
The ERK1/2 MAP 3-kinase tumour progression locus 2 (TPL-2, also known as
COT or MAP3K8) has been characterised primarily as a regulator of MAP kinase
signalling in macrophages.
It was first identified as an oncogene in a human thyroid carcinoma cell line
and in Moloney murine leukaemia virus-induced T cell lymphomas (Miyoshi et al.,
1991; Patriotis et al., 1993). Pro-virus insertion into the final intron of the TPL-
2 gene, between exons 7 and 8, produces a C-terminally truncated protein with
transforming potential (Ceci et al., 1997; Uren et al., 2005). Furthermore, the Cata-
logue of SomaticMutations in Cancer (COSMIC) database shows 83 uniquemuta-
tions in the Map3k8 gene in human cancer (http://cancer.sanger.ac.uk/cosmic,
accessed 5/11/15; Forbes et al., 2015).
TPL-2 is a serine/threonine protein kinase, expressed as two isoforms: M1
(467 amino acids, 58 kDa) and M30 (437 amino acids, 52 kDa), differing at their
N-terminal due to initiation of translation from either methionine 1 or methionine
30, respectively (Aoki et al., 1993). Both isoforms are cytoplasmic, but M1 has a
longer half-life than M30 suggesting they are regulated differently (Cho and Tsich-
lis, 2005), although the functional consequences of this difference have not been
investigated. The TPL-2 kinase domain extends between residues 146 and 386
(M1 isoform).
1.3.1 Regulation of TPL-2
The majority of TPL-2 in a cell is sequestered in a complex with NFκB1 p105 and
ABIN-2 (figure 1.5). Interaction with both these proteins is essential for optimal
stability of TPL-2, whose steady-state levels are very low in cells lacking either
NFκB1 p105 or ABIN-2 (Waterfield et al., 2003; Lang et al., 2004; Papoutsopoulou
et al., 2006).
Other than maintaining steady-state levels of TPL-2, the function of ABIN-2
is not yet known. However, by retroviral expression of TPL-2 in Tnip2-/- (ABIN-2
“knock-out”) macrophages, it has been established that ABIN-2 is not required for
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TPL-2 activation and phosphorylation of MEK1/2 (Papoutsopoulou et al., 2006).
Degradation of NFκB1 p105 releases ABIN-2, in addition to TPL-2, and it is pos-
sible that ABIN-2 mediates its signalling function once released from the TPL-2
complex. ABIN-2 binds to linear and K63-linked poly-ubiquitin chains through
its conserved UBAN domain. However, the importance of the UBAN domain in
ABIN-2 function, and the polyubiquitinated proteins to which ABIN-2 binds under
physiological conditions have yet to be determined.
Figure 1.5: Interactions between TPL-2, NFκB1 p105 and ABIN-2.
In unstimulated cells, TPL-2 is held in a complex with NFκB1 p105 and ABIN-2.
The C-terminus of TPL-2 (residues 398-467) interacts with part of the processing
inhibitory domain (PID) of NFκB1 p105 (residues 497-539), masking the TPL-2
degron sequence. In addition, the kinase domain (KD) of TPL-2 interacts with the
death domain (DD) of NFκB1 p105, inhibiting TPL-2MEK-kinase activity and form-
ing a very strong association between the two proteins. The TPL-2 C-terminus
also associates with ABIN-2 through a region (residues 194-250) containing one
of the ABIN homology domains (AHD). The N-terminal half of ABIN-2 also associ-
ates with NFκB1 p105. RHD = Rel homology domain, GRR = glycine-rich region,
PEST = domain rich in proline (P), glutamate (E), serine (S) and threonine (T).
[Adapted from Gantke et al. (2011)]
NFκB1 p105 functions as a cytoplasmic inhibitor of NFκB (IκB), preventing
NFκB transcription factors, particularly p50 homodimers and the p50-containing
heterodimers p50-cRel and p50-RelA, entering the nucleus in the absence of stim-
ulation (Sriskantharajah et al., 2009). NFκB1 p105 is also constitutively processed
by the proteasome into the mature transcription factor p50. This processing is reg-
ulated by the E3 ubiquitin ligase, KPC1 (Kravtsova-Ivantsiv et al., 2015).
Following receptor activation, NFκB1 p105 is phosphorylated in its PEST
region on serines 927 and 932 by IKK2 (Orian et al., 2000; Salmerón et al.,
2001; Lang et al., 2003). These modifications allow recognition by the E3 ligase
SCFβTrCP, which catalyses K48-linked polyubiquitination of NFκB1 p105 triggering
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predominantly complete degradation by the proteasome rather than processing
to p50 (Belich et al., 1999; Heissmeyer et al., 2001; Lang et al., 2003). This re-
leases associated NF-κB dimers to translocate into the nucleus and modulate
gene transcription. TPL-2 forms a strong stoichiometric association with NFκB1
p105 through 2 interactions (figure 1.5); the C-terminal of TPL-2 binds to a region
of NFκB1 p105 adjacent to the ankyrin repeats, and the kinase domain of TPL-2
binds to the NFκB1 p105 death domain (Belich et al., 1999; Beinke et al., 2003).
The association with NFκB1 p105 maintains TPL-2 stability by masking a degron
sequence, which lies between residues 435 and 457 (Gándara et al., 2003). When
in the complex, TPL-2 is incapable of phosphorylating MEK1 because access to
the kinase domain is prevented by the interaction with the NFκB1 p105 death do-
main. In contrast, the intrinsic kinase activity of TPL-2 is not inhibited by NFκB1
p105 association, as evidenced by the ability of TPL-2 to phosphorylate associ-
ated NFκB1 p105 (Babu et al., 2006b; Robinson et al., 2007). Activation of the
MEK1/2 kinase activity, following stimulation of receptors such as TLR4, requires
release of a fraction of TPL-2 fromNFκB1 p105, triggered by IKK2-induced NFκB1
p105 proteolysis (figure 1.6). Interestingly, this suggests a possible functional link
between NFκB and MAP kinase pathways.
Intra-molecular interactions are also important for the regulation of TPL-2 activ-
ity. Oncogenic mutants of TPL-2 are always truncated at the C-terminus (TPL-
2ΔC), indicating an important regulatory role for the C-terminal in the full-length
protein (Gantke et al., 2012). The isolated C-terminus has been shown to interact
with the kinase domain of TPL-2, reducing its catalytic activity (Ceci et al., 1997;
Gándara et al., 2003). Based on these data, it has been suggested that the C-
terminal end of TPL-2 (residues 425-467) forms intra-molecular interactions with
its kinase domain, preventing phosphorylation of substrates in unstimulated cells.
TPL-2ΔC is more stable, with a half life of 95 mins versus 35 mins for full length
human TPL-2, and expressed at increased levels than the full length protein, prob-
ably due to absence of the C-terminal degron motif (Gándara et al., 2003). Trun-
cation may also increase the specific activity of the oncogenic form of TPL-2 by
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removing the auto-inhibitory interaction and also blocking negative regulation by
NFκB1 p105 which partly relies on the TPL-2 C-terminus (figure 1.5).
A key phosphorylated residue is serine 400 (S400) in the C-terminal tail of
TPL-2 which is a target site for IKK2 after LPS-stimulation (Roget et al., 2012).
Expression of TPL-2 in Nfκb1-/- macrophages has shown that stimulation-induced
phosphorylation of S400 is required in addition to release from NFκB1 p105 to in-
duce TPL-2 signalling (Robinson et al., 2007). Phosphorylation at S400 is essen-
tial for intracellular MEK1/2 kinase activity in LPS-stimulated macrophages. S400
phosphorylation triggers TPL-2 signalling by promoting the interaction between
TPL-2 and 14-3-3 dimers, increasing TPL-2 kinase activity (Ben-Addi et al., 2014).
The TPL-2 auto-phosphorylation at serine 443 is also required for optimal 14-3-3
interaction in addition to S400 trans-phosphorylation by IKK2. C-terminal dele-
tion may trigger the oncogenic potential of TPL-2 by rendering its kinase activity
independent of 14-3-3 binding.
Table 1.2: Phosphorylation sites in the TPL-2 protein
Site Method Notes References
S62 pAb, MS Required for maximal
activation
Stafford et al. (2006)
T80 MS - Black et al. (2007)
S125 MS - Stafford et al. (2006)
S141 MS Present prior to
stimulation
Stafford et al. (2006)
Weintz et al. (2010)
T290 pAb Required for MEK1/2
kinase activity,
regulates NFκB1
p105 binding
Stafford et al. (2006)
S334 MS - Stafford et al. (2006)
S400 pAb, KA, MS Phosphorylated by
IKK2. Required for
14-3-3 binding and
intracellular MEK1/2
kinase activity
Robinson et al.
(2007); Ben-Addi
et al. (2014)
S413 KA - Robinson et al.
(2007)
S443 pAb, MS Autophosphorylation.
Required for optimal
14-3-3 binding
Ben-Addi et al.
(2014)
pAb = phospho-specific antibody, MS = mass spectrometry, KA = in vitro kinase
assay
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Mass spectrometry has identified multiple other phosphorylated residues on
TPL-2 (table 1.2) (Luciano et al., 2004; Stafford et al., 2006; Black et al., 2007). Of
these, only one has been shown to be functionally important. Phosphorylation of
threonine 290 (T290) within the activation loop is essential for TPL-2 kinase activ-
ity (Luciano et al., 2004; Stafford et al., 2006) and LPS-induced MEK1/2 phos-
phorylation is blocked in TPL-2 knock-out macrophages retrovirally expressing
TPL-2T290A (Cho and Tsichlis, 2005). T290 phosphorylation may activate TPL-2
both by reducing its affinity for its inhibitor NFκB1 p105 and promoting interac-
tion with MEK1/2. There is also contention over the kinase responsible for phos-
phorylating T290. High concentrations of the IKK2 inhibitor, PS1145, were re-
ported to block its phosphorylation (Cho et al., 2005), however this was refuted
by a subsequent study using lower concentrations (Stafford et al., 2006). Serine
62 phosphorylation has also been reported as an autophosphorylation required
for maximal activation of TPL-2 following IL-1 stimulation of IL-1R-expressing
HEK293 cells (Stafford et al., 2006). However, phosphorylation of this residue
is not important for LPS activation of TPL-2 in macrophages (Roget et al., 2012).
The availability of nutrients appears to be important for regulating TPL-2 activa-
tion by phosphorylation (Mieulet et al., 2010). When macrophages are deprived of
arginine, the interaction between TPL-2 and protein phosphatase 2A is enhanced,
leading to dephosphorylation of TPL-2 residues T290 and S400 and abrogation
of kinase activity towards substrates following LPS stimulation.
Thus in response to stimulation through receptors like TLR4 and IL-1R, TPL-2
transduction of signals to its downstream targets is regulated by post-translational
modification, intra-molecular interactions and protein-protein interactions.
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Figure 1.6: Regulation and signalling of TPL-2.
Ligation of receptors such as TLR4 or TNFR1 activates the canonical IKK com-
plex. The IKK complex then phosphorylates NFκB1 p105, leading to its K48-linked
polyubiquitination followed by degradation by the proteasome and release of TPL-
2. The IKK complex also directly phosphorylates the C-terminus of TPL-2 inducing
14-3-3 binding. Once released from the NFκB1 p105 complex, TPL-2 can phos-
phorylate MEK1/2, resulting in changes in cytokine and chemokine expression.
ABIN-2 is also released from TPL-2 following NFκB1 p105 degradation, but its
function remains unknown. [Adapted from Gantke et al. (2011)]
1.3.2 TPL-2 MAP 3-kinase in immune responses and disease
TPL-2 functions as aMAP 3-kinase, activated by TIR domain-containing receptors
from the Toll-like receptor/IL-1 receptor family, and the TNF receptor superfam-
ily (Gantke et al., 2011). TPL-2 is essential for activation of the MEK1/2/ERK1/2
pathway in macrophages stimulated via TLRs, TNFR1 and IL-1R. ERK1/2 activ-
ation in B cells stimulated through CD40 and TLR4 is also mediated via TPL-2
(Eliopoulos et al., 2003; Gantke et al., 2012).
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In vitro evidence
TPL-2 has roles in both the innate and adaptive arms of the immune system. In
innate immune responses, signalling through TPL-2 leads to changes in expres-
sion of inflammatory mediators such as COX2 and cytokines (Eliopoulos et al.,
2002b). TPL-2 signalling positively regulates TNFα, IL-1β, IL-10 and IL-23 pro-
duction by macrophages (Dumitru et al., 2000; Mielke et al., 2009; Kakimoto et al.,
2010), whereas IFNβ and IL-12p70 are negatively regulated, independent of the
autocrine effects of increased IL-10 release (Kaiser et al., 2009; Yang et al., 2011).
The effects of TPL-2 on cytokine expression are largely mediated at the transcrip-
tional level (e.g. IL-1β and IL-10). However, levels of TNFα mRNA and pre-TNFα
protein in Map3k8-/- BMDM are normal, but mature TNFα secretion is substan-
tially reduced compared to wild type (Dumitru et al., 2000). TPL-2 therefore reg-
ulates TNFα production at a post-translational level (figure 1.2). It has been sug-
gested that TPL-2 deficiency in macrophages reduces transport of pro-TNFα to
the cell surface in response to TLR stimulation (Rousseau et al., 2008). How-
ever, MEK1/2 inhibition does not effect pro-TNFα trafficking from the Golgi to the
plasma membrane in LPS-stimulated RAW264.7 macrophages. Rather, ERK1/2
phosphorylates TACE at Thr735, thereby regulating the levels of mature TACE at
the cell surface (Soond et al., 2005). TACE may facilitate transport of pre-TNFα
to the cell surface for subsequent TACE-mediated proteolysis (Rousseau et al.,
2008).
TPL-2 also regulates the movement of innate immune cells by controlling the
production of and response to chemokines. For example, the mRNA levels of
the chemokines CCL2, CCL7, CXCL2 and CXCL3 are reduced in LPS-stimulated
Map3k8-/- BMDM compared to wild type, whereas CCL5, CCL8, CXCL9, CXCL10
and CXCL13 are increased (Bandow et al., 2012). TPL-2-deficient macrophages
also express lower levels of the chemokine receptor CCR1 than wild type cells
after LPS stimulation and are impaired in trafficking to the peritoneal cavity after
thioglycollate injection (Rowley et al., 2014). In addition to regulating macrophage
trafficking, TPL-2 regulates their phagocytic function. Phagocytosis of beads by
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peritoneal macrophages stimulated ex vivo with adiponectin is reduced in the ab-
sence of TPL-2 (Sanz-Garcia et al., 2014). Therefore it seems that TPL-2 is im-
portant for a range of functions in innate immune cells.
In vivo evidence
Consistent with these in vitro experiments, analyses of Map3k8-/- mice have also
established important roles for TPL-2 regulation of inflammation. For example,
Map3k8-/- mice are protected in a model of endotoxic shock induced by LPS and
D-galactosamine due to the critical role of TPL-2 in regulating TNFα production by
macrophages (Dumitru et al., 2000). TPL-2 deficient mice are also protected from
experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis
(Sriskantharajah et al., 2014). Similarly, Kontoyiannis et al. (2002) found that, in
the TNFΔARE/ΔARE mouse model of Crohn’s-like inflammatory bowel disease (IBD),
Map3k8-/- mice show attenuated intestinal pathology, with later onset and reduced
inflammation. TPL-2 has also been linked to this disease in patients by a genome
wide association study that showed an association between aMap3k8 single nuc-
leotide polymorphism and IBD (Jostins et al., 2012).
TPL-2 expression in T cells is required for efficient differentiation of CD4+ T
cells into Th1 effector cells. TPL-2-deficient CD4+ T cells have a reduced capacity
to induce the transcription factors, T-bet and Stat4, which drive optimal Th1 po-
larisation. In line with these observations, TPL-2 is required for a normal immune
response to the Th1-inducing parasite Toxoplasma gondii due to compromised
IFN-γ production. Furthermore, transplantation of Rag2-/- mice with T cells con-
firmed a T cell-intrinsic role for TPL-2 in resistance to T. gondii infection (Watford
et al., 2008). Map3k8-/- mice are also more susceptible to Mycobacterium tuber-
culosis and Listeria monocytogenes due to the increased production of IFNβ by
innate immune cells that is detrimental in this infection (McNab et al., 2013).
However, the majority of studies into TPL-2 immune function use TPL-2-
deficient macrophages/mice which also have substantially reduced amounts of
ABIN-2 protein compared to wild type (Sriskantharajah et al., 2014). Therefore,
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until these results are confirmed in TPL-2 kinase-inactive macrophages/mice,
where presence of the kinase-inactive TPL-2 protein acts as a scaffold to stabilise
ABIN-2, it cannot be ruled out that some of these effects could be dependent on
ABIN-2.
1.3.3 TPL-2 signalling in cancer
Oncogenic functions of TPL-2
TPL-2 was initially identified by several laboratories by virtue of its transforming
activity when its C-terminus is deleted. However, there is only one reported ex-
ample of TPL-2 truncation occurring in human cancer. Clark et al. (2004) found
TPL-2 truncated at residue 421 in a human lung adenocarcinoma. There are also
two cancers in which mutation of residues within the C-terminus might contribute
to carcinogenesis; an alanine to threonine mutation at residue 387 in a patient with
glioblastoma multiforme (Parsons et al., 2008) and a proline to leucine mutation
was found at residue 461 in breast cancer and metastasis samples from a patient
(Ding et al., 2010). It is possible that these mutations impair the interaction of
TPL-2 with its inhibitor NFκB1 p105, thereby augmenting TPL-2 signalling.
There is clearer evidence linking TPL-2 over-expression to cancer develop-
ment. Studies by Sourvinos et al. (1999) and Christoforidou et al. (2004) im-
plicated elevated levels of TPL-2 in breast tumours and large granular lymph-
ocyte proliferative disorders, respectively. Higher TPL-2 expression may aug-
ment ERK1/2 activation, a key survival signal in cancers driven by Ras and Raf
mutations (Vougioukalaki et al., 2011). Indeed, increased TPL-2 expression can
drive the acquisition of B-Raf inhibitor drug-resistance in melanoma patients who
have constitutively activating B-Raf mutations (Johannessen et al., 2010; Monsma
et al., 2015). Furthermore, TPL-2 constitutively activates ERK1/2 in anaplastic
large-cell lymphoma (ALCL), and TPL-2 inhibition reduces ALCL cell proliferation
in vitro (Fernández et al., 2011).
Other studies which have linked TPL-2 with advanced and invasive cancer
include Lee et al. (2013) who showed that lung metastasis in animals given a
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renal cell carcinoma (RCC) xenograft was reduced in the absence of TPL-2. The
same study also found that RNAi “knock-down” of TPL-2 in RCC cell lines im-
paired their proliferation, migration and invasion capabilities. An alternative role
for TPL-2 in cancer could be through co-operating in signalling deregulated by
activation of a separate oncogene. For example, the Epstein-Barr virus protein,
LMP-1 that has transforming capacity, can induce kinase activity of co-transfected
TPL-2 (Eliopoulos et al., 2002a). Similarly, after human T cell leukaemia virus type
I transformation of human leukaemia cell lines, TPL-2 disassociates from NFκB1
p105 and becomes constitutively active (Babu et al., 2006a).
In addition to these cell-intrinsic roles in cancer, Hope et al. (2014) showed
a non-cell-intrinsic role for TPL-2 in a genetic murine model of myeloma. During
disease progression, wild type myeloma-associated macrophages switch towards
an inflammatory phenotype associated with tumour progression. This switch was
blocked in the absence of TPL-2, resulting in delayed disease development.
Tumour suppressor functions of TPL-2
Several studies with Map3k8-/- mice suggest that TPL-2 can act as a tumour sup-
pressor in certain contexts. Map3k8−/− mice crossed onto a transgenic MHCClass
I-restricted T-cell receptor background, develop T-cell lymphomas as a result of
excessive activation of CD8+ T cells after TCR stimulation (Tsatsanis et al., 2008).
TPL-2 also limits the generation of adenocarcinomas in the urethane-model of
lung cancer, possibly via cell intrinsic regulation of JNK activation (Gkirtzimanaki
et al., 2013). Map3k8−/− mice also have a higher incidence of skin tumours than
wild type in a two-stage skin carcinogenesis model. However, in this case, TPL-2
signalling inhibits carcinogenesis by regulating the inflammatory mileau in which
cancer cells develop (DeCicco-Skinner et al., 2011). Similarly, using the Apcmin
genetic model of intestinal cancer crossed with Map3k8−/− mice, Serebrennikova
et al. (2012) showed that the absence of TPL-2 results in an increase in intestinal
adenomas, which correlates with higher inflammation.
However, as mentioned previously, the majority of studies use TPL-2-
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deficient macrophages/mice which are also ABIN-2 deficient at the protein level
(Sriskantharajah et al., 2014). Therefore, these studies may be looking at ABIN-
2 signalling defects rather than TPL-2, and this will have to be addressed using
TPL-2 kinase-inactive mutants.
1.3.4 TPL-2 as a drug target
Due to its importance in production of TNFα by TLR/IL-1/TNFR1 stimulated mac-
rophages, and apparent role in disease models, TPL-2 is considered a potential
therapeutic target for treating conditions such as inflammatory bowel disease and
rheumatoid arthritis.
Homozygous Map3k8D270A “knock-in” mutation results in viable mice lacking
any catalytically active TPL-2 (Sriskantharajah et al., 2014). Consequently, it
would be expected that small molecule TPL-2 inhibitors should be tolerated and
not cause any developmental defects, although immune function might be sub-
stantially reduced. However, studies suggesting TPL-2-deficiency exacerbates
models of asthma or promotes tumour progression (detailed above) call this into
question.
The kinase domain of TPL-2 displays marked differences to other kinases,
sharing only 35 % identity with its closest homolog, MST4. Furthermore, TPL-
2 has a proline (P154) in place of the first glycine in the conserved glycine-rich
loop that contributes to ATP binding and enables the phosphoryl transfer reac-
tion. Computer modelling of this residue suggested it would confer important
differences to the ATP binding pocket (Gantke et al., 2012). This was recently
confirmed by Gutmann et al. (2015), who determined the crystal structure of hu-
man TPL-266-395 and TPL-230-404 in combination with ATP-competitive inhibitors
and found the TPL-2 kinase domain has a unique, flexible structure. The unusual
features of TPL-2 make development of highly specific inhibitors more likely. TPL-
2 may also be easier to inhibit pharmacologically than other kinases due to its high
Michaelis-Menten constant (Km) for ATP (Cohen, 2002). The Km, determined in
vitrowith the cofactor Mg2+ using TPL-230-397 purified from insect cells, was greater
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than 300 μM (Jia et al., 2005). This implies that high concentrations of ATP are
needed to reach maximum activity, and therefore the potency of ATP-competitive
inhibitors needed to out-compete this in vivo is lower. Several inhibitors have
already been developed which are highly selective for TPL-2 and exhibit low IC50s
in vitro, meaning they are very potent as the amount needed to reduce the kinase
activity to half its maximum is low. These compounds are effective at inhibiting
LPS-induced production of TNFα in primary human macrophages, whole human
blood and mice (Hall et al., 2007; George et al., 2008; Hu et al., 2011). However,
so far TPL-2 inhibitors have not been tested in clinical trials. Work in the Ley
laboratory (unpublished data) has suggested that this could be due to the poor
aqueous solubility of at least one of these potent inhibitors from Wyeth (now part
of Pfizer, USA). Additionally these inhibitors have been developed using a peptide
substrate based on the activation loop of MEK1/2 insect cell-purified TPL-230-397
which is known to partially aggregate and associate with chaperone proteins (Jia
et al., 2005). Inhibitors developed in this way may not be optimal for inhibiting the
biologically active form and work in the Ley laboratory is currently focused on op-
timising the method for screening compound libraries to identify more promising
leads.
1.3.5 Downstream targets of TPL-2
MAP 2-kinases are currently the only established substrates of TPL-2. The most
prominent of these in myeloid cells are MEK1 and 2, which are phosphorylated on
residues S217/S221 and S218/S222, respectively, resulting in their activation and
subsequent phosphorylation and activation of ERK1/2 MAP kinases. Analyses of
Map3k8-/- macrophages has shown that TPL-2 regulates the activation of ERK1/2
after ligation of TLRs, IL-1R and TNFR1 (Gantke et al., 2012). There are also re-
ports of TPL-2 phosphorylating other MAP 2-kinases, for example immunoprecip-
itated TPL-2 can phosphorylate the MAP 2-kinase MKK4 in vitro (Salmeron et al.,
1996). Similarly, over-expressed TPL-2 can directly phosphorylate and activate
MEK5 leading to ERK5 activation (Chiariello et al., 2000). Analyses of Map3k8-/-
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fibroblasts have also suggested that TPL-2 can regulate JNK activation via phos-
phorylation of MKK4 following TNFα and IL-1β stimulation (Das et al., 2005).
Figure 1.7: TPL-2 regulates TNFα production by BMDM independently of
ERK1/2.
During the first 2 hours of LPS stimulation, treatment with a MEK1/2 inhibitor does
not effect the amount of TNFα produced by wild type (WT) BMDM. From 1.5 hours
to 6 hours pre-treatment with the MEK1/2 inhibitor reduces the amount of TNFα
produced. However TNFα production in the presence of MEK1/2 inhibitor is higher
than that ofMap3k8-/- BMDM at all time points. PD = PD184352, MEK1/2 inhibitor.
[Reproduced from Yang et al. (2012)]
It was widely thought that most TPL-2 functions were regulated through
ERK1/2, including the post-translational regulation of TNFα. However, recently
the Ley Laboratory published several lines of evidence that TPL-2 induces TNFα
production in LPS-stimulated macrophages independently of ERK1/2 activation
(Yang et al., 2012). Firstly, when wild type BMDM were stimulated with LPS, ex-
periments with MEK1/2 inhibitor indicated that the early release of TNFα was inde-
pendent of ERK1/2 signalling (figure 1.7). Pharmacological blockade of ERK1/2
activation only reduced TNFα production over 2 hours after LPS stimulation. In
contrast, TPL-2 was required for TNFα production as early as 1 hour after LPS
stimulation. These results suggest that TPL-2 regulated the early release of TNFα
independently of its activation of ERK1/2 and that regulation of TNFα production
by ERK1/2 was a late and potentially secondary effect.
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Analyses of BMDM from the Nfκb1SSAA/SSAA mice, in which the IKK2 phos-
phorylation sites on NFκB1 p105 are mutated to alanine, have also indicated
that TPL-2 can induce TNFα production independently of ERK1/2 activation.
Nfκb1SSAA mutation prevents IKK2-induced degradation of NFκB1 p105 and re-
lease of TPL-2, blocking ERK1/2 activation following LPS stimulation. However,
the production of TNFα after LPS stimulation is comparable between wild type
and Nfκb1SSAA/SSAA BMDM (figure 1.8). However, Nfκb1SSAA mutation does not af-
fect the TPL-2 dependence of TNFα production as demonstrated by experiments
with LPS-stimulatedNfκb1SSAA/SSAA,Map3k8-/- orNfκb1SSAA/SSAAMap3k8D270A/D270A
macrophages. These results suggest that TPL-2 is able to regulate TNFα produc-
tion when bound in the ternary complex with NFκB1 p105 and ABIN-2, independ-
ently of its ability to activate the ERK1/2 MAP kinase pathway.
Figure 1.8: TPL-2 regulates production of TNFα when bound in the ternary
complex.
Nfκb1SSAA mutation prevents activation of ERK1/2 in LPS-stimulated macro-
phages (left hand panel) but does not impair TNFα production (right hand
panel). However, production of TNFα is abrogated in Nfκb1SSAA/Map3k8D270A
and Nfκb1SSAA/Map3k8-/- compound mutant macrophages showing that TPL-2
is still required to stimulate TNFα production in the Nfκb1SSAA/SSAA mutant back-
ground. Map3k8D270A = TPL-2 kinase-inactive BMDM, Map3k8-/- = TPL-2 knock
out BMDM. [Reproduced from Yang et al. (2012)]
Additional evidence of ERK1/2-independent TPL-2 signalling comes fromRNA
sequencing experiments conducted in the Ley laboratory. Of the genes which are
dependent on TPL-2 kinase activity, a large proportion are regulated independ-
ently of ERK1/2 activation (unpublished data).
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Moreover, TPL-2 has been demonstrated to phosphorylate a number of non-
MAP 2-kinase substrates (table 1.3) in vitro or after over-expression. However, it
remains to be determined if any of these are physiologically relevant using TPL-2
kinase-inactive cells. It is also important to note that many of the studies were
not conducted in macrophages and did not test the effect of inhibiting MEK1/2 to
ensure that the TPL-2-dependent phosphorylation was not mediated via ERK1/2.
In order to fully understand its functions in immune responses and cancer, it
is essential to have a complete understanding of the proteins endogenous TPL-
2 phosphorylates in cells. This is also important to predict potential side-effects
from therapeutic TPL-2 inhibition. Therefore this project will address the lack of
knowledge of TPL-2 downstream signalling in order to better understand its role
in innate immune responses. To achieve this goal, it is necessary to employ an
unbiased method for identifying physiological kinase substrates in situ.
1.4 Hypothesis
As discussed earlier, recent studies by the Ley laboratory have indicated that
TPL-2 regulation of innate immunity is partly mediated independently of ERK1/2.
Therefore the specific aim of this study was to identify ERK1/2-independent sig-
nalling pathways regulated by TPL-2. To do this, it was first necessary to develop
a systemwhereby global phosphorylation could bemonitored in an unbiased, site-
specific and quantifiable way. The overall aim was to generate a list of ERK1/2-
independent TPL-2 regulated phosphoproteins and then to test whether any of
these were direct TPL-2 targets. A final aim was to understand how novel TPL-
2 substrates identified contribute to the function of TPL-2 in innate immune re-
sponses.
51
Table 1.3: Published substrates of TPL-2, excluding MAP 2-kinases.
Protein Residue(s) Limitations Reference
PLCβ3 S537
Retrovirally reconstituted immortalised
MEFs. Overexpression. In vitro kinase
assay.
Hatziapostolou
et al. (2011)
Nfκb1 p105 ND Cell lines. In vitro kinase assay. Babu et al.
(2006b)
Histone H3 S10 Cell lines. In vitro interaction andkinase assays. Overexpression. Choi et al.
(2008)
Tvl-1 ND Cell lines. In vitro kinase assay. Patriotis
et al. (2001)
NPM T199 Cell lines. In vitro kinase assay. Kanellis et al.
(2014)
p70S6K T389 MEK1/2 inhibition blocksphosphorylation. Lopez-
Pelaez et al.
(2011)
Akt1 S473 MEK1/2 inhibition blocksphosphorylation. Lopez-
Pelaez et al.
(2011)
Pin1 S16 Cell lines. In vitro kinase assay.Overexpression. Kim et al.
(2015)
PLK1 S137 Peptide substrate screen. Cell lines.
In vitro kinase assay. Overexpression. Wu et al.
(2009)
Histone H2B S33 Peptide substrate screen. Notvalidated. Wu et al.
(2009)
Chk1 S345 Peptide substrate screen. Notvalidated. Wu et al.
(2009)
Eif4ebp1 T70 Peptide substrate screen. Notvalidated. Wu et al.
(2009)
Abl1 T735 Peptide substrate screen. Notvalidated. Wu et al.
(2009)
CDK1 T161 Peptide substrate screen. Notvalidated. Wu et al.
(2009)
CREB1 S133 Peptide substrate screen. Notvalidated. Wu et al.
(2009)
Eif4g1 S1147 Peptide substrate screen. Notvalidated. Wu et al.
(2009)
Moesin /
Ezrin /
Radixin
T558 / T567
/ T564
Peptide substrate screen. Not
validated. Wu et al.
(2009)
ND = not determined
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2 Introduction to Kinase Substrate Identification
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Protein phosphorylation by kinases is a central mechanism by which protein func-
tion is regulated and controls multiple aspects of cell physiology. Methods for
the systematic identification of kinase substrates are vital for a complete under-
standing of kinase function. However, this is not a trivial problem, since there are
over 500 protein kinases in the human genome, which are responsible for phos-
phorylating an estimated 30 % of proteins. Consequently, linking the responsible
kinases to each substrate clearly poses a major challenge (Cohen, 2000; Ubersax
and Ferrell Jr, 2007; Duong-Ly and Peterson, 2013). This is made more difficult
still by the structural similarity of kinases, which limits the specificity of inhibitors,
and potential for functional redundancy, which can confound results from genetic
elimination of kinase function (Elphick et al., 2007). Furthermore the deletion of
one kinase can disrupt expression or stability of others or alter cell development,
making interpretation of knock-out mutant cells lacking specific kinasesmore com-
plex than it initially appears.
Identification of kinase substrates was previously dependent on low throughput
in vitro assays, such as incubation of a purified kinase with a predicted substrate
and assessing incorporation of radioactive phosphate into the target protein. Ed-
man degradation was used to determine the site(s) of phosphorylation by mon-
itoring when the radiolabel was released (Elphick et al., 2007). This approach
demonstrates a direct kinase-substrate relationship but requires optimisation for
individual proteins and pre-existing knowledge to identify candidate substrates.
One way to circumvent the need to predict individual kinase-substrate rela-
tionships is through the use of libraries of potential protein substrates. For ex-
ample it is possible to identify proteins which interact specifically with a particular
kinase domain by yeast two-hybrid assay (Municio et al., 1995). Alternatively,
purified potential substrates can be adsorbed onto slides to generate protein ar-
rays that can be screened for phosphorylation by the selected kinase (MacBeath
and Schreiber, 2000; Zhu et al., 2001). Another method is KESTREL (kinase
substrate tracking and elucidation), in which cell extracts are subjected to ion ex-
change chromatography and aliquots of the fractions collected are incubated with
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radioactive magnesium-ATP in presence and absence of closely related protein
kinases, such as different p38 isoforms (Cohen and Knebel, 2006). The aim is
to detect proteins that are phosphorylated selectively by just one of these kinase
isoforms, minimising the possibility of false positives.
All of the methods outlined thus far are limited by the artificial environment
in which the kinase and candidate substrates interact; temporal and spatial con-
straints, as well as the role of accessory proteins, are ignored and amounts of
both kinase and substrate can be significantly higher than those in vivo (Elphick
et al., 2007). The potential for artefact is considerable.
2.1 Analysis of phosphopeptides by mass spectrometry
With advances in mass spectrometry (MS) techniques, it has become possible to
vastly increase coverage and quantification accuracy of the physiological phos-
phoproteome. In a single experiment a huge number of phosphorylation sites can
be identified and quantified from a complex mixture such as cell lysate, allowing
a greater proportion of a specific kinase’s potential substrates to be investigated
simultaneously.
Analysis of phosphopeptides uses tandem MS (MS/MS), which involves two
rounds of MS, termed MS1 and MS2. The most abundant peptides, as determ-
ined by quantification of the relative intensity of the signals in MS1, are subjected
to further fragmentation prior to MS2 (Palumbo et al., 2011). The masses of the
resulting fragment ions are used to identify the original peptide as well as the phos-
phorylated residue by comparison with predicted spectra from in silico digestion of
the proteome. Common fragmentation techniques used include collision induced
dissociation (CID), multistage activation (MSA) and higher-energy collisional dis-
sociation (HCD). These different methods result in different fragment ions. For
example CID is efficient in removal of the phosphate group but not fragmentation
of the backbone (Palumbo et al., 2011), whereas HCD provides better disruption
of the peptide backbone and therefore more sequence information (Olsen et al.,
2007).
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2.2 Enrichment of phosphopeptides
Signalling proteins are commonly expressed at low levels and phosphorylation of
these proteins is often sub-stoichiometric, with as little as 1 % of the total protein
being modified (Villen and Gygi, 2008). This makes the study of global phos-
phorylation changes inefficient from complex mixtures, with a bias towards de-
tection of abundant proteins. To overcome this, early MS methods fractionated
cell lysates, for example by two-dimensional gel electrophoresis with or without
phosphatase treatment, to identify phosphorylated proteins. These were then ex-
cised and identified by MS (Mann and Jensen, 2003). However this approach
lacked resolution and accuracy and has been superseded by introduction of spe-
cific phospho-enrichment techniques. These fall into two categories, chemical
methods and affinity methods. Chemical methods include the chemical replace-
ment of the phosphate group on a serine or threonine with an affinity tag (Oda
et al., 2001). However, such strategies suffer from side reactions which increase
complexity of the sample and complicate data analysis.
Affinity enrichment using phospho-specific antibodies has been used to enrich
phosphopeptides but has give variable results due to use of different immunogens
to raise the antibodies (Wang, 1988; Gronborg, 2002). Consequently the most
common affinity based techniques are based on physicochemical differences
between phosphopeptides and their non-phosphorylated counterparts. Strong
cation exchange (SCX) chromatography for example uses a negatively charged
resin to retain non-phosphorylated peptides slightly better than phosphorylated
ones (Zhou et al., 2011). This is because trypsin cleaves proteins at the basic
amino acids arginine and lysine so, at low pH, each peptide will have two positive
charges, one on its amino terminus and one on the arginine or lysine (the carboxy
terminus is neutral at low pH). Phosphopeptides are less positively charged than
non-phosphorylated peptides due to the addition of the negatively charged phos-
phate group. Another common method for enriching phosphopeptides is using
titanium dioxide beads that bind phosphopeptides specifically via their attached
phosphate groups (Pinkse et al., 2004; Sano and Nakamura, 2004).
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Various studies have suggested that the enrichment protocol can significantly
influence the type of phosphopeptides (e.g. singly or multiply phosphorylated) that
are subsequently detected (Bodenmiller et al., 2007; Li et al., 2009; Zarei et al.,
2011). As each of thesemethods are reliant on small differences in peptide proper-
ties, contaminating peptides are usually co-purified. For example, acidic peptides
can also bind titanium dioxide although this can be reduced by addition of certain
acids (Jensen and Larsen, 2007;Wu et al., 2007). For SCX, phosphopeptides with
basic residues like histidine canmimic un-phosphorylated peptides in their interac-
tion with the anionic resin (Zhou et al., 2011). Moreover multiply phosphorylated
peptides have a net neutral or even negative charge and will not bind the SCX
matrix so that they are lost in the flow-through. Affinity enrichment techniques
are therefore most powerful when used in combination (e.g. SCX fractionation
followed by titanium dioxide enrichment of phosphopeptides from the fractions) .
2.3 Use of labelling techniques
In spite of the accuracy that can be achieved with MS, it is not inherently suitable
for quantification because of errors introduced through liquid handling steps and
changes in chromatographic conditions over time (Mann, 2006). For this reason
label free techniques such as iBAQ (Schwanhäusser et al., 2011), which uses the
number of observed peptides for each protein as a surrogate for its abundance,
are not generally applied to studies of global phosphorylation. To compensate for
such errors, methods for peptide labelling have been introduced into MS work-
flows.
2.3.1 In vitro labelling
A number of methods for labelling peptides in vitro during or following trypsinisa-
tion have been developed, including 18O (Ye et al., 2009) or iTRAQ (Wiese et al.,
2007). Once the peptides in each lysate are labelled, they can be combined for
subsequent steps of the enrichment and analysis procedure thus reducing the im-
pact of errors. A relative quantification between the labelled and unlabelled forms
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is determined from the MS signals obtained. However, in vitro labelling involves
enzymatic or chemical steps, which can have variable labelling efficiency and the
possibility of side reactions, as well as errors introduced in steps prior to labelling
(Mann, 2006).
Figure 2.1: SILAC labelling and subsequent analysis by mass spectrometry.
Amino acids labelled with stable isotopes are added to culture medium and incor-
porated into proteins by cells through their normal metabolic processes. Differen-
tial labelling in this way allows proteins to be pooled directly following lysis of the
cells. Any errors introduced during subsequent steps of trypsin digestion, phos-
phopeptide enrichment and LC-MS/MS analysis will effect both samples identic-
ally and therefore the relative abundance of phosphopeptides will not be altered.
Upon LC-MS/MS analysis of the mixtures, peptides from the labelled culture will
have a greater mass than their unlabelled counterparts, meaning the two signals
can be distinguished and a ratio corresponding to their relative abundance can be
calculated. [Adapted from Weintz et al. (2010)]
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2.3.2 Stable isotope labelling with amino acids in cell culture
Stable isotope labelling with amino acids in cell culture (SILAC) is a metabolic la-
belling technique whereby cultured cells take up and incorporate a label into their
proteins through their normal metabolic processes (Jiang and English, 2002; Ong
et al., 2002; Zhu et al., 2002). Relative quantification of two differentially labelled
conditions is achieved by comparing the relative signal intensity between condi-
tions for each peptide. The label consists of the amino acids arginine and lysine
containing ”heavy” isotopes of hydrogen, carbon and nitrogen that are added into
the culture media and can be used by the cells in the synthesis of new proteins.
Arginine and lysine are ideal for this for several reasons. Most importantly
these residues are exclusively recognised and cleaved by trypsin meaning that,
when proteins are digested, every resulting peptide will carry exactly one label
(assuming 100 % cleavage efficiency). Therefore all peptides (except the most
C-terminal) will be quantifiable and have a predictable mass shift, which simplifies
analysis of the peaks (Ong et al., 2003; Olsen, 2004; Ong, 2012). Arginine and
lysine are essential amino acids not produced by cells. This is beneficial for la-
belling because if cells could produce unlabelled arginine or lysine it would lead to
incomplete labelling. However, some cell types have been shown to convert pro-
line to arginine, and vice versa (Mann, 2006). In addition to introducing unlabelled
arginine, this could result in the presence of labelled proline and hence peptides
with two labels. This would cause errors in peptide quantification by making it
harder to identify which peaks correspond to a particular peptide.
SILAC has become the gold standard labelling technique for proteomic studies
and has been used to identify substrates for a variety of kinases, for example
Grb10 as a substrate of mTORC1 in fibroblasts (Yu et al., 2011) and AEG-1 as a
substrate of IKKβ in MCF-7 breast cancer cells (Krishnan et al., 2015).
The main drawback of MS-based phosphoproteomics, regardless of the la-
belling method used, is that it does not only identify direct substrates but also sec-
ondary phosphorylation events resulting from activation of downstream kinases.
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Table 2.1: Strengths and weaknesses of the standard SILAC approach.
Strengths Weaknesses
Proteins should have normal
functions and post-translational
modifications.
Biology of cells may be altered by the
culture conditions.
Eliminates variability in sample
preparation.
Labelling efficiency is not 100 %.
Labelled peptides have the same
physico-chemical properties and
behave the same in the mass
spectrometer, reducing variability in
analysis.
No more than 3 conditions can be
compared at one time.
Predictable mass shifts between
labels.
Complexity of the mixture is
increased.
2.4 Analogue-sensitive kinases
To address the issue of direct phosphorylations, another technology developed
specifically to identify kinase substrates is the use of “analogue-sensitive” kinases.
This requires an engineered form of the kinase of interest in which the “gate-
keeper” residue in the kinase domain is mutated to allow use of an unnatural ATP
analogue with a bulky side group (Shah et al., 1997). By using an analogue where
the γ-phosphate (which a kinase transfers to a substrate) has been replaced by a
thiol, only direct substrates of the kinase will be labelled with the thiol group and
these can be isolated before being identified and quantified by MS (Carlson et al.,
2011).
Analogue-sensitive kinases can increase the identification of specific sub-
strates because, in theory, other kinases cannot use the unnatural ATP ana-
logue. It is also an effective method for establishing causal relationships between
a kinase and its substrates on a large scale. However this is not universally ap-
plicable with about 30 % of kinases intolerant of the gatekeeper mutation and po-
tentially requiring further mutations to rescue kinase activity (Zhang et al., 2005).
Furthermore, the assay currently has to be done in vitro using cell lysates as the
ATP analogues are not cell permeant. Consequently, the subcellular context is
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lost and phosphorylations detected using this method may not be physiological.
Of the available technologies, SILAC labelling and MS currently provide the
highest accuracy data and the most widely applicable methodology, so this ap-
proach will be implemented in the current study.
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3 Materials and Methods
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3.1 Buffers
ACK Buffer (0.2 μm filter sterilised)
Ingredient Supplier Final Concentration
Ammonium chloride Sigma-Aldrich, USA 155 mM
EDTA Sigma-Aldrich, USA 100 μM
Potassium bicarbonate Sigma-Aldrich, USA 10 mM
Water - To 1 L
S-Lysis Buffer
Ingredient Supplier Final Concentration
Tris/HCl Sigma-Aldrich, USA 50 mM
Sodium chloride Sigma-Aldrich, USA 150 mM
EDTA Sigma-Aldrich, USA 2 mM
Sodium fluoride Sigma-Aldrich, USA 50 mM
Sodium pyrophosphate Sigma-Aldrich, USA 2 mM
Igepal* Sigma-Aldrich, USA 1 %
cOmplete, EDTA-free protease
inhibitor mix*
Roche, Switzerland 1 x
Sodium orthovanadate* Sigma-Aldrich, USA 1 mM
*Ingredients added immediately prior to use.
Detergent Free Lysis Buffer
Ingredient Supplier Final
Concentration
Urea Sigma-Aldrich, USA 8 M
Tris/HCl pH 8.2 Sigma-Aldrich, USA 50 mM
Glycerol 2-phosphate Sigma-Aldrich, USA 10 mM
Sodium fluoride Sigma-Aldrich, USA 50 mM
Sodium pyrophosphate Sigma-Aldrich, USA 5 mM
EDTA Sigma-Aldrich, USA 1 mM
Sodium orthovanadate* Sigma-Aldrich, USA 1 mM
Dithiothreitol* Sigma-Aldrich, USA 1 mM
Phenylmethylsulfonyl
fluoride*
Sigma-Aldrich, USA 1 mM
Aprotinin* Merck Millipore, USA 153 nM
Leupeptin* Chemicon, Japan 2 μM
Okadaic acid* Enzo Life Sciences, USA 100 nM
MilliQ water - To 500 ml
*Ingredients added immediately prior to use.
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HEPES Lysis Buffer
Ingredient Supplier Final
Concentration
Hepes Sigma-Aldrich, USA 50 mM
Sodium chloride Sigma-Aldrich, USA 100 mM
Sodium fluoride Sigma-Aldrich, USA 50 mM
Glycerol 2-phosphate Sigma-Aldrich, USA 50 mM
EDTA Sigma-Aldrich, USA 2 mM
EGTA Sigma-Aldrich, USA 2 mM
Glycerol Sigma-Aldrich, USA 10 %
Igepal* Sigma-Aldrich, USA 1 %
cOmplete, EDTA-free
protease inhibitor mix*
Roche, Switzerland 1 x
Sodium orthovanadate* Sigma-Aldrich, USA 1 mM
Okadaic acid* Enzo Life Sciences, USA 100 nM
*Ingredients added immediately prior to use.
Lysis Buffer A (Risco et al., 2012)
Ingredient Supplier Final
Concentration
Tris/HCl (pH7.5) Sigma-Aldrich, USA 50 mM
EDTA Sigma-Aldrich, USA 1 mM
EGTA Sigma-Aldrich, USA 1 mM
Sodium pyrophosphate Sigma-Aldrich, USA 5 mM
Glycerol 2-phosphate Sigma-Aldrich, USA 50 mM
2-mercaptoethanol Sigma-Aldrich, USA 0.1 %
Sodium chloride Sigma-Aldrich, USA 150 mM
Sodium fluoride Sigma-Aldrich, USA 10 mM
Sucrose Sigma-Aldrich, USA 270 mM
cOmplete, EDTA-free
protease inhibitor mix*
Roche, Switzerland 1 x
Phenylmethylsulfonyl
fluoride*
Sigma-Aldrich, USA 0.1 mM
Sodium orthovanadate* Sigma-Aldrich, USA 1 mM
Triton-X100* Sigma-Aldrich, USA 1 %
*Ingredients added immediately prior to use.
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Laemmli Buffer
Ingredient Supplier Final Concentration
Glycerol Sigma-Aldrich, USA 20 %
Sodium dodecyl sulphate Sigma-Aldrich, USA 4 % (w/v)
Tris/HCl pH 6.8 Sigma-Aldrich, USA 120 mM
Bromophenol blue Sigma-Aldrich, USA 0.02 % (w/v)
Distilled H20 - To 50 ml
+/- 2-Mercaptoethanol Sigma-Aldrich, USA 10 %
Strong Cation Exchange Buffers
Ingredient Buffer A Buffer B
Ammonium formate 10 mM 500 mM
Acetonitrile 25 % 25 %
pH 3.0 6.8
LC-MS/MS Buffers
Ingredient Buffer A Buffer B
Formic acid 0.1 % 0.1 %
DMSO 5 % 5 %
Acetonitrile - 77.5 %
Water 95 % 17.5 %
Kinase Buffer
Ingredient Supplier Final Concentration
HEPES pH 7.4 Sigma-Aldrich, USA 50 mM
MnCl2 Sigma-Aldrich, USA 10 mM
TCEP Sigma-Aldrich, USA 1 mM
Brij 35 Sigma-Aldrich, USA 0.03 %
Bovine serum albumin Sigma-Aldrich, USA 0.01 %
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3.2 Cell culture media
All foetal calf serum (FCS) was heat inactivated by incubation at 56 ºC for 30 mins.
SILAC RAW264.7 Medium
Ingredient Supplier K0R0 FinalConcentration
K8R10 Final
Concentration
RPMI without
arginine or lysine
NIMR Media
Kitchen
To 500 ml
5 kDa MWCO
dialysed FCS
Dundee Cell
Products, UK
10 %
12C614N4 L-arginine Sigma-Aldrich,
USA
482 μM -
12C614N2 L-lysine Sigma-Aldrich,
USA
799 μM -
13C615N4 L-arginine Sigma-Aldrich,
USA
- 482 μM
13C615N2 L-lysine Cambridge
Isotope
Laboratories Inc.,
USA
- 799 μM
Proline Sigma-Aldrich,
USA
261 μM 261 μM
Standard BMDM Medium
Ingredient Supplier Differentiation
Medium
Starvation
Medium
Final Concentration
RPMI 1640 Sigma-Aldrich,
USA
To 500 ml To 500 ml
Foetal calf serum Biosera, France 10 % 1 %
L929-cell
conditioned media
NIMR Media
Kitchen
20% -
Sodium pyruvate Sigma-Aldrich,
USA
1 mM 1 mM
HEPES Sigma-Aldrich,
USA
10 mM 10 mM
L-glutamine
PenStrep
Sigma-Aldrich,
USA
1/500 1/500
Non-essential
amino acids
Life
Technologies,
USA
1 x 1 x
2-Mercaptoethanol Life
Technologies,
USA
50 μM 50 μM
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Weintz et al. BMDM Medium
Ingredient Supplier
Non-
Differentiating
Medium
Differentiating
Medium
DMEM without
arginine or lysine
NIMR Media
Kitchen
To 500 ml
5 kDa MWCO
dialysed FCS
Dundee Cell
Products, UK
10 %
Sodium pyruvate Sigma-Aldrich,
USA
1 mM
HEPES Sigma-Aldrich,
USA
10 mM
L-glutamine
PenStrep
Sigma-Aldrich,
USA
1/500
Non-essential
amino acids
Life
Technologies,
USA
1 x
2-Mercaptoethanol Life
Technologies,
USA
50 μM
IL-3 Insight
Biotechnology,
UK
20 ng/ml -
IL-6 Insight
Biotechnology,
UK
50 ng/ml -
SCF Insight
Biotechnology,
UK
50 ng/ml -
M-CSF Life
Technologies,
USA
40 ng/ml 40 ng/ml
12C614N4 L-arginine Sigma-Aldrich,
USA
482 μM 482 μM
12C614N2 L-lysine Sigma-Aldrich,
USA
799 μM 799 μM
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Ley Laboratory SILAC BMDM Medium
Ingredient Supplier
Differentiation Medium Starvation Medium
Final K0R0
Concentra-
tion
Final K8R10
Concentra-
tion
Final K0R0
Concentra-
tion
Final K8R10
Concentra-
tion
RPMI without
arginine or lysine
NIMR Media
Kitchen
To 500 ml To 500 ml
1 kDa MWCO
dialysed FCS
Dundee Cell
Products, UK
10 % 1 %
2 kDa MWCO
dialysed L929-cell
conditioned media
NIMR Media
Kitchen, dialysed
by CRUK Cell
Services
20% -
Sodium pyruvate
Sigma-Aldrich,
USA
1 mM 1 mM
HEPES
Sigma-Aldrich,
USA
10 mM 10 mM
L-glutamine
PenStrep
Sigma-Aldrich,
USA
1/500 1/500
Non-essential
amino acids
Life Technologies,
USA
1 x 1 x
2-Mercaptoethanol
Life Technologies,
USA
50 μM 50 μM
12C614N4
L-arginine
Sigma-Aldrich,
USA
482 μM - 482 μM -
12C614N2 L-lysine
Sigma-Aldrich,
USA
799 μM - 799 μM -
13C615N4
L-arginine
Sigma-Aldrich,
USA
- 482 μM - 482 μM
13C615N2 L-lysine
Cambridge Isotope
Laboratories Inc.,
USA
- 799 μM - 799 μM
Methionine
Sigma-Aldrich,
USA
201 μM 201 μM
3.3 Cell culture
3.3.1 Generation of bone marrow-derived macrophages (BMDM)
Protocol adapted from Weintz et al. (2010)
All work was done in compliance with the United Kingdom Home Office regula-
tions. Mouse strains were bred in specific pathogen-free environments at The
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Francis Crick Institute, Mill Hill Laboratory. All experimental mice were fully back-
crossed onto the C57BL/6 background and genotyped to ensure they carried the
correct mutations. On day 0, stem cells were harvested frommale mice aged 8-12
weeks by flushing femurs and tibias with media. The stem cells were centrifuged
(277 x g, 5 mins) and resuspended in 1 ml ACK buffer for 1 minute to lyse erythro-
cytes, before blank media was added to stop the hypotonic lysis. The stem cells
were centrifuged as before, washed with blank media and finally resuspended in
media. Cell numbers were determined using a CASY® Technology Cell Counter
(Roche, Switzerland). Cells were plated at 5 x 106 on 9 cm Sterilin bacteriolo-
gical dishes (Thermo Fisher Scientific, USA) in 10 ml Weintz et al. (2010) BMDM
Medium without cytokines and rested overnight to allow differentiated bone mar-
row resident macrophages to adhere to the dish. The following day non-adherent
cells were collected and adherent cells were discarded. Non-adherent cells were
centrifuged (277 x g, 5 mins) and resuspended in 1 ml Weintz et al. (2010) BMDM
Non-Differentiating Medium. Cells were plated in triplicate at 1 x 107 cells per 9
cm bacteriological dish in Weintz et al. (2010) BMDMNon-Differentiating Medium.
On days 4, 7 and 10 the non-adherent cells were collected and placed on ice.
Adherent cells were detached by incubating at 37 ºC for 15 mins using 4 ml ac-
cutase (Sigma-Aldrich, USA) diluted 1:4 with PBS and scraping. Cells were then
centrifuged (277 x g, 5 mins), resuspended with the non-adherent cells plus fresh
Weintz et al. (2010) BMDM Non-Differentiating Medium and replated on Sterilin
bacteriological dishes. On day 13 adherent and non-adherent cells were collec-
ted as above, washed with PBS, then replated on bacteriological plates in Weintz
et al. (2010) BMDM Differentiating Medium. On day 16 non-adherent cells were
discarded and adherent cells were collected and centrifuged at 277 x g for 5 mins.
The cells were resuspended in Weintz et al. (2010) BMDM Medium with only 1 %
FCS and without cytokines, plated at 25 x 106 cells per 14 cm Nunc™ tissue cul-
ture treated dish (Thermo Fisher Scientific, USA), and rested overnight to reduce
background signalling levels.
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Ley laboratory protocol for generation of BMDM
Stem cells were harvested and processed as detailed above then 8 x 106cells
were plated in 20 ml Standard BMDM Differentiation Medium on 14 cm bacteri-
ological dishes. On day 4, an additional 20 ml fresh media was added. On day 7
the cells were detached by incubating for 10 mins at 37 ºC with Dulbecco’s PBS
(Life Technologies, USA) supplemented with 5 % FCS (Biosera, France) and 2.5
mM EDTA (Life Technologies, USA). The cells were centrifuged at 277 x g for 5
mins and then counted using the CASY® Technology Cell Counter. Finally cells
were re-plated at 12 x 106cells on 14 cm tissue culture treated dishes in Standard
BMDM Starvation Medium and rested overnight.
Ley laboratory protocol for SILAC BMDM
To generate K0R0 unlabelled or K8R10 labelled SILAC BMDM, stem cells were
harvested and processed as detailed above then 8 x 106cells were plated per 14
cm Sterilin bacteriological dish in 25 ml K0R0 or K8R10 Ley Laboratory SILAC
BMDM Differentiation Medium. The same mice were used to produce both K0R0
and K8R10 lysates for each condition by dividing the precursor cells in half prior to
culture. The cells from each mouse were cultured and treated separately. On day
4, the media was removed and cells still in suspension were collected by centrifu-
gation at 277 x g for 5 mins. The cells were re-suspended in 25 ml fresh K0R0 or
K8R10 Ley Laboratory SILAC BMDM Differentiation Medium per plate and then
returned to the original plates. On day 6, the adherent cells were detached from
the dishes by incubating with Dulbecco’s PBS/2.5 mM EDTA for 10 mins at 37
ºC, collected by centrifugation at 277 x g for 5 mins and then counted using the
CASY® Technology Cell Counter. 12 x 106cells were plated per 14 cm Nunc™
tissue culture treated dish in K8R10 Ley Laboratory SILAC BMDM Starvation Me-
dium and rested overnight.
To establish the length of time required to achieve sufficient incorporation of
labelled amino acids, parallel cultures were set up in Ley Laboratory SILACBMDM
Differentiation Medium. In this instance, the media were also changed a second
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time on day 7. Cells were lysed every second day up to 10 days; on days 2 and
4 this included collection and lysis of the non-adherent as well as adherent cells.
However at later time points only adherent cells were lysed becausemacrophages
should have differentiated and attached by this stage.
Stimulation in SILAC lysates was checked individually by immunoblotting to
ensure that activation of the NFκB1 p105/TPL-2/ERK1/2 pathway and other MAP
kinase pathways was in line with what we expect from the stimulation, inhibition
and mutant conditions (Appendix A). Finally the lysates were combined in pro-
tein ratios of 1:1 according to the mixes shown in the experimental design table
(table 5.1). Only stimulated cell lysates were compared.
3.3.2 RAW264.7 cell culture
SILAC labelling
RAW264.7 cells, obtained from Dundee University (UK), were cultured in SILAC
RAW264.7 media (section 3.2). The cells were split every 3 days by detaching
with Dulbecco’s PBS/2.5 mM EDTA and seeded in tissue culture treated flasks.
After 6 passages, cells were lysed to check SILAC incorporation was greater than
90 % and stocks of the labelled RAW264.7 cells were frozen in FCS with 10 %
DMSO. The cells were then expanded and the spike-in lysate produced in 3 equal
batches over 7 days. In preparation for stimulation the cells were plated in SILAC
RAW264.7 Medium without FCS. Cells were either stimulated with 100 ng/ml LPS
from Salmonella minnesota R595 (Enzo Life Sciences Inc., USA) for 15 mins or
left unstimulated. On ice themediumwas removed and the cells were washedwith
ice cold Dulbecco’s PBS and lysed in Detergent Free Lysis Buffer by scraping the
plates. Lysates were collected and clarified by centrifugation at 21,100 x g for 15
mins, followed by snap freezing in liquid nitrogen for storage at -70 ºC. All K8R10
SILAC labelled lysates from the stimulated and unstimulated RAW264.7 cells were
combined to produce a spike-in lysate which contained asmany relevant phospho-
peptides as possible. This spike-in lysate was then combined in a 1:1 protein ratio
with 2.5 mg of the unlabelled BMDM lysate.
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3.4 Cell treatments, lysis and protein extraction
Cells were stimulated with 100 ng/ml LPS from Salmonella minnesota R595 (Enzo
Life Sciences Inc., USA) for 15 mins or left unstimulated. 15 mins was chosen as
the peak of ERK1/2 activation and a time point where secondary effects of protein
production and release of autocrine signals should be minimal. MEK1/2 inhibitor
treated cells were pre-treated with 0.1 μM PD0325901 (University of Dundee, UK)
for 10 mins (Bain et al., 2007). To block IKK2 catalytic activity, cells were pre-
treated with 10 μM BI605906 (University of Dundee, UK) for 1 hour (Clark et al.,
2011). Mock-treatment with similarly diluted DMSO was used to control for use of
the use of inhibitors.
After stimulation, tissue culture plates were placed on ice, medium was re-
moved and cells were washed with ice cold Dulbecco’s PBS. Cells were lysed
by scraping the plates in appropriate lysis buffer. For western blotting, cells were
lysed in S-Lysis Buffer, while those for mass spectrometry were lysed in Detergent
Free Lysis Buffer. For MKK3, MKK4 and MKK6 immunoprecipitation, cells were
lysed in HEPES Lysis Buffer. Cells for p38γ/δ immunoprecipitation were stimu-
lated with 100 ng/ml LPS for 30 mins, as the peak of p38 activation occurs later
than ERK1/2, and lysed in Lysis Buffer A (Risco et al., 2012). Lysates were collec-
ted and clarified by centrifugation at 21,100 x g for 15 mins, followed by storage at
-20 ºC or snap freezing in liquid nitrogen for storage at -70 ºC. Protein concentra-
tions were measured by Pierce™ reducing agent-compatible BCA assay (Thermo
Fisher Scientific, USA), according to the manufacturer’s instructions.
3.5 Immunoblotting and antibodies
For immunoblotting cells were lysed standard lysis buffer. Equal amounts of pro-
tein were separated by SDS-PAGE and transferred to PVDF membranes (Bio-
Rad, USA). Non-specific binding was prevented by incubating the membranes in
PBS/0.05 % Tween/5 % milk for 1 hour. Membranes were incubated with primary
antibody overnight, followed by incubation with an appropriate secondary antibody
for approximately 2 hours. Bound antibody was visualised using ECL (enhanced
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chemiluminescence; GE Healthcare, UK) and exposing an X-ray film. Quantifica-
tion of relative signal levels was performed by densitometry using a Bio-Rad (USA)
GS-800 densitometer and the QuantityOne software v4.6.9 (Bio-Rad, USA).
Primary antibodies used were: ERK1/2 (#44654, lot 913234A), phospho-
T185/Y187 ERK1/2 (#44680, lot 1440090A), and phospho-T183/Y185 JNK
(#44682 lot 290218D), all from Life Technologies (USA); phospho-S933 NFκB1
p105 (#4806 lot 4), phospho-S217/221 MEK1/2 (#9121 lot 31), phospho-
T180/Y182 p38 (#4511 lot 5), p38 (#9212 lot 20), phospho-S176/180 IKKα/β
(#2697 lot 16), phospho-S257/T261 MKK4 (#9156 lot 2), phospho-S189/207
MKK3/6 (#9236 lot 5 and #9231 lot 9), MKK3 (#5674 lot 1), MKK6 (#9264 lot
2), eEF2 (#2332 lot 5), phospho-T56 eEF2 (#2331 lot 7), RSK2 (#9340 lot 1),
phospho-S380 p90RSK (#9341 lot 8) and phospho-T573 p90RSK (#9346 lot 4) all
fromCell Signaling Technology (USA); MEK1/2 (9G3) (#sc-81504 lot E0911), TPL-
2 (H-7) (#sc-373677 lot F1112), and MKK4 (#sc-837 lot E077), all from Santa Cruz
Biotechnology (USA); α-tubulin (produced in-house from a clone kindly provided
by Keith Gull, University of Oxford, UK) was used as a loading control protein
for whole cell lysates. Secondary antibodies used were goat anti-rabbit and goat
anti-mouse (#4050-05 and #1010-05 respectively, Southern Biotech, USA) con-
jugated to horse radish peroxidase.
3.6 Flow cytometry
On day 7 of culture SILAC labelled and unlabelled BMDM were collected from
culture dishes by incubating with Dulbecco’s PBS/2.5 mM EDTA for 10 mins at 37
ºC. They were then counted using the CASY® Technology Cell Counter. Approx-
imately 5 x 106 BMDM cells per condition were washed with PBS/3 mM sodium
azide/1 % FCS. They were then incubated in 100 μl 24G2 Fc receptor blocker (in
house) diluted 1/10 in PBS Azide/1 % FCS for 15 mins on ice in order to block
the Fc receptors on the cell surface. The Fc receptor blocker was washed off
and then the cells were incubated with 100 μl anti-F4/80 antibody coupled to the
fluorophore APC (#17-4801 lot, E07285-1634) from eBioscience (USA) which had
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been diluted 1/200 in PBS Azide/1 % FCS on ice with protection from light. After
incubating for at least 20 mins the antibody was washed off and the cells were
resuspended in 300 μl 7-amino-actinomycin D (7-AAD, in house) diluted 1/200 in
PBS Azide/1 % FCS. Levels of F4/80 on the cell surface were measured on the
FACSCalibur™ (BD Biosciences, USA) and analysed using FlowJo v8.8.7 (USA).
Dead cells were excluded based on forward scatter and presence of 7-AAD stain-
ing.
3.7 Sample preparation for mass spectrometry
Carried out by Dr. Helen Flynn and Dr. Bram Snijders at The Francis Crick Insti-
tute, Clare Hall Laboratory.
3.7.1 Protein digestion
Lysates were reduced with 7 μl 1 M dithiothreitol (DTT) for 25 mins at 56 °C and
then alkylated in the dark with 14 μl 1 M iodoacetamide for 30 mins at room tem-
perature. This reaction was quenched with a further 7 μl 1 M DTT. Lysates were
diluted with 6 ml 50 mM ammonium bicarbonate (pH 8) to reduce the urea concen-
tration to 2 M. To digest proteins into peptides, sequencing grade porcine trypsin
(#V5280, Promega, USA) was added at 1:50 (based on protein concentrations)
and incubated overnight at 37 °C. 24 μl trifluoroacetic acid (TFA) was then added
to give a final concentration of 0.4 % and samples were centrifuged for 5 mins at
3,220 x g. Supernatants were filtered through 0.22 μm filters.
To desalt samples, C18 Sep Pak Lite columns with 130 mg bed volume (Wa-
ters, USA) were used with a vacuum manifold set at -1 psi to pass each solution
slowly through the solid phase extraction cartridge. Columns were washed with
3.2 ml acetonitrile, conditioned with 1.1 ml 50 % acetonitrile, 0.5 % acetic acid and
then equilibrated using 3.2 ml 0.1 % TFA. Loaded samples were desalted using
3.2 ml 0.1 % TFA followed by washing with 325 μl 0.5 % acetic acid. 1.8 ml 50 %
acetonitrile, 0.5 % acetic acid (vacuum pressures up to -5 psi) was used to elute
samples. A 10 μl aliquot of each eluate was used to evaluate the efficiency of the
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digest by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and the
remainder was dried by vacuum centrifugation.
Dried samples were then resuspended by adding 50 μl 50 mM ammonium bi-
carbonate, 10 % acetonitrile and sonicating. A further 100 μl of 50 mM ammonium
bicarbonate, 10 % acetonitrile containing 5 μg of Lys-C (#V1671, Promega, USA)
was added to the samples, which were then mixed vigorously and incubated for 2
hours at 37 °C. Sequencing grade porcine trypsin (#V5280, Promega, USA) was
added to each and incubated overnight at 37 °C. 1.75 ml 0.5 % TFA was added
to the digested samples which were then vortexed and sonicated before centrifu-
gation at 20,817 x g. Supernatants were then filtered through 0.22 μm filters and
then desalted using C18 Sep-Pak® Lite columns with 130 mg bed volume with a
vacuum manifold, as described above. As previously, 10 μl aliquots were taken
to evaluate the digest by LC-MS/MS and the remaining samples were dried by
vacuum centrifugation.
3.7.2 Phosphopeptide enrichment
Strong cation exchange fractionation
Samples were fractionated by strong cation exchange (SCX) to reduce the com-
plexity of each fraction. This was done using an Agilent Technologies (USA) liquid
chromatography systemwith a PolySULFOETHYL A™ column (100 x 4.6 mm, av-
erage particle size 5 μm, average pore size 200 Å) (Poly LC, USA). Samples were
resuspended in 110 μl SCX buffer A, sonicated for 15 mins and then centrifuged
at 20,817 x g for 5 mins prior to injection. Samples were separated over a 10 min
gradient to 80 % SCX buffer B with a flow rate of 1 ml/min. Six fractions of 2 ml
were collected, starting 1 min after injection. Between each sample, the column
was washed with 100 % buffer B and re-equilibrated for 15 mins. All fractions
were dried by vacuum centrifugation.
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Titanium dioxide enrichment
SCX fractions were solubilised in 1 ml 80 % acetonitrile, 5 % TFA, 1 M glycolic
acid and sonicated for 10 mins. Each fraction was then added to 5 mg of titanium
dioxide beads (GL Sciences, Japan) and mixed thoroughly to resuspend. Peptide
samples and beads were incubated for 10 mins with shaking at 1400 rpm on the
thermomixer at room temperature to allow phospho-peptides to bind to the beads.
Beads were pelleted by centrifugation at 1,000 x g for 1 min. Supernatants con-
taining non-phosphorylated peptides were carefully aspirated without disturbing
the beads.
For the first wash step, 150 μl 80 % acetonitrile, 5 % TFA, 1 M glycolic acid
was added to the beads and samples were incubated for 10 mins with shaking at
room temperature. Beads were pelleted by centrifugation at 1,000 x g for 1 min
and the supernatant discarded. 150 μl of 80 % acetonitrile, 1 % TFA was added
to the beads for the second wash step and samples were incubated for 10 mins
with shaking at room temperature. Beads were pelleted by centrifugation at 1,000
x g for 1 min and the supernatant discarded. 150 μl of 10 % acetonitrile, 0.2 %
TFA was added to the beads for the third wash step. Samples were incubated for
10 mins with shaking at room temperature, the beads pelleted by centrifugation at
1,000 x g for 1 min and supernatant discarded. Any remaining supernatant was
removed by drying in a vacuum centrifuge.
In order to elute the phosphopeptides 100 μl 1 % ammonium hydroxide was
added followed by incubation for 10 mins with shaking at room temperature. Elu-
ate was removed and transferred to a fresh tube. A second elution was then done
using 100 μl 5 % ammonium hydroxide and incubating for 10 mins with shaking
at room temperature. Eluate was collected and combined with that from the first
elution. The combined eluate was then filtered through C8 material to remove any
remaining beads. The C8 material was washed with 50 μl 60 % acetonitrile which
was collected ensure good recovery of peptides. Finally, samples were dried by
vacuum centrifugation.
76
Sample clean-up
200 μl tips packed with an Empore C18 membrane (3M, USA) were washed with
100 μl methanol and centrifuged for 2 mins (425 - 1700 x g). 200 μl 1 % TFA was
then used to equilibrate the C18 tips followed by centrifugation for 3 mins. The
enriched phosphopeptides were resuspended in 100 μl 1 % TFA by sonicating for
15 mins and loaded onto the C18 tips by centrifugation (3 mins). C18 tips were
washed 4 times by addition of 300 μl 1 % TFA and centrifugation (4 mins). Phos-
phopeptides were eluted with 50 μl 80 % acetonitrile, 5 % TFA by centrifugation
at for 2 mins and dried by vacuum centrifugation.
3.7.3 Liquid chromatography-tandem mass spectrometry
Each phosphopeptide fraction was resuspended in 35 μl 1 % TFA and sonicated
for 15 mins. 10 μl of each sample was injected onto a PepMap™ 100 C18 pre-
column (5 mm x 300 μm, average particle size 5 μm and pore size 100 Å; Thermo
Fisher Scientific, USA) followed by an EASY-Spray™ PepMap RSLC C18 ana-
lytical column (50 cm x 75 μm, average particle size 2 μm and pore size 100 Å;
Thermo Fisher Scientific, USA). Phosphopeptides were eluted over a 3 hour multi-
step gradient using LC-MS/MS buffers A and B increasing from 2 % to 90 % buf-
fer B. Samples were injected onto an LTQ-Orbitrap Velos™ mass spectrometer
(Thermo Fisher Scientific, USA) in triplicate using a different activation method
(collision induced dissociation - CID, multi-stage activation - MSA or higher en-
ergy collisional dissociation - HCD) for each replicate. In each case the top 10
most abundant phosphopeptides were fragmented for identification.
3.8 Phosphoproteomic data processing and analysis
3.8.1 Spike-in SILAC
The raw mass spectrometry files were analysed using MaxQuant v1.3.0.5 soft-
ware (Cox and Mann, 2008) to identify and quantify the phosphopeptides present.
The obtained spectra were searched against mouse (Mus musculus) proteome
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sequences obtained from the UniProt database (Magrane and Consortium, 2011,
accessed 14/3/11) concatenated with a list of common contaminants. In addi-
tion, the spectra were searched against a decoy database of reverse peptide
sequences to gauge the number of false positive identifications present in the
dataset. The list of identified phosphopeptides was truncated using a 1 % false
discovery rate (FDR) cutoff (determined by matches in the reverse sequence
decoy database). For sites found on multi-phosphorylated peptides, the least
modified peptide ratio was reported. From the MaxQuant output, the “Phospho
(STY)Sites” table was uploaded into the Perseus v1.2 analysis program (Cox and
Mann, 2012). The ratios were logarithmically transformed with a base of 2 in or-
der to distribute the ratios between zero and 1 evenly with those of 1 and greater.
The log ratios for the RAW264.7 vs TPL-2D270A were then subtracted from the log
ratios for RAW264.7 vs PD0325901-treated wild type in order to produce a ratio-
of-ratios, the values of which represent the relative phosphopeptide level between
wild type and TPL-2D270A. The intensities were logarithmically transformed with a
base of 10.
The identified phospho-sites were annotated with further information includ-
ing Gene Ontology protein annotations (Ashburner et al., 2000, v1.2, accessed
22/9/11), known phosphorylation sites and regulatory kinases downloaded from
the PhosphoSitePlus® database (www.phosphosite.org, Hornbeck et al., 2012
accessed 9/6/12), and information on whether the site conforms to the known se-
quence motifs of various kinases. In order to identify proteins that were likely to
be regulated by TPL-2, the built-in Perseus test, Significance B was used with a
p-value cutoff of 0.05. This test is based on z-statistics for identifying outliers from
the mean in a normal distribution. A posterior error probability (PEP) cutoff of 1 x
10-5was used to remove poor quality peptide identifications.
3.8.2 Standard SILAC
The raw mass spectrometry data were processed using MaxQuant v1.3.0.5 and
Perseus v1.4.0.2 software (Cox and Mann, 2008, 2012). A 1 % FDR cutoff and 1 x
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10-5 PEP cutoff were used and the least modified peptide ratio was reported. For
one member of each pair of label reversal mixes the ratios were inverted in order
to simplify what changes in each direction mean for the level of phosphorylation of
a particular site; this was achieved by dividing 1 by the ratio for each phosphosite.
The ratios were logarithmically transformed with a base of 2 in order to distribute
the ratios between zero and 1 evenly with those of 1 and greater. The intensities
were logarithmically transformed with a base of 10.
The identified phosphosites were annotated with further information including
Gene Ontology (GO) Slim annotations (Ashburner et al., 2000, v1.2, accessed
22/9/11), known phosphorylation sites and regulatory kinases downloaded from
the PhosphoSitePlus® database (www.phosphosite.org, Hornbeck et al., 2012
accessed 3/6/13 and 25/11/13 respectively), and information on whether the site
conforms to the known sequencemotifs of various kinases. In addition, consensus
motifs for TPL-2 were added (Ley Laboratory, unpublished data and Parikh et al.,
2009). The built in Perseus test, Significance B, was used to identify significant
outliers with a p-value of 0.01 in each of the mixes. Phosphosites that were B
significant in both mixes of a label reversal pair (e.g. heavy-labelled wild type
versus light-labelled mutant and heavy-labelled mutant versus light-labelled wild
type) and were showing a consistent (positive or negative) response between the
mixes were considered to be likely candidates for TPL-2-dependent phosphoryla-
tion sites.
3.8.3 Bioinformatics analysis
To determine significantly enriched GO cell compartment Slim terms, annotations
in the phosphoproteomics dataset were compared against the annotations of all
genes expressed by mouse BMDM (Ley laboratory, unpublished data) using the
Chi2 test with p value cut-off of 0.05. Enrichment of GO biological process terms
was determined by comparison with the entire dataset of phosphopeptides iden-
tified in this study, using the DAVID bioinformatics resource functional annotation
enrichment tool (Huang et al., 2008, 2009) with a p-value cut-off of 0.02.
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3.9 Immunoprecipitation
3.9.1 MKK3, MKK4 and MKK6
Cells were lysed in 500 μl HEPES Lysis Buffer per 14 cm dish. Lysates were
clarified by centrifugation at 21,100 x g for 15 mins and protein concentrations
determined by Pierce™ BCA assay. Lysate concentrations were equalised to 2
mg/ml by addition of lysis buffer and 1 mg of protein lysate from each condition
was added to 10 μl packed Protein A Sepharose™ 4 Fast Flow beads (GE Health-
care, UK) covalently coupled to antibodies against either MKK3, MKK4 or MKK6
(#9238 lot 1, #9152 lot 3 and #8550 lot 1 respectively, Cell Signaling Technology,
USA) which had been washed in HEPES Lysis Buffer. The beads and lysate were
incubated for 3 hrs at 4 ºC with shaking at 1,000 rpm. The beads were pelleted
by centrifugation at 100 x g for 5 mins and the supernatant collected for west-
ern blotting. The beads were then washed 3 times with 500 μl of HEPES Lysis
Buffer followed by elution of bound protein using 1 bead volume of non-reducing
Laemmli buffer.
3.9.2 p38γ/δ
p38γ (SAPK3) and p38δ (SAPK4) were immunoprecipitated from BMDM following
a method described in Risco et al. (2012) with minor modifications. 120 x 106
cells per condition were lysed in Lysis Buffer A. The protein concentration in the
lysates was determined by Pierce™ reducing agent-compatible BCA assay and
concentrations were adjusted to 3.75 mg/ml with the lysis buffer. 10 μl of Protein
G Sepharose™ 4 Fast Flow beads (GE Healthcare, UK) were coupled to 10 μg
of antibody per condition by shaking for 30 min at 4 ºC. The antibodies were anti-
SAPK3 (352-367) S476 2nd bleed and anti-SAPK4 (353-365) S580 2nd bleed
(Dundee University, UK). 15 mg of protein per condition was added to 10 μl of anti-
p38γ coupled beads and incubated on a rotor for 2 hours at 4 ºC. The supernatant
from the first immunoprecipitation was added to 10 μl of anti-p38δ coupled beads
and incubated on a rotor for a further 2 hours at 4 ºC. All beads were washed twice
in Lysis Buffer A with 0.5MNaCl and twice with Lysis Buffer A alone. Proteins were
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eluted by boiling in 1 bead volume of Laemmli buffer without 2-mercaptoethanol.
3.10 In vitro kinase assays
Unactive recombinant MBP-MKK6 and inactive GST-MEK1 was obtained from
Dundee University (UK). Recombinant NFκB1 p105/ABIN-2/TPL-2 and NFκB1
p105ΔDD/ABIN-2/TPL-2 complexes were produced in the Ley laboratory. 4 nM
TPL-2 complex ± NFκB1 p105DD, 200 nM MBP-MKK6 or GST-MEK1 and 200
μM ATP were mixed in a final reaction volume of 40 μl using Kinase Assay Buf-
fer (section 3.1). The reactions were incubated at room temperature for 1 hour
to allow phosphorylation to proceed. Identical control reactions were incubated
on ice. Reaction mixtures were resolved by SDS-PAGE and western blotted for
phospho/total-MKK6 or phospho/total-MEK1/2.
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4 Development of Phosphoproteomics for Primary
Macrophages
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4.1 Introduction
To identify TPL-2 regulated signalling pathways, a suitable cellular system was
needed. As TPL-2 is essential for TLR activation of the ERK1/2 MAP kinase
pathway and induction of the pro-inflammatory cytokine TNFα in macrophages,
we chose to use in vitro cultured bone marrow-derived macrophages (BMDM)
for all experiments. This widely used model system has the added advantage
of providing a large quantity of homogeneous cells, a requirement for biochem-
ical studies. In addition, genetic and pharmacological tools allowed the selective
manipulation of TPL-2 and ERK1/2 signalling in this cell type.
4.1.1 Map3k8D270A/D270A mice
As discussed earlier, TPL-2 forms a complex with NFκB1 p105 and ABIN-2 in
unstimulated cells and this is essential for maintenance of TPL-2 stability (Beinke
et al., 2003; Papoutsopoulou et al., 2006). BMDM from TPL-2-deficient also have
substantially reduced ABIN-2 levels suggesting a reciprocal relationship where
TPL-2 stabilises ABIN-2 (Sriskantharajah et al., 2014). Although no function has
yet been attributed to ABIN-2, TPL-2 “kinase dead” (Map3k8D270A/D270A) mice were
generated in the Ley laboratory to eliminate any possible confounding effects of
altered ABIN-2 levels. These mice express TPL-2 and ABIN-2 at levels similar to
the wild type (Sriskantharajah et al., 2014) but the mutation of aspartate (D) 270 to
alanine (A) renders TPL-2 catalytically inactive (Salmeron et al., 1996). Asp270
lies in the conserved aspartate-phenylalanine-glycine (DFG) motif in the TPL-2
kinase domain and its mutation disrupts binding of the metal cofactor necessary
for catalytic activity, preventing phosphorylation of substrates (Kornev et al., 2006;
Duong-Ly and Peterson, 2013).
4.1.2 PD0325901 inhibitor
A small molecule inhibitor developed by Pfizer (USA), PD0325901, was the most
potent MEK1/2 inhibitor available at the time of this study (Barrett et al., 2008).
This compound is a non-ATP-competitive inhibitor which binds the inactive form
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of MEK1/2 and prevents its activation, similar to the earlier MEK1/2 inhibitor,
PD98059 from which it was derived. The IC50 for inhibition of MEK1 by this com-
pound in vitro has been shown to be close to 1 μM and even lower in cells (Bain
et al., 2007). Activation of ERK1/2 (as a read out of MEK1/2 activity) is inhibited
using concentrations of PD0325901 as low as 25 nM in EGF-stimulated HeLa
cells with minimal effects on other kinases at these sub-μM concentrations.
To test the effects of these tools on TPL-2 signalling pathways in an unbiased
manner, it was decided to use mass spectrometry-based phosphoproteomic ana-
lysis of BMDM. It was first necessary to establish a method by which different
conditions could be relatively quantified to yield the most reliable and accurate
data. To this end, the use of SILAC labelling was investigated which allows direct
comparison of two conditions in a physiological setting.
4.2 Can primary bonemarrow derivedmacrophages be SILAC
labelled?
Due to the strengths of SILAC labelling for accurate relative quantification of phos-
phopeptides (detailed above), a SILAC/mass spectrometry approach was taken
for this study. SILAC labelling and phosphoproteomic analysis of BMDM was first
published by the group of Prof. Matthias Mann (Weintz et al., 2010). In this study,
a cocktail of cytokines was used to maintain bone marrow stem cells in an un-
differentiated state for 13 days, to allow them to undergo multiple cell divisions
and incorporate labelled amino acids, prior to differentiation using L929-cell con-
ditioned medium (LCCM) for 3 days. Using this method, incorporation levels of 90
- 95 % could be achieved. Initially this protocol was implemented as described.
However, it soon became apparent that bone marrow precursors were not surviv-
ing under these altered culture conditions. The most likely explanation for this was
the use of FCS dialysed at 5 kDa MWCO, which lacked unlabelled amino acids
but also potentially other low molecular weight components required to maintain
cell viability. Comparison of cell numbers throughout the culture protocol con-
firmed that supplementation of medium with dialysed FCS could not support cell
84
expansion, in contrast to whole serum control (figure 4.1).
Figure 4.1: FCS dialysed at a MWCO of 5,000 Da does not support the expan-
sion of bone marrow precursors into bone marrow derived macrophages.
Bone marrow cells were cultured in SILAC media supplemented with either whole
or 5,000 Da MWCO dialysed FCS. Cells were subcultured and counted every 3
days. Two independent experiments, significance determined by multiple t-tests
with multiple comparison testing by the Holm-Sidak method, * = p < 0.05.
4.3 Is there an alternative if BMDM cannot be labelled?
4.3.1 Spike-in SILAC
Spike-in SILAC is a variation on the SILAC labelling technology which is particu-
larly useful for samples that are difficult or impossible to label such as non-dividing
primary cells or human tissue samples including cancer samples (Geiger et al.,
2010). Spike-in SILAC uses metabolic labelling of a cell line to produce internal
standards for the whole proteome of a cell population (Geiger et al., 2011). A
cell line similar to the target cells of interest is labelled with stable carbon and ni-
trogen isotopes using SILAC and a pool of lysate is generated from this cell line
(figure 4.2). This pool of lysate is then “spiked” into unlabelled test cell lysates.
As long as the same spike-in lysate is used for all test conditions, the test cell
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phosphoproteomes can be compared by calculating a ratio-of-ratios. Generat-
ing a ratio-of-ratios effectively eliminates the contribution of the spike-in values
leaving a value for the relative expression between the different test conditions.
Figure 4.2: The spike-in SILAC approach.
A cell line (e.g. RAW264.7 macrophages) similar to the cells of interest is labelled
by SILAC, expanded, left unstimulated or stimulated with LPS and then lysed to
give amixture of ”heavy”-labelled proteins, compositionally similar to the proteome
of the cells to be investigated. This labelled “spike” lysate, from the 50:50 mixture
of LPS stimulated and unstimulated ”heavy”-labelled RAW264.7 cells, can then
be mixed with lysates from unlabelled test cells (e.g. BMDM from wild type or
TPL-2D270A), to provide the SILAC pairs for relative quantification of peptide levels
in the test lysate. For each phosphopeptide, a ratio is calculated between the test
condition and the spike lysate that allows comparison of phosphopeptide levels
between different test conditions. [Adapted from Monetti et al. (2011)]
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Table 4.1: Strengths and weaknesses of the spike-in SILAC approach.
Strengths Weaknesses
Test cells are not labelled; their
biology is normal and comparable to
previous experiments.
Calculating a ratio-of-ratios
compounds errors.
Possible to compare many conditions
if sufficient spike-in lysate.
Protein sequences must be identical
between the spike-in and the test
cells.
Can be used for in vivo samples,
non-dividing cells or those which are
sensitive to SILAC culture conditions.
Missing data are common as
peptides must be found in 2 different
mixes to give one ratio-of-ratios.
RAW264.7 cell line
The RAW264.7 cell line is a macrophage cell line, which was derived in 1978
from a Abelson murine leukaemia virus-transformed tumour in a male BAB/14
mouse (Raschke et al., 1978) and is commonly used to studymacrophage biology.
Although the strain differs from that used here for generation of BMDM (C57BL/6),
it is likely that the characteristics of RAW264.7 cells will be sufficiently similar to
BMDM to allow quantification of the majority of the phosphopeptides of interest.
Furthermore RAW264.7 cells have previously been SILAC-labelled by Clark et al.
(2012) to investigate the biology of macrophages by phosphoproteomic analysis.
Consistent with this, the RAW264.7 cells used here were successfully labelled to
roughly 98 % incorporation.
Can RAW264.7 cells be used to quantify BMDM peptides?
To quantify all of the phospho-peptides present in BMDM, RAW264.7 cells must
contain all the same phospho-peptides. For this reason, the response of unla-
belled and SILAC-labelled RAW264.7 cells to LPS stimulation was checked (fig-
ure 4.3). LPS activation of ERK1/2 and JNK MAP kinases was found to be normal
in SILAC-labelled RAW264.7 cells compared to unlabelled cells. Furthermore,
LPS induction of these phosphorylations in SILAC labelled RAW264.7 cells was
similar to that of unlabelled BMDM stimulated with LPS (Beinke et al., 2004).
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Having confirmed that known TPL-2-dependent phosphorylations in ERK1/2
were also present in RAW264.7 cells, it was possible to use these cells for the
spike-in lysate to enable quantification of different conditions in BMDM. To fully
maximise the coverage of the primary BMDM phosphoproteome, both stimulated
and unstimulated RAW264.7 cell lysates were included in the spike-in lysate.
Figure 4.3: Unlabelled and SILAC labelled RAW264.7 cell responses to LPS
are comparable and similar to those of BMDM.
RAW264.7 cells were SILAC labelled or left unlabelled, wild type BMDM were
generated under unlabelled culture conditions. Cells were left unstimulated or
stimulated with 100 ng/ml LPS for the indicated times before lysis. Proteins were
separated by gel electrophoresis and transferred to PVDF membranes, followed
by immunoblotting with the indicated antibodies. Representative of 3 independent
experiments.
4.3.2 Can TPL-2-dependent phosphorylations be identified by spike-in
SILAC?
A single spike in lysate was created from heavy-labelled RAW264.7 cells stimu-
lated and lysed in 3 equal batches over 7 days. Using this one spike-in lysate,
phosphoproteomics experiments were done using test lysates from a pool of 3
mice each for wild type, MEK1/2 inhibitor-treated and TPL-2 kinase dead BMDM.
These conditions allowed comparison of the absence of TPL-2 activity with the
absence of ERK1/2 activity from which TPL-2-dependent, ERK1/2-independent
phosphorylations could be inferred. These interventions could also be compared
with the control situation in wild type macrophages to ensure the phosphorylation
was being affected specifically by the applied perturbation.
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In order to assess the spike-in SILACmethod, we first looked at the distribution
of phosphopeptide ratios in the data. From ratio versus intensity scatterplots, it
could be seen that the RAW264.7 and BMDMphosphoproteomes overlapped sub-
stantially as a ratio was found for large numbers of peptides (8,149 for RAW264.7
versus wild type, 9,022 for RAW264.7 versus PD0325901-treated wild type, 9,971
for RAW264.7 versusMap3k8D270A/D270A). Thus, through the presence of the same
peptides in both RAW264.7 and BMDM lysates, many phosphopeptides from the
different BMDM conditions could be compared (figure 4.4). The RAW264.7 and
wild type BMDM proteins do however display a large degree of variability in their
phosphorylation status as seen through the wide distribution along the x-axis in
figure 4.4A. However, after calculating the ratio-of-ratios, the consensus between
phosphorylation status in the different BMDM phosphoproteomes was shown to
be greater than with the RAW264.7 cells as indicated by a much narrower distri-
bution for the ratios of ratios along the x-axis of figure 4.4B; this illustrates how
the spike-in SILAC approach can work by cancelling out the contribution of the
RAW264.7 peptides.
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Figure 4.4: Comparison of the phosphoproteomes of RAW264.7 cells and
BMDM.
A: Unlabelled WT and K8R10 SILAC-labelled RAW264.7 lysates were compared
by mass spectrometry. X-axis shows Log2 ratio comparing RAW264.7 cell lys-
ates with wild type BMDM lysates; y-axis shows Log10 intensity for each identi-
fied phosphopeptide in this comparison. B: Ratio-of-ratios was calculated from 2
BMDM versus RAW264.7 comparisons to give a relative quantification between
PD0325901-treated WT and Map3k8D270A/D270A BMDM. X-axis shows the ratio-
of-ratios comparing MEK1/2 inhibitor-treated wild type with Map3k8D270A/D270A
BMDM; y-axis shows Log10 intensity for each identified phosphopeptide in the
RAW264.7 versus MEK1/2 inhibitor-treated wild type BMDM. BMDM lysates gen-
erated from a pool of 3 individual mice per condition. WT = wild type, RAW =
RAW264.7 cells, PD0325901 = MEK1/2 inhibitor treated wild type BMDM, D270A
= Map3k8D270A/D270A BMDM.
Potential TPL-2-regulated phosphorylations were identified as significant out-
liers using z-statistics, which allows identification of points which deviate from
the mean value of a normal distribution (figure 4.5). This identified 1,042 pos-
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sible TPL-2-dependent, ERK1/2-independent phosphorylation sites, which was
reduced to 839 sites by removing those for which the protein had a low iden-
tification score (PEP > 1 x 10-5). The behaviour of the known TPL-2-dependent
phosphorylations in the activation loops of MEK1/2 and ERK1/2 was used to verify
that the detected phosphosites were behaving as expected (figure 4.6). MEK1/2
can be phosphorylated on its activating sites in the presence of the MEK1/2 inhib-
itor, but not in the absence of TPL-2 kinase activity, and a MEK1/2 activation loop
phosphorylation was visible by its presence as a significant outlier to the left hand
side in the distribution of ratio-of-ratios (p = 2.80 x 10-20). It was also present in
the top 10 largest ratio-of-ratios that show TPL-2 dependence (table 4.2). Phos-
phorylation of ERK1/2 activating sites on the other hand was not expected to be
induced in either MEK1/2 inhibitor-treated or TPL-2 kinase dead conditions; there-
fore these sites should not have varied from the mean of the distribution, where
unchanging phosphorylations (the majority of sites) fell. The data did follow this
trend, although there was a slight deviation towards lower ratios for two of the
three ERK1/2 activating sites. This may be because the block in ERK1/2 phos-
phorylation was incomplete using the small molecule inhibitor whereas the genetic
blockade was complete.
Overall, analysis of the MEK1/2 and ERK1/2 internal controls confirmed
that the spike-in SILAC technique could identify regulated phosphorylation sites.
There is however a drawback with this comparison in that off-target effects of the
MEK1/2 inhibitor were not controlled for and, due to their presence in only one
side of the comparison, could potentially be false positives in the TPL-2-regulated
sites. These off-target effects have been shown to include inhibition of JAK activity
by experiments at GlaxoSmithKline (Dr. David Powell, personal communication).
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Figure 4.5: Phosphosites showing significant deviation from the average
ratio.
A ratio-of-ratios was calculated from 2 BMDM versus RAW264.7 compar-
isons to give a relative quantification between PD0325901-treated WT and
Map3k8D270A/D270A BMDM lysates. The Perseus algorithm, “B significance”, based
on z-statistics for identifying outliers from a normal distribution, was used to
identify significant outliers in the comparison of PD0325901-treated wild type
and Map3k8D270A/D270A BMDM. Outliers significant at p < 0.01 are highlighted.
X-axis shows the ratio-of-ratios comparing MEK1/2 inhibitor-treated wild type
with Map3k8D270A/D270A BMDM; y-axis shows Log10 intensity of phosphopeptides
in the RAW264.7 comparison with MEK1/2 inhibitor-treated wild type BMDM.
BMDM lysates generated from a pool of 3 individual mice per condition. RAW =
RAW264.7 cells, PD0325901 = MEK1/2 inhibitor-treated wild type BMDM, D270A
= Map3k8D270A/D270A BMDM.
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Figure 4.6: The activation loop phosphorylations of MEK1/2 and ERK1/2 act
as internal controls.
A ratio-of-ratios was calculated from 2 BMDM versus RAW264.7 com-
parisons to give a relative quantification between PD0325901-treated WT
and Map3k8D270A/D270A BMDM. Activation loop phosphorylations from MEK1/2
(Map2k1 - S222) and ERK1/2 (Mapk3 - T203/Y205 - and Mapk1 - T183/Y185 -
respectively) are highlighted. X-axis shows the ratio-of-ratios comparing MEK1/2
inhibitor-treated wild type with Map3k8D270A/D270A BMDM; y-axis shows Log10 in-
tensity of phosphopeptides in the RAW264.7 comparison with MEK1/2 inhibitor-
treated wild type BMDM. BMDM lysates generated from a pool of 3 individual mice
per condition. RAW = RAW264.7 cells, PD0325901 = MEK1/2 inhibitor-treated
wild type BMDM, D270A = Map3k8D270A/D270A BMDM.
From the 839 phosphorylation sites, only the 403 sites with a negative ratio-
of-ratios were taken for subsequent analysis because these were reduced in the
absence of TPL-2 kinase activity and consequently more likely to be direct TPL-
2 substrates. At this stage, it became clear that a complication with interpret-
ing the data arose from the quantification of ratios where changes could have
been occurring in either the numerator or the denominator values. To establish
whether it was the PD0325901-treated wild type or the Map3k8D270A/D270A cells
which were showing a change in phosphorylation for each peptide, the original
RAW264.7/BMDM ratios were taken into account. This drastically reduced the list
to 74 potentially interesting phosphorylation sites, the top 15 of which are shown
in table 4.2. In addition, this list should be free from the risk of false positives res-
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ulting from the MEK1/2 inhibitor treatment mentioned above. Unfortunately this
analysis highlighted another difficulty with using spike-in SILAC to identify TPL-2
regulated pathways; there were 107 phosphosites from the list of 403 for which
it was not possible to say whether the changes were in the Map3k8D270A/D270A
or the PD0325901 inhibitor-treated wild type cells. These phosphopeptides had
not been detected in the RAW264.7 versus wild type experiment and therefore
did not have a measurement representing the unperturbed state against which
to compare the effect of the perturbations. This was indicative of a much wider
problem with the spike-in SILAC approach where, due to the need to calculate
the ratio-of-ratios from identification of the same peptide in two different BMDM
versus RAW264.7 comparisons, a large amount of data was being lost. As a fur-
ther illustration, from a total of 12,726 quantified sites across all conditions in this
study, only 7,273 sites could be compared between the Map3k8D270A/D270A and
the MEK1/2 inhibitor-treated conditions, clearly limiting the amount of useful data
that could be obtained with this approach (figure 4.7). Calculating this ratio-of-
ratios had the added drawback of compounding errors, making quantification less
accurate. This contrasted with standard SILAC where the comparison is made
within one sample and is thus more accurate and less susceptible to loss of data.
Although the spike-in SILAC yielded some useful results, this approach was not
taken further due to the problem of compounding errors as well as the loss of
useful data.
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Figure 4.7: The spike-in SILAC method leads to loss of data due to limited
overlap between mass spectrometry runs.
Three different unlabelled BMDM conditions were each compared with K8R10
SILAC-labelled RAW264.7 lysates by mass spectrometry. The overlap between
each of these comparisons is shown. TPL-2D270A = TPL-2 kinase dead,
PD0325901 = MEK1/2 inhibitor.
4.4 Optimisation of BMDM SILAC labelling
4.4.1 Can the Ley laboratory BMDM culture protocol be adapted for SILAC
labelling?
Due to the limitations with the spike-in SILAC protocol, we attempted to adapt the
standard Ley laboratory BMDM protocol for SILAC labelling. This 7 day protocol
is well established and reliably produces large numbers of differentiated BMDM.
In order to make it appropriate for SILAC labelling, both the FCS and the L929-
cell conditioned media (LCCM) were dialysed with a low molecular weight cut-off
(1 kDa and 2 kDa respectively). This lower cut-off should have removed amino
acids, yet retained more low molecular weight factors to promote BMDM genera-
tion than 5 kDa dialysis. Arginine and lysine were omitted from the basal media
and labelled versions were supplemented. Using this protocol, incorporation of
SILAC amino acids was tested over 10 days of culture to find the optimum cul-
ture length for greatest incorporation (figure 4.8). This showed that BMDM were
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successfully labelled to over 90 % after 6 days of culture, which was sufficient
to achieve good coverage in a phosphoproteomics experiment. A high degree
of incorporation is important to avoid skewing of the quantification between light-
labelled and heavy-labelled test conditions. After 6 days, the incorporation level
unexpectedly began to decline. This was difficult to explain because there was
no obvious source of unlabelled amino acids; media was changed rather than ad-
ded to when cells were fed in order to prevent re-incorporation. Additionally, from
inspection of the incorporation check mass spectrometry data, there was no evid-
ence of partial incorporation within individual peptides (Dr. Helen Flynn, personal
communication).
Based on these results, BMDM will be cultured under SILAC conditions for 6
days but not longer to ensure the maximum degree of labelling is achieved.
Figure 4.8: BMDM can incorporate SILAC amino acids to over 90 %.
BMDM were cultured under SILAC conditions using FCS dialysed at 1,000 Da
MWCO. Parallel cultures were lysed every 2 days and their percentage incorpor-
ation of “heavy” amino acids determined by mass spectrometry. Mean and stand-
ard deviation of all identified peptides from 4 separate cultures in 2 independent
experiments.
4.4.2 Are SILAC-labelled cells comparable to unlabelled BMDM?
As the culture conditions for SILACwere non-standard, it was necessary to ensure
that the biology of the cells was comparable to BMDM produced using the normal
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Ley laboratory methodology. As mentioned above, the medium is supplemented
with 2 kDa dialysed LCCM which contains a mixture of growth factors which drive
differentiation of stem cells towards a macrophage phenotype. However, dialysis
could have removed low molecular weight factors necessary for normal BMDM
differentiation. Flow cytometric analysis determined that the percentage of cells
expressing the macrophage marker, F4/80, was comparable between the stand-
ard culture protocol and the SILAC culture protocol (figure 4.9) suggesting that
the majority of cells being analysed were indeed macrophages. Another important
measure of normal biology was pathway activation in response to LPS stimulation.
SILAC “heavy”-labelled wild type BMDM showed similar activation of IKK2 and
phosphorylation of NFκB1 p105, known to be upstream of TPL-2/MEK1/2/ERK1/2
pathway activation, to unlabelled BMDM (figure 4.10). Activation of ERK1/2, p38α
and JNK MAP kinases were also comparable between labelled and unlabelled
cells. Furthermore, TPL-2 expression was normal after SILAC labelling wild type
BMDM. Therefore, in terms of differentiation and response to stimulation, SILAC
BMDM were comparable to unlabelled BMDM and could be used for phosphop-
roteomic comparisons to identify TPL-2-regulated signalling pathways.
Figure 4.9: Differentiation of BMDM is normal in SILAC conditions.
BMDM were cultured for 6 days under normal or K8R10 SILAC conditions. Cells
were detached using Dulbecco’s PBS/2.5 mM EDTA and stained with APC-
conjugated anti-F4/80 antibodies and 7-amino-actinomycin D. Cells were ana-
lysed by flow cytometry. Dead cells were excluded based on forward scatter and
presence of 7-AAD staining. Mean and standard deviation of 6-9 replicate cultures
from 3 independent experiments.
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Figure 4.10: Unlabelled and SILAC labelled BMDM show similar responses
to LPS stimulation.
BMDM were cultured for 6 days under either unlabelled conditions or K8R10
SILAC conditions with 1,000 Da MWCO dialysed FCS. Cells were left unstimu-
lated or stimulated with 100 ng/ml LPS for 15 or 30 minutes before lysis. Proteins
were separated by gel electrophoresis and transferred to PVDF membranes, fol-
lowed by immunoblotting with the indicated antibodies. Three technical replicates
shown; representative of 6 replicate cultures over 2 independent experiments.
4.5 Summary
To identify TPL-2-dependent signalling pathways, we developed a method to ana-
lyse the phosphoproteome of BMDM by mass spectrometry and SILAC labelling.
Initial experiments using a published SILAC labelling protocol for BMDM did not
support the differentiation and expansion of macrophages from bonemarrow stem
cells, due to the use of FCS dialysed at 5 kDa. Subsequently, an alternative spike-
in SILAC approach was evaluated in a pilot experiment, as it has the advantage
of labelling an established macrophage cell line, leaving the BMDM biology un-
altered. Using RAW264.7 cell lysate as the spike-in standard, a comparison was
made between MEK1/2 inhibitor-treated wild type and TPL-2 kinase dead BMDM
producing a large number of potentially TPL-2-regulated phosphorylations. This
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method was validated using the known TPL-2-dependent phosphosites in MEK1/2
and ERK1/2. However, there were limitations; in particular the loss of data vastly
reduced coverage of the phosphoproteome and subsequently the chances of
identifying TPL-2-regulated pathways. This could be overcome to some extent
by increasing the lysate fractionation during phosphopeptide enrichment and/or
increasing the mass spectrometry run time to identify as many phosphopeptides
as possible. However, we concluded that it was unlikely this would solve the prob-
lem completely given that mass spectrometric analyses only sampling a fraction
of the phosphoproteome (Boekhorst et al., 2011).
Having established that the use of 5 kDa dialysed FCS was a limiting factor
in the primary BMDM culture, a method for SILAC labelling was devised using 1
kDa dialysed FCS and a simpler culture protocol. In spite of reports that SILAC
conditions can alter cell biology (Imami et al., 2010), wild type BMDM appeared
to have normal biology after culture under SILAC conditions. However, it is not
possible to rule out that SILAC labelling subtly altered BMDM physiology. Using
this newly developed method for SILAC labelling of BMDM, it was now possible to
carry out mass spectrometric phosphoproteome analyses to identify TPL-2 regu-
lated pathways.
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5 Characterisation of the TPL-2 regulated phos-
phoproteome
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5.1 Introduction
Once a system for ensuring accurate relative quantification between different
BMDM lysates using SILAC had been established, TPL-2-regulated pathways
could be identified by mass spectrometry-based phosphoproteomics (table 5.1).
Pairwise comparisons between different perturbations to TPL-2 signalling were
made to identify regulated phosphorylation sites. For each pair of conditions, two
comparisons were made: a forward comparison and a label reversal comparison,
where the condition which was “heavy”-labelled in the forward experiment was
instead “light”-labelled and vice versa. This controlled for any phosphorylations
that were altered by the presence of the “heavy”-labelled amino acids, as well as
providing a biological replicate.
Each condition consisted of a pool of BMDM lysate from 6-7 mice which were
cultured in 2-3 separate groups. This method of controlling for biological vari-
ation was chosen in preference to carrying out multiple mass spectrometry runs
with lysates from individual mice. Due to the stochastic nature of phosphopeptide
sampling, the degree of overlap between replicate mass spectrometry analyses
of the same sample can be as low as 50 % (Gauci et al., 2009). Prior to pooling,
all lysates were checked individually by immunoblotting to confirm ERK1/2 MAP
kinase activation in response to LPS stimulation. In addition, mass spectrometry
determined the percentage incorporation of labelled amino acids and conversion
between proline and arginine, as these factors can affect phosphopeptide quan-
tification. All heavy-labelled BMDM lysates had incorporation greater than 89 %
and low arginine/proline conversion.
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Table 5.1: Phosphoproteomics experimental design table
Comparisons highlighted blue were made in the spike-in SILAC experiment, those
in red were compared in the standard SILAC experiment. K0R0 = ”light” label,
K8R10 = ”heavy” label, PD0325901 = MEK1/2 inhibitor.
5.2 Identification of TPL-2-dependent phosphorylations and
indirect removal of ERK1/2-dependent sites
5.2.1 Internal variation in the SILAC-labelled BMDM system
In order to gauge the intrinsic variation in the system, a comparison was first made
between “light”-labelled and “heavy”-labelled wild type BMDM. The narrow distri-
bution of the phosphopeptides identified in this comparison showed that few phos-
phorylations differed between the labelled and unlabelled conditions, as expected
in these equivalent conditions (figure 5.1). Only a small fraction of phosphosites
showed variation from the mean ratio suggesting the impact of incompletely la-
belled low turnover proteins or changes in biology caused by the SILAC amino
acids was low. This was promising as it made it possible to detect smaller differ-
ences between the test conditions. A slight deviation of the mean away from zero,
towards negative ratios, suggested a bias for phosphopeptides to be present at
higher levels in the ”light”-labelled wild type BMDM. Although this could suggest
that the labelled amino acids reduced overall phosphorylation levels in the cells,
it is more likely that this was the result of label incorporation levels being between
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89 - 94 % and therefore incomplete. Whilst this prevented the value being used
for exact quantification of the difference between the compared conditions, it was
still possible to identify TPL-2 dependent phosphorylations by their variation from
the tight cluster of unregulated sites around this experimental mean.
Figure 5.1: Internal variation in the SILAC-labelled BMDM system.
Lysates fromK0R0 SILAC-labelledWT and K8R10 SILAC-labelledWT, stimulated
with 100 ng/ml LPS for 15 mins, were compared by mass spectrometry. X-axis
shows Log2 ratio comparing ”light”-labelled with ”heavy”-labelled wild type BMDM;
y-axis shows Log10 intensity of phosphopeptides in this comparison. Pearson
correlation factor = -0.026. WT = wild type BMDM.
5.2.2 Identification of TPL-2-dependent phosphorylations
To identify all the phosphorylations which were dependent on TPL-2 kinase activ-
ity, a comparison was made between wild type and Map3k8D270A/D270A BMDM,
which express kinase-inactive TPL-2. In this and all subsequent comparisons, a
positive Log2 ratio value indicated that the phosphorylation was potentially TPL-
2-dependent.
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Internal controls
An initial check of the known TPL-2 target phosphorylations, MEK1/2 and ERK1/2
activation loop residues, showed that these phosphorylations were outliers and
therefore differentially present between wild type and Map3k8D270A/D270A samples,
as expected (figure 5.2). This demonstrated that it was possible to identify TPL-
2-dependent phosphorylations from the global phosphoproteome.
Figure 5.2: Map3k8D270A/D270A mutation reduces activation loop phosphoryla-
tion of MEK1/2 and ERK1/2.
Lysates from SILAC-labelled WT and Map3k8D270A/D270A, stimulated with 100
ng/ml LPS for 15 mins, were compared by mass spectrometry in label reversal
experiments. Activation loop phosphorylations from MEK1/2 (Map2k1 - S222)
and ERK1/2 (Mapk3 - T203/Y205 - and Mapk1 - T183/Y185 - respectively) are
highlighted. X-axis shows Log2 ratio comparing wild type with Map3k8D270A/D270A
BMDM, y-axis shows the label reversal experiment of x-axis. Pearson correlation
factor = 0.43. Lysates generated from a pool of 6 individual mice per condition.
WT = wild type BMDM, D270A = TPL-2 kinase-inactive BMDM.
105
Mass spectrometric analyses of other published TPL-2 substrates
Several other TPL-2 substrates have been identified, largely be candidate-base
approaches (summarised in table 1.3). We next determined whether any of these
putative TPL-2 substrates were identified using our unbiased, mass spectrometry
approach. The previously reported target sites in eIF4BP1 and PLCβ3 were
present in the mass spectrometry dataset, but did not display TPL-2-dependent
regulation (figure 5.3). Other phosphopeptides for each of these proteins also
showed no TPL-2-dependent regulation. These results suggest that these pro-
teins are not regulated by TPL-2 catalytic activity in LPS-stimulated BMDM. The
phosphorylation sites were not determined in the original report showing TPL-2
phosphorylation of NFκB1 p105 so all identified phosphosites were analysed for
this protein. Residues Ser949 and Ser953 did show TPL-2-dependent regulation
(figure 5.4) which was consistent with previous reports indicating that TPL-2 can
phosphorylate NFκB1 p105 with which it is associated (Babu et al., 2006b; Robin-
son et al., 2007). As only LPS-stimulated samples were analysed, it was not clear
whether these phosphorylations were constitutive or inducible, or whether TPL-2
was phosphorylating these residues directly or indirectly via ERK1/2. Since these
phosphorylation sites on NFκB1 p105 are not known to be functionally important,
these possibilities were not investigated further.
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Figure 5.3: Phosphorylation of published TPL-2 target phosphosites in wild
type versus Map3k8D270A/D270A BMDM - localised sites.
Lysates from SILAC-labelled WT and Map3k8D270A/D270A BMDM, stimulated with
100 ng/ml LPS for 15 mins, were compared by mass spectrometry in label re-
versal experiments. The published TPL-2 target sites in eIF4BP1 and PLCβ3 are
highlighted. X-axis shows Log2 ratio comparing wild type with Map3k8D270A/D270A
BMDM; y-axis shows the Log2 ratio of the label reversal experiment. WT = wild
type BMDM, D270A = TPL-2 kinase-inactive BMDM.
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Figure 5.4: Phosphorylation of published TPL-2 target proteins in wild type
versus Map3k8D270A/D270A BMDM - non-localised sites.
Lysates from SILAC-labelled WT and Map3k8D270A/D270A BMDM, stimulated with
100 ng/ml LPS for 15mins, were compared bymass spectrometry in label reversal
experiments. All phosphorylation sites in NFκB1 p105 are highlighted. X-axis
shows Log2 ratio comparing wild type withMap3k8D270A/D270A BMDM; y-axis shows
the Log2 ratio of the label reversal experiment. WT = wild type BMDM, D270A =
TPL-2 kinase-inactive BMDM.
Identification of TPL-2 regulated phosphoproteins
In order to systematically identify TPL-2 regulated phosphorylations, z-statistics
was used to establish a list of significant outliers. This resulted in a total of 469
outlier phosphopeptides, which could be directly phosphorylated by TPL-2 or an
intermediate downstream kinase. Since this was a large number of proteins, it was
necessary to incorporate other data to shorten the list. A number of bioinformatic
approaches were taken, as detailed below:
• The Ley laboratory has previously shown that TPL-2 controls TNFα pro-
duction independently of ERK1/2 via some unknown substrate (Yang et al.,
2012). The list of outliers was searched for proteins annotated with Gene
Ontology (GO) terms (Ashburner et al., 2000, accessed 22/9/11) related to
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the production and release of TNFα; however none of the identified phos-
phoproteins were annotated with these terms.
• The consensus motif for TPL-2 has previously been determined in the Ley
laboratory (unpublished data) and this, along with a published TPL-2 con-
sensus sequence determined by another group (Parikh et al., 2009), was
used to search the sequences of the identified phosphopeptides. These
sequences were only matched in very few of the 16,769 identified phos-
phosites; 137 sites contained the loosest combination of preferred residues
determined in the Ley laboratory and 55 matched to the motif determined by
(Parikh et al., 2009). Sites that matched the TPL-2 sequence motif were not
enriched in the significant outliers compared to the background data (Chi2
p = 0.37) and in fact only one of the matched sites was a significant outlier
in both wild type versus TPL-2 kinase dead comparisons (from the protein
Ahnak). The use of TPL-2 consensus motifs, therefore, did not suggest any
direct targets for TPL-2.
• The Ley laboratory has generated an interactome dataset for the TPL-
2/ABIN-2/NFκB1 p105 complex when over-expressed in HEK293 cells (un-
published data). Proteins from the phosphoproteomics dataset that are
associated with TPL-2 are more likely to be direct substrates. Cross-
referencing this list with the 469 outliers from the current study found 12
matches (Ahnak, Bag3, CDK14, Crebbp, Ep300, Map2k3/Map2k6, NFκB1,
NFκB2, Sec16A, TNRC6B, Vim, YBX1). Although this comparison may ul-
timately help to identify direct TPL-2 substrates, these proteins were not
followed up at this stage because we did not want to exclude indirect phos-
phorylations that may indicate biological processes regulated by TPL-2.
• RNA sequencing experiments have identified TPL-2 regulated genes in
LPS-stimulated BMDM (Ley laboratory, unpublished data). Transcription
factor enrichment analysis on these data has identified a number of tran-
scription factors that are likely to be activated after 30 minutes of LPS stim-
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ulation. Of the 7 suggested transcription factors, only 2 were found in the
phosphoproteome dataset (CREB1 and SRF), but neither showed regula-
tion of the detected sites. However, few transcription factors were identified
in the TPL-2-dependent phosphoproteome as a whole, probably due to their
low abundance.
Ultimately, given the length of the list and absence of leads from current inform-
ation about TPL-2 biology, it was not possible to gain any further insights on the
downstream signalling of TPL-2 from bioinformatic analyses of this dataset alone.
5.2.3 Indirect identification of TPL-2-dependent phosphorylations inde-
pendent of ERK1/2 activation
Our major aim was to identify ERK1/2-independent TPL-2 signalling pathways.
We first determined ERK1/2-dependent phosphorylations by a comparative mass
spectrometric analysis of LPS-stimulated wild type macrophages with LPS-
stimulated wild type macrophages treated with a small molecule MEK1/2 inhibitor,
PD0325901.
Internal controls
As before, the activation loop phosphorylation sites of MEK1/2 and ERK1/2 were
used as internal controls (figure 5.5). PD0325901 treatment reduced ERK1/2
phosphorylations as expected. MEK1/2 phosphorylation was not reduced in this
comparison, consistent with the action of the PD0325901 compound in inhibiting
the active form of MEK1/2 which has already been phosphorylated (Bain et al.,
2007). Indeed, serine 222 phosphorylation was slightly increased by PD0325901
treatment, as could be seen from the negative Log2 ratios in the wild type versus
PD0325901-treated wild type comparison. Immunoblotting confirmed an increase
in MEK1/2 phosphorylation in the presence of the MEK1/2 inhibitor compared to
vehicle control (figure 5.6). PD0325901 also blocked the decrease in electrophor-
etic mobility of MEK1/2 detected after LPS stimulation in vehicle control cells. This
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may be indicative of negative feedback pathways downstream of MEK1/2/ERK1/2
which are being blocked by the inhibitor (Caunt and Keyse, 2013).
Figure 5.6: MEK1/2 activation loop phosphorylation is increased in the pres-
ence of a small molecule MEK1/2 inhibitor.
Wild type BMDM were left untreated, or treated with 0.1 μM PD0325901 and/or
100ng/ml LPS prior to lysis. Proteins were separated by gel electrophoresis and
transferred to PVDF membranes, and immunoblotted with the indicated antibod-
ies. Three technical replicates shown; representative of 3 independent experi-
ments.
Identification of interesting hits
By combining the results of this wild type versus MEK1/2 inhibitor comparison with
those from the previous wild type versus Map3k8D270A/D270A comparison, it was
possible to subtract the ERK1/2-dependent phosphorylation from the list of TPL-2
regulated phosphorylations. To do this, phosphosites which were significant out-
liers in the wild type versus PD0325901 comparison were subtracted from the list
of 469 significant outliers from the wild type versus Map3k8D270A/D270A compar-
ison, leaving 123 outliers. Although this list was a much more manageable size,
there were limitations with this approach. Due to the stochastic nature of peptide
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detection by mass spectrometry, there may have been ERK1/2-dependent phos-
phosites in the wild type versus TPL-2 kinase dead comparison which were not
found in the wild type versus MEK1/2 inhibitor comparison. These would score as
false positives in the list of 123 phosphosites. Furthermore, it was possible that
PD0325901 had off-target effects independent of MEK1/2 inhibition, confounding
the results. In light of these two points, a more valid way to identify ERK1/2-
independent TPL-2-regulated phosphorylations was sought.
5.3 Genetic inhibition of TPL-2-dependent ERK1/2 activation
In light of the problems with indirectly determining which of the outliers are
ERK1/2-independent we decided to take a more direct approach and block
ERK1/2 activation genetically.
5.3.1 Nfκb1SSAA/SSAA mutation inhibition of ERK1/2 activation by TPL-2
The Nfκb1SSAA/SSAA mice were previously generated in the Ley laboratory
(Sriskantharajah et al., 2009). These mice carry serine to alanine mutations of
the two residues in the PEST region of NFκB1 p105 (Ser930 and Ser935) which
are phosphorylated by IKK2 upon agonist stimulation (Lang et al., 2003). If NFκB1
p105 is not phosphorylated it cannot be recognised or K48-ubiquitinated by the
E3 ligase SCFβTrCP and is therefore not targeted for proteosome-mediated de-
gradation (Lang et al., 2003). Constitutive processing of the mutant p105 to p50
is partially inhibited, although it is unclear why as stimulus induced phosphoryla-
tion is not required for recognition by KPC1, which controls this partial proteolysis
(Yang et al., 2012; Kravtsova-Ivantsiv et al., 2015). Although generation of p50
is not altered this mutation disrupts NFκB signalling through the other function of
NFκB1 p105 as an IκB (inhibitor of NFκB). Due to inhibition of stimulus induced
NFκB1 p105 proteolysis, NFκB subunits (p50 homodimers and heterodimers with
c-Rel and RelA) are not released and consequently are retained in the cytoplasm
bound to with NFκB1 p105 (Sriskantharajah et al., 2009). Genes which depend
on these NFκB subunits for their expression are therefore presumably expressed
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at lower levels in the Nfκb1SSAA/SSAA mice compared to wild type.
Earlier work by the Ley laboratory established that Nfκb1SSAA/SSAA mutation
blocks LPS activation of ERK1/2 in macrophages. Mutant NFκB1 p105SSAA/SSAA
is resistant to signal-induced proteolysis and consequently TPL-2 remains as-
sociated with its inhibitor, NFκB1 p105, when Nfκb1SSAA/SSAA macrophages are
stimulated with LPS. This prevents TPL-2 phosphorylation of MEK1/2 (figure 5.7
and Yang et al., 2012). Blocking ERK1/2 activation genetically has the ad-
vantage of avoiding off-target effects of inhibitor treatment which are partic-
ularly difficult to control for in MS proteomics experiments where large num-
bers of phosphorylations are sampled with high accuracy. For this reason it
was predicted that a phosphoproteomic comparison between Nfκb1SSAA/SSAA and
Nfκb1SSAA/SSAAMap3k8D270A/D270A macrophages would identify TPL-2-regulated
phosphorylations that were independent of ERK1/2 activation.
Figure 5.7: Phosphorylation of ERK1/2 activation loop phosphorylations in
response to LPS stimulation is absent in BMDM from NFκB1SSAA/SSAA mice.
Lysates from wild type, NFκB1SSAA/SSAA and NFκB1SSAA/SSAAMap3k8D270A/D270A
BMDM unstimulated or stimulated with 100 ng/ml LPS for 15 or 30 minutes were
compared by mass spectrometry in label reversal experiments. Representative
of 3 independent experiments.
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5.3.2 Nfκb1SSAA/SSAA mutation does not block LPS-induced phosphoryla-
tion of MEK1/2 by TPL-2 in SILAC-labelled macrophages
Activation loop phosphorylations of MEK1/2 and ERK1/2 were monitored by mass
spectrometry to determine whetherNfκb1SSAA/SSAA mutation blocked TPL-2 activa-
tion of MEK1/2/ERK1/2 as expected. Surprisingly, however, the level of phospho-
ERK1/2 was reduced by Map3k8D270A/D270A mutation even in the Nfκb1SSAA/SSAA
background (figure 5.8). This was contrary to previous immunoblotting results
and implied that Nfκb1SSAA/SSAA mutation did not completely block TPL-2 activa-
tion of ERK1/2 activation loop phosphorylation. However, as the data were ex-
pressed as ratios, it was not possible to distinguish which component was chan-
ging. One possibility was that the mass spectrometric analysis wasmore sensitive
than immunoblotting. Consequently, the levels of ERK1/2 phosphorylation detec-
ted in Nfκb1SSAA/SSAA may have been very low (too low to detect by immunoblot-
ting), but when compared to the complete absence of ERK1/2 phosphorylation in
Nfκb1SSAA/SSAAMap3k8D270A/D270A, the difference between these conditions resul-
ted in a ratio that deviated from zero.
To understand these results better, a mass spectrometry comparison was
made between Nfκb1SSAA/SSAA and wild type macrophages, in which the difference
in ERK1/2 activation loop phosphorylation between genotypes was expected to
be much greater based on immunoblotting experiments (Yang et al., 2012). Phos-
phopeptide enrichment for this experiment was done using titanium dioxide batch
enrichment alone because these sites were very abundant in all previous compar-
isons. This comparison confirmed that the level of ERK1/2 phosphorylation was
decreased by Nfκb1SSAA/SSAA mutation compared to wild type as these sites were
outliers in this comparison (figure 5.9).
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Figure 5.8: ERK1/2 activation loop phosphorylations are differentially phos-
phorylated between Nfκb1SSAA/SSAA and Nfκb1SSAA/SSAAMap3k8D270A/D270A
BMDM.
Lysates from SILAC-labelled Nfκb1SSAA/SSAA BMDM and
Nfκb1SSAA/SSAA Map3k8D270A/D270A BMDM, stimulated with 100 ng/ml LPS for
15 mins, were compared by mass spectrometry in label reversal experiments.
Activation loop phosphorylations from MEK1/2 (Map2k1 - S222 - upper panel)
and ERK1/2 (Mapk3 - T203/Y205 - and Mapk1 - T183/Y185 - respectively,
lower panel) are highlighted. X-axis shows Log2 ratio comparing Nfκb1SSAA/SSAA
and Nfκb1SSAA/SSAA Map3k8D270A/D270A BMDM; y-axis shows the Log2 ratio of
the label reversal experiment. SSAA = Nfκb1SSAA/SSAA BMDM, D270ASSAA =
Nfκb1SSAA/SSAA Map3k8D270A/D270A BMDM.
When looking at the ratio values for the four ERK1/2 activation loop
phosphorylation sites there was evidence of a pattern which could explain
the mass spectrometry results from the comparison of Nfκb1SSAA/SSAA and
Nfκb1SSAA/SSAAMap3k8D270A/D270A macrophages (table 5.2). The wild type versus
116
Map3k8D270A/D270A comparison had the maximum possible ratios for these phos-
phopeptides because they were present at wild type levels on one side of the
comparison, and completely absent from the other. The Nfκb1SSAA/SSAA versus
Nfκb1SSAA/SSAAMap3k8D270A/D270A comparison had slightly smaller ratios for these
phosphopeptides because they were present at low levels in Nfκb1SSAA/SSAA cells
and completely absent in Nfκb1SSAA/SSAAMap3k8D270A/D270A cells. These phos-
phopeptide ratios could theoretically take values of infinity in both these com-
parisons because the phosphopeptide is completely absent in one side of the
comparison. However, in practise, the mass spectrometry signal is not linear
and ratio suppression prevents the ratios exceeding certain limits (Dr. Bram
Snijders, personal communication). Consequently, the ratios do not reach in-
finity and the difference between ERK1/2 activation loop phosphopeptides in wild
type and Nfκb1SSAA/SSAA can be seen. Finally, the smallest ratios were seen in the
wild type versus Nfκb1SSAA/SSAA comparison because the phosphopeptides were
present in both conditions so the difference between two measurable values was
being determined.
One important caveat with this analysis is that the ratios cannot be taken as
exact measures of the difference because they can be affected by many errors,
not least by different labelling levels between samples. However, from these
data we concluded that there was a gradient of ERK1/2 phosphorylation levels
across these genotypes, with wild type cells having the highest levels followed by
Nfκb1SSAA/SSAA, and Nfκb1SSAA/SSAAMap3k8D270A/D270A with the lowest levels.
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Table 5.2: Ratios of ERK1/2 activation loop phosphorylations from SILAC
comparisons.
Colour indicates Log2 ratio magnitude, from lowest ratio (lightest colour) to highest
ratio (darkest colour). WT = wild type, PD0325901 = MEK1/2 inhibitor-treated wild
type.
5.3.3 SILAC conditions altered signalling through the IKK2/NFκB1
p105/TPL-2/ERK1/2 pathway in Nfκb1SSAA/SSAA BMDM
This gradient of ERK1/2 phosphorylation detected by mass spectrometry was
not expected from earlier immunoblotting analyses of BMDM lysates, which in-
dicated that Nfκb1SSAA/SSAA mutation completely blocked ERK1/2 activation loop
phosphorylation (Yang et al., 2012). One possible explanation for this was that
the SILAC culture conditions altered the behaviour of the signalling pathways in
the BMDM. This hypothesis was tested by comparing wild type, Nfκb1SSAA/SSAA
and Nfκb1SSAA/SSAAMap3k8D270A/D270A macrophages grown in standard, “light”-
labelled SILAC or “heavy”-labelled SILAC conditions. It was clear from immun-
oblotting of cell lysates that culturing BMDM in SILAC conditions led to LPS-
inducible ERK1/2 phosphorylation in the Nfκb1SSAA/SSAA cells which was not evid-
ent under normal culture conditions (figure 5.10). This phosphorylation was
dependent on TPL-2 kinase activity because it was absent from cultures of
Nfκb1SSAA/SSAAMap3k8D270A/D270A macrophages under SILAC conditions. This did
not appear to be due to the presence of the labelled amino acids because a low
level of ERK1/2 phosphorylation could be seen in both the K0R0 “light” label and
the K8R10 “heavy” label conditions. It was more likely that this resulted from one
119
of the other changes compared to standard culture conditions, such as the use of
dialysed FCS, which has previously been reported to alter phosphorylation pat-
terns compared to whole FCS (Imami et al., 2010).
Figure 5.10: SILAC culture conditions lead to altered signalling in BMDM
from Nfκb1SSAA/SSAA mice.
BMDM were cultured for 6 days under normal conditions, K0R0 SILAC conditions
or K8R10 SILAC conditions. Cells were left unstimulated or stimulated with 100
ng/ml LPS for 15 mins and lysed. Proteins were separated by gel electrophoresis
and transferred to PVDF membranes, prior to immunoblotting with the indicated
antibodies. Relative phosphorylation levels were quantified from immunoblots by
densitometry. Phosphorylation of ERK1/2 was normalised against total ERK1/2
levels, JNK phosphorylation was normalised against total α-tubulin levels; both
were expressed relative to the signal in stimulated unlabelled BMDM. Standard
= normal conditions, K0R0 = ”light”-labelled SILAC conditions, K8R10 = ”heavy”-
labelled SILAC conditions.
These results validate the presence of a gradient of ERK1/2 phosphorylation
predicted by the mass spectrometry results. Unfortunately this meant that the
results from the Nfκb1SSAA/SSAA and Nfκb1SSAA/SSAAMap3k8D270A/D270A comparison
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could not be used because there were still ERK1/2 dependent phosphorylations
present in Nfκb1SSAA/SSAA that would be extremely hard or impossible to identify
and remove. One possible way to overcome this would be to use a different type
of labelling, such as in vitro iTRAQ labelling (Wiese et al., 2007), or to use an al-
ternative approach to directly analyse the TPL-2-dependent, ERK1/2-independent
phosphorylations.
5.4 Alternative approaches to removing ERK1/2 activation
Due to problems with SILAC labelling Nfκb1SSAA/SSAA BMDM, an alternative ap-
proach was taken to directly identify the ERK1/2-independent TPL-2 targets using
a small molecule inhibitor to block ERK1/2 activation. To do this, a final mass spec-
trometry comparison was made where the MEK1/2 inhibitor, PD0325901, was ad-
ded to both wild type and Map3k8D270A/D270A BMDM, ensuring that the difference
being compared was the presence or absence of TPL-2 activity in a background
of no ERK1/2 signalling.
5.4.1 Whole dataset summary statistics
This study has thus produced data from a total of 11 different SILAC comparisons.
Across all 11 mass spectrometry comparisons made throughout this work, there
were 31,457 phosphosites identified representing 4,721 proteins, making this a
comparatively large phosphoproteomics dataset. The composition of the phos-
phorylated residues was ~ 2 % tyrosine, 21 % threonine, 77 % serine (figure 5.11)
which is consistent with previous estimates of the phosphoproteome which have
put the proportions in the range of < 1 - 4 % tyrosine, 10 - 17 % threonine and 80
- 90 % serine (Hunter and Sefton, 1980; Weintz et al., 2010). This suggests that
the phosphopeptide enrichment protocol used in this study did not lead to a bias
in the phosphorylated residues which were detected.
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Figure 5.11: Distribution of phosphorylation sites across serine, threonine
and tyrosine residues.
Lysates from various SILAC-labelled BMDM, stimulated with 100 ng/ml LPS for
15 mins, were compared by mass spectrometry. Number of phosphorylations
on each type of residue were calculated. Absolute number of phosphosites are
indicated.
In the comparison between MEK1/2 inhibitor-treated wild type and MEK1/2
inhibitor-treated Map3k8D270A/D270A there were a total of 16,353 unique phosphos-
ites identified representing 2,655 proteins. Of these, 7,143 phosphosites were
also found in the wild type versus wild type, wild type versus PD0325901 and
wild type versus Map3k8D270A/D270A. This has to be viewed in the context of the
whole (phospho-)proteome which currently stands at 45,188 proteins in the Uni-
Prot Mus musculus proteome on (Consortium, 2015, accessed 11/3/15) and over
250,000 non-redundant phosphorylation sites in the PhosphoSitePlus® database
(www.phosphosite.org, Hornbeck et al., 2012, accessed 11/3/15).
From this point onwards, only the 7 comparisons consisting of wild type
versus wild type, wild type versus PD0325901-treated wild type, wild type versus
Map3k8D270A/D270A and PD0325901-treated wild type versus PD0325901-treated
Map3k8D270A/D270A were considered, as these provided the most valid and useful
information about potential TPL-2 substrates (total and ERK1/2-independent). GO
cellular compartment slim annotations (Ashburner et al., 2000, accessed 22/9/11)
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of all identified phosphoproteins were compared with those of all genes expressed
in murine BMDM, as determined by RNA sequencing (Ley laboratory, unpub-
lished data), to identify whether any subcellular locations were over- or under-
represented. Proteins from all the major subcellular compartments were found in
the current dataset. There was a significant enrichment of proteins annotated as
macromolecular complex (figure 5.12) which is in line with the function of phos-
phorylation in providing docking sites for formation of multi-protein signalling com-
plexes (Cohen, 2000). On the other hand, terms which were significantly under-
represented included several which indicate a membrane or membrane-bound
compartment e.g. membrane, vesicle, endomembrane system. This may be due
to the increased difficulty of extracting proteins from lipid membranes and their
increased tendency to aggregate (Smith, 2011). Unsurprisingly there was also an
under-representation of extracellular proteins in the phosphoprotein data as cell
lysates and not culture supernatants were analysed.
5.4.2 Identifying ERK1/2-independent TPL-2 substrates
As before, we first checked for the behaviour of the internal control phosphoryla-
tions from the ERK1/2 activation loop. For both ERK1 and ERK2, the threonine
(Thr203/183 respectively) phosphosite was not found in the PD0325901-treated
wild type comparison with PD0325901-treatedMap3k8D270A/D270A cells which sug-
gested, as expected, that these residues were not being phosphorylated in either
of the conditions. These phosphopeptides were otherwise very abundant in com-
parisons including wild type cells without PD0325901 (table 5.3). Activation loop
phosphorylation of ERK2 Tyr185 was found in one of the two label reversal repeats
but the ratio suggested it did not differ between wild type andMap3k8D270A/D270A in
the presence of the MEK1/2 inhibitor; again this was as expected. However phos-
phorylation of Tyr203 in the activation loop of ERK1 was regulated by TPL-2 even
in the presence of PD0325901 (wild type and Map3k8D270A/D270A plus MEK1/2 in-
hibitor comparison). This could have been due to incomplete MEK1/2 inhibition by
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PD0325901, allowing some inducible phosphorylation to continue. Alternatively,
it could be that MEK1/2 phosphorylation is blocked but the rate of removal of
baseline activation loop phosphorylation (i.e. present before inhibitor added) dif-
fers; if this ERK1 tyrosine residue were de-phosphorylated more slowly than the
other activation loop residues then its phosphorylation would persist for longer. As
the inhibitor treatment only provides an acute block, whereas the genetic block is
long term, this would result in differential levels of the phosphorylation between
these conditions for a period of time. In support of this conclusion, differential
regulation of the two activation loop residues of ERK1/2 has been shown previ-
ously (Robbins et al., 1993). The same study found that ERK1/2 was partially
active and able to auto-phosphorylate when phosphorylated at only the tyrosine
activation loop residue. However, phosphorylation on both residues was ne-
cessary for stable binding of the substrate, myelin-basic protein (Prowse et al.,
2001). Moreover, we could be sure that the phosphorylation in the presence of
PD0325901 was reduced relative to the level of fully active ERK1 because, when
wild type BMDMwere compared with PD0325901-treated wild type BMDM, all the
ERK1/2 activating residues were differentially regulated (see above and table 5.3).
Therefore, it is likely that ERK1/2 downstream signalling is also much reduced.
Table 5.3: Behaviour of ERK1/2 activation loop phosphorylations in
the phosphoproteomic comparison of PD0325901-treated wild type and
Map3k8D270A/D270A macrophages.
Comparison ERK1 T203 ERK1 Y205 ERK2 T183 ERK2 Y185
WT vs WT -0.40 -0.27 -0.28 -0.23
WT vs PD0325901 2.85 3.96 3.66 4.081.14 2.81 3.10 2.59
WT vs TPL-2D270A 4.03 4.43 2.85 4.663.24 3.73 3.64 4.03
WT+PD0325901 vs
TPL-2D270A+PD0325901
X 3.53 X 0.40
X 2.54 X X
X = not found, WT = wild type, PD0325901 = MEK1/2 inhibitor-treated wild type.
Using z-statistics to determine significant deviation from the mean in the wild
type versus Map3k8D270A/D270A comparison in the presence of the MEK1/2 inhib-
itor, resulted in a list of 145 outliers at significance of p = 0.01. These outliers were
125
assessed using the DAVID resource (Huang et al., 2008, 2009) for enrichment of
GO biological process slim terms relative to all proteins found in the current phos-
phoproteomics data. This was chosen as the background dataset, rather than
the whole mouse genome, because not all genes will be expressed in BMDM.
Additionally, aspects of the methodology (e.g. chromatographic separation, ion-
isation) may prevent identification of certain proteins so their inclusion could skew
the background population against any terms which are enriched in the regulated
proteins. Predictably most of the enriched terms were related to phosphoryla-
tion and intracellular signalling, including MAP kinase pathways (table 5.4). Other
terms which were present were “nucleosome positioning”, which had the highest
fold enrichment, “locomotion” and “cell projection organisation” as well as several
related to synthesis of steroids; with current knowledge it is hard to interpret these
terms in relation to TPL-2 biology. However one term which could be equated with
our understanding of TPL-2 biology is “regulation of transcription factor activity”
because a recent RNA sequencing study in the Ley laboratory found TPL-2 regu-
lated expression of 51 genes independently of ERK1/2, compared with 43 genes
which were dependent on both TPL-2 and ERK1/2 (unpublished data).
The list of 145 significant outliers was further narrowed down by looking at the
behaviour of the sites across multiple comparisons to include more information
on the likely regulation of each site. To qualify as an ERK1/2-independent TPL-2
regulated site, the expected pattern of behaviour was such that was unregulated
in the wild type versus wild type control and the wild type plus/minus MEK1/2
inhibitor but regulated in the wild type versus Map3k8D270A/D270A. This analysis
identified two groups of phosphosites (figure 5.13, table 5.5 and table 5.6); one
group of 11 sites which were likely to be TPL-2-dependent, ERK-independent sub-
strates based on a large divergence from themean Log2 ratio andmostly complete
data across all the conditions, and a further 32 sites which were possible TPL-2-
dependent, ERK-independent substrates. It is harder to draw conclusions about
the regulation of this second group of possible substrates due to their smaller di-
vergence from the mean Log2 ratio and/or missing data, making it more likely that
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these were false positives. It may also be more difficult to detect any real differ-
ence by other assays (e.g. immunoblotting) due to the need for greater sensitivity
to detect a small difference.
Table 5.4: Enriched GO biological process slim terms in all significant out-
liers found in the comparisons between PD0325901-treated wild type and
PD0325901-treated Map3k8D270A/D270A BMDM.
GOBP Slim term P value Fold enrichment
Protein amino acid phosphorylation 1.61E-05 2.97
Phosphorylation 3.31E-05 2.83
Phosphorus metabolic process 2.54E-04 2.44
Phosphate metabolic process 2.54E-04 2.44
Biopolymer modification 5.55E-04 2.05
Protein modification process 6.48E-04 2.08
Post-translational protein modification 7.03E-04 2.13
Signal transduction 1.67E-03 1.94
Nucleosome positioning 1.72E-03 40.58
Response to stimulus 2.64E-03 1.88
Regulation of cell communication 4.24E-03 2.28
Regulation of MAP kinase activity 5.48E-03 6.76
Sterol biosynthetic process 5.57E-03 24.35
Cholesterol biosynthetic process 5.57E-03 24.35
Regulation of signal transduction 6.56E-03 2.26
Positive regulation of molecular function 7.16E-03 3.45
Steroid biosynthetic process 8.22E-03 20.29
Activation of MAPK activity 8.67E-03 9.02
Regulation of molecular function 8.69E-03 2.41
Locomotion 9.61E-03 3.74
Positive regulation of MAP kinase activity 1.17E-02 8.12
Regulation of phosphorylation 1.22E-02 3.12
Protein kinase cascade 1.29E-02 3.09
Cell projection organization 1.37E-02 3.46
Regulation of transcription factor activity 1.53E-02 7.38
MAPKKK cascade 1.66E-02 4.95
Regulation of phosphorus metabolic process 1.71E-02 2.93
Regulation of phosphate metabolic process 1.71E-02 2.93
Protein metabolic process 1.80E-02 1.49
Multicellular organismal process 1.81E-02 1.53
Analysed using DAVID functional annotation enrichment tool (Huang et al., 2008,
2009). Background dataset for comparison was all identified phosphoproteins,
cutoff p < 0.02.
The list was next filtered to remove those sites for which the confidence of
protein identification, as assessed by the posterior error probability (PEP), was
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higher than 1 x 10-5. Low scoring localisation of the phosphorylation was not
used as grounds to remove a hit because at this stage as the main aim was to
find substrate proteins and the site of modification could be identified in future
if necessary. Finally, the list was compared against the results of the digestion
and mixing check to give an indication as to whether the total protein level was
changing for a particular hit. This check was not a comprehensive proteomic
analysis, so the total number of proteins represented was low, however peptides
were found for Map2k1/Map2k2, Luc7l2, Hist1h1c and Fermt3 and did not show
much variation across the 7 comparisons (Appendix B). Arg1 on the other hand
had 20 peptides showing a deviation from a Log2 ratio of zero in the comparisons
between wild type and Map3k8D270A/D270A in the presence of the MEK1/2 inhibitor.
Hsp90b1 also showed changes at the protein level in several of the conditions
compared. This suggested that the changes in phosphopeptide level could be
due to changes in total protein level rather than changing phosphorylation status.
Arg1 and Hsp90b1 were therefore excluded from further analysis leaving a final
list of 37 sites from 21 proteins.
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Figure 5.13: Phosphosite profiles across the phosphoproteomic data reveal
TPL-2-dependent phosphorylations.
Lysates from SILAC-labelled BMDM, stimulated with 100 ng/ml LPS for 15 mins,
were compared by mass spectrometry. Likely TPL-2-dependent phosphosites are
highlighted in the upper panel and possible TPL-2-dependent phosphosites are
highlighted in the lower panel. WT = wild type BMDM, PD0325901 = MEK1/2
inhibitor-treated BMDM, TPL-2D270A = TPL-2 kinase-inactive BMDM.
The resulting shortlist of proteins with likely and possible TPL-2-regulated
phosphorylations were classified according to their functions based on UniProt an-
notation (Consortium, 2015, accessed 11/3/15), Gene Ontology terms (Ashburner
et al., 2000, accessed 11/3/15) and literature review (figure 5.14). Consistent with
the GOBP enrichment analysis discussed above, the most common function was
“transcription/DNA metabolism”. This category included proteins involved in DNA
topology and histone modification which could play a role in the ERK-independent
changes in gene expression which have been observed in TPL-2 kinase dead
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mice by RNA sequencing (Ley laboratory, unpublished data). The second largest
groups included proteins related to “cytoskeleton” and “MAPK signalling” which
have been demonstrated to be key outcomes in the macrophage response to
LPS by a previous phosphoproteomic study (Weintz et al., 2010). However due
to the low numbers of proteins in the list it is difficult to draw conclusions about
the function of TPL-2 regulated pathways from this analysis.
Figure 5.14: Biological functions of proteins with likely and possible TPL-2-
dependent, ERK1/2-independent phosphorylations.
Proteins with identified phosphosites showing regulation by TPL-2, independent
of ERK1/2, were grouped according to biological function determined using in-
formation from GO terms, Uniprot and literature review. Gene names of proteins
in each category are shown; highlighted in red are phosphorylations decreased
in the absence of TPL-2 kinase activity, those highlighted in blue are increased
without TPL-2 kinase activity. Absolute numbers of proteins in each category are
shown.
As no confirmed ERK1/2-independent TPL-2 targets are known, it was not
possible to establish whether the process outlined above would be able to se-
gregate the ERK1/2-dependent and -independent TPL-2 targets. Therefore, a
known ERK1/2 target, RSK1/2/3, was used to illustrate that these sites could be
discriminated by comparing the conditions that have been used in this study. The
activating residues of the 3 isoforms RSK1/2/3, S380 and T573, were found in
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the phosphoproteomics data (figure 5.15). These sites were not regulated when
both conditions in the comparison had been treated with PD0325901, which on its
own could suggest either that the site is not regulated by TPL-2 kinase activity or
that the site is regulated by TPL-2 in an ERK1/2-dependent manner. By including
the information from the wild type versus MEK1/2 inhibitor-treated and wild type
versus Map3k8D270A/D270A comparisons it became evident that the latter of these
two scenarios was the more likely because the sites showed differential regula-
tion in both these comparisons. This demonstrated that ERK1/2-dependent TPL-2
targets could be distinguished from the ERK1/2-independent ones with which this
study is concerned.
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Figure 5.15: ERK1/2-dependent phosphorylations could be distinguished
from ERK1/2-independent sites using the comparisons.
A: Lysates from SILAC-labelled BMDM, stimulated with 100 ng/ml LPS for 15
mins, were compared by mass spectrometry. RSK1/2/3 phosphorylation sites
(Ser380 and Thr573) are highlighted. B: wild type, and Map3k8D270A/D270A BMDM
were left untreated or treated with PD0325901 and 100 ng/ml LPS for the indicated
times. C: wild type, Nfκb1SSAA/SSAA and Nfκb1SSAA/SSAAMap3k8D270A/D270A BMDM
were left untreated or stimulated with 100 ng/ml LPS for 15mins. Cells were lysed,
proteins separated by gel electrophoresis and transferred to PVDF membranes.
The indicated antibodies were used for immunoblotting. Immunoblots are rep-
resentative of 3 independent experiments. WT = wild type BMDM, PD0325901 =
MEK1/2-inhibitor treated wild type BMDM, D270A = TPL-2 kinase-inactive BMDM.
5.4.3 Identifying ERK1/2 targets in LPS-stimulated macrophages
A second interesting question which could be investigated with this dataset was
which ERK1/2 targets were becoming phosphorylated in LPS-stimulated BMDM?
Starting in this case with the 681 significant outliers from the wild type versus
MEK1/2 inhibitor-treated wild type comparison and considering the mass spec-
trometry data from across the different comparisons we could again narrow down
the phosphosites which behavemost like ERK1/2-dependent targets (figure 5.16).
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This gave a list of 318 phosphorylations in 219 proteins after filtering by PEP (Ap-
pendix C). Of these sites, 236 were decreased when TPL-2 or MEK1/2 activity
was blocked and 82 were increased. Interestingly, only 13 had been previously
identified as ERK1/2 downstream targets (Carlson et al., 2011; Courcelles et al.,
2013). These included RSK1 and RSK3, which are MAPKAPKs, key effector
kinases activated by canonical MAP kinase pathways.
Figure 5.16: Behaviour across the phosphoproteomic comparisons reveals
ERK1/2-dependent phosphorylations.
Lysates from SILAC-labelled BMDM, stimulated with 100 ng/ml LPS for 15 mins,
were compared by mass spectrometry. ERK1/2-dependent phosphosites are
highlighted. WT = wild type BMDM, PD0325901 = MEK1/2 inhibitor treated; TPL-
2D270A = TPL-2 kinase-inactive BMDM.
The biological functions of proteins phosphorylated by TPL-2/ERK1/2 sig-
nalling after LPS stimulation of BMDM are shown in figure 5.17. Consistent
with previous studies of the substrates of ERK2 (Carlson et al., 2011; Courcelles
et al., 2013), this analysis suggested that ERK1/2 controlled changes in cell shape
and/or motility (“Cytoskeleton” and “GTPase regulator”). This was also consist-
ent with the large numbers of cytoskeletal and actin binding proteins previously
shown to be regulated as a major outcome of LPS activation of BMDM (Weintz
et al., 2010). Other key processes suggested by this data to be regulated by TPL-
2/ERK1/2 were gene expression (“Transcription/DNA metabolism”) and RNA pro-
cessing, including translation which is also consistent with these previous studies.
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Figure 5.17: Biological functions of proteins with TPL-2/ERK1/2 regulated
phosphorylations.
Proteins with identified phosphosites showing regulation by ERK1/2-dependent
TPL-2 signalling were grouped according to biological function determined using
information from GO terms, Uniprot and literature review. Absolute numbers of
proteins in each category are shown.
5.5 Summary
By combining the information from 4 different comparisons to build a description of
phosphorylation site behaviour across conditions, it was possible to narrow down
a list containing thousands of phosphorylation sites to 37 that are worthy of further
investigation. However, it should be noted that these phosphorylations have yet
to be validated and this will be a critical next step in this project.
A selection of ERK1/2-independent TPL-2 regulated phosphoproteins are dis-
cussed below:
TPL-2 Ser141
One of the likely TPL-2-dependent, ERK-independent sites was TPL-2
(Map3k8) Ser141 (table 5.5). Although this phosphorylation site was previously
identified, it was not known how it is regulated or if it has functional consequences
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(Stafford et al., 2006). Its behaviour in the current study suggests that it is likely to
be an autophosphorylation as it is not dependent on the MEK1/2/ERK1/2 known
downstream pathway of TPL-2. However the possibility remains that it could be
a feedback mechanism induced by unidentified TPL-2 pathways and this would
require further study once novel pathways have been established.
Ece2
Ece2 phosphorylation was decreased in the absence of TPL-2 kinase activity.
As a metalloprotease, Ece2 belongs to the same family as TACE (ADAM17), the
cell surface enzyme responsible for cleavage of soluble TNFα from the membrane
bound form which has been shown to be regulated by ERK1/2 signalling in LPS-
stimulated macrophages. Ece2 is localised to intracellular vesicles and processes
co-expressed big endothelin to produce endothelin-1 (Emoto and Yanagisawa,
1995; Russell and Davenport, 1999). Interestingly, Hinsley et al. (2012) found
that endothelin-1 stimulated release of soluble bioactive molecules from fibro-
blasts. This was shown to be ADAM17-dependent using a small molecule inhib-
itor and siRNA knock-down of ADAM17. It is possible that a similar mechanism
could be contributing to the TPL-2-dependent release of TNFα frommacrophages,
whereby TPL-2 phosphorylation of Ece2 leads to release of endothelin and pro-
motion of TACE activity.
Pdlim2 and osteopontin
Two members of the list of ERK1/2-independent TPL-2-regulated proteins,
Pdlim2 and osteopontin (OPN), are known to functionally interact with one an-
other. OPN expression is essential for the Ser137 phosphorylation and activation
of Pdlim2 which polyubiquitinates STAT1, leading to its degradation and termin-
ation of STAT1 signalling (Guo et al., 2010). In the present study Pdlim2 phos-
phorylation at Thr142 was decreased in the absence of TPL-2 kinase activity,
indicating that TPL-2 promotes Pdlim2 phosphorylation at a site close to the ac-
tivating residue. It will be important in future studies to determine whether Thr142
phosphorylation is required for Pdlim2 activation. Pdlim2 has also been repor-
ted to negatively regulate RelA activity, again by acting as an E3 ubiquitin ligase
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(Tanaka et al., 2007). This may provide a mechanism by which TPL-2-dependent
genes are regulated, as transcription factor enrichment analysis of these genes
identified RelA as a possible regulator (Ley laboratory, unpublished data).
OPN is found in both extracellular soluble, and intracellular forms and has
separate effects on inflammatory signalling in each context. In the secreted form
it functions like a cytokine, driving Th1 skewed T cell responses over Th2 re-
sponses, whereas in the intracellular form it can function as part of the signal
transduction complex in IFNα induction in TLR9 stimulated plasmacytoid dend-
ritic cells (Cao, Wei and Liu, Yong-Jun, 2006; Shinohara et al., 2006). TPL-2
has been shown to negatively regulate IFNβ production (Kaiser et al., 2009). The
phosphorylation of OPN is increased in the absence of TPL-2 kinase activity, rais-
ing the possibility that TPL-2 signalling might suppress IFNβ induction via down-
regulation of OPN phosphorylation.
Crebbp
Crebbp was previously found by mass spectrometry to interact with over-
expressed TPL-2/ABIN-2/NFκB1 p105 triple complex immunoprecipitated from
HEK293 cells (Ley laboratory, unpublished data). Therefore, it is a likely candid-
ate for direct phosphorylation by TPL-2, although this will need to be confirmed
by kinase assays.
TPL-2-regulated phosphorylation of Crebbp may also be linked to RelA-
dependent transcriptional regulation. The transcriptional coactivator, Crebbp, as-
sociates with RelA and promotes efficient transcription of a subset of RelA target
genes (Zhong et al., 1998). This suggests an alternative way that TPL-2 may reg-
ulate transcription of certain RelA target genes, by altering the interaction between
RelA and Crebbp.
Prkaa1
The current study identified two sites in Prkaa1 (AMPK) which appeared to be
phosphorylated in a TPL-2-dependent manner, one of which was the activating
residue (Thr183) (Lizcano et al., 2004; Shaw et al., 2004). AMPK is a negat-
ive regulator of inflammatory signalling in macrophages and is down-regulated as
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a consequence of dephosphorylation as early as 10 minutes after LPS stimula-
tion (Sag et al., 2008; Yang et al., 2010). The data in the current study showed
phosphorylation of both AMPK sites increased in the absence of TPL-2 kinase
activity. These data suggested that LPS-induced dephosphorylation of AMPK,
which blocks its inhibition of inflammatory signalling, could be regulated by TPL-
2. Moreover, reducing AMPK signalling using a dominant negative AMPK or short
hairpin RNA AMPK knock-down increased the amount of TNFα produced follow-
ing LPS stimulation in RAW264.7 macrophages or BMDM respectively (Sag et al.,
2008; Yang et al., 2010). However, this increase was apparent at both the mRNA
and protein levels and therefore does not correlate with TPL-2 regulation of TNFα
which is predominantly mediated at the protein level.
Yang et al. (2010) also showed that activation of AMPK inhibited NFκB activ-
ity on a luciferase reporter and also RelA binding to target genes. TPL-2 sig-
nalling may induce NFκB-dependent gene expression by increasing RelA activity
as a consequence of AMPK inhibition. Other key roles of AMPK include energy
sensing and homeostatic changes in anabolic and catabolic pathways, and, whilst
some reports have implicated TPL-2 in similar processes such as obesity, its role
in such settings remains to be clarified (Perfield et al., 2011; Lancaster et al.,
2012). The proposed modification of AMPK activity by TPL-2 must be indirect as
AMPK phosphorylation is increased in Map3k8D270A/D270A compared to wild type.
This suggests that TPL-2 may phosphorylate and activate an AMPK phosphatase.
Alternatively TPL-2 may phosphorylate and inactivate an AMPK kinase. Many
kinases have been reported to phosphorylate AMPK at this site and it will be im-
portant in future experiments to determine whether any of these are negatively
regulated by TPL-2.
This study has shown that SILAC labelling alters signalling in Nfκb1SSAA/SSAA
BMDM . In order for phosphorylation of ERK1/2 to remain in this mutant either
NFκB1 p105 is being targeted for degradation in another way, thus enabling free
TPL-2 to phosphorylate MEK1/2 as in wild type cells, or release is no longer ne-
cessary for TPL-2 to activate MEK1/2. This latter possibility is consistent with
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previous findings that TPL-2 is still active in the triple complex. The presence of
NFκB1 p105 prevents TPL-2 from accessing MEK1/2 in an all-or-nothing manner
in cells whereas in vitro TPL-2 remains able to phosphorylate substrates; the ef-
ficiency of this phosphorylation is dependent on which NFκB1 p105 domains are
present (Babu et al., 2006b; Robinson et al., 2007 and Ley laboratory, unpub-
lished data). The results presented do raise the possibility that labelling cells from
any genotype can change their signalling patterns compared to the physiological
state. Although MAP kinase pathway activation was normal in wild type BMDM in
this study it cannot be ruled out that other pathways were not, and this could lead
to false positives or negatives in the phosphoproteomic dataset. This highlights
the need to validate leads in unlabelled cells. Furthermore, these data have not
been corrected for changes in protein expression. Although the label incorporation
check, performed on digested whole cell lysate, indicated that overall expression
level changes were minimal, it cannot be excluded that expression levels of spe-
cific substrates were changed and explain differences in phosphopeptide levels.
As well as ERK1/2-independent TPL-2 regulated targets, the data generated
in the current study allowed identification of targets downstream of TPL-2/ERK1/2
signalling in LPS stimulated macrophages, which have not been looked at spe-
cifically on a large scale before. A far greater number of phosphopeptides fitted
the expected behaviour of an ERK1/2 regulated site than a ERK1/2-independent
TPL-2 regulated site, demonstrating the central role of ERK1/2 in orchestrating
responses to external stimuli. This was further supported by analysis of the biolo-
gical functions of TPL-2/ERK1/2 signalling which reflected the major responses of
BMDM to LPS determined byWeintz et al. (2010). As these sites have been identi-
fied using a small molecule inhibitor, they would ideally be validated using a struc-
turally unrelated MEK1/2 inhibitor, such as trametanib. Under standard cell cul-
ture conditions, it would also be possible to compare wild type with Nfκb1SSAA/SSAA
macrophages, in which activation of ERK1/2 is blocked (Yang et al., 2012) in order
to rule out off-target effects.
The most likely direct target of TPL-2 identified by the phosphoproteomics ex-
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periments in this study were MKK3 and MKK6, since TPL-2 is known to be a MAP
3-kinase (Salmeron et al., 1996). MKK3/6 has also been found to specifically
associate with the TPL-2/ABIN-2/NFκB1 p105 triple complex by mass spectro-
metric analyses of immunoprecipitates from transiently transfected HEK293 cells
(Ley laboratory, unpublished data). Together, these data indicate that the link
between TPL-2 and MKK3/6 phosphorylation is worthy of further investigation.
The identification of TPL-2-dependent, ERK1/2-independent targets indicated that
the SILAC/mass spectrometric methodology used in the current study worked and
is likely to contribute to the increased understanding of downstream signalling
pathways regulated by TPL-2.
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6 Delineating the TPL-2/MKK3/6 pathway
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6.1 Introduction
As detailed in Chapter 4, mass spectrometry identified MKK3/6 activation
loop residues (Ser218/Ser207) as a TPL-2-dependent phosphorylation in LPS-
stimulated BMDM (table 5.5). These phosphosites stood out as interesting be-
cause TPL-2 can contribute to p38 activation in LPS or CpG-treated dendritic
cells, and canonical activation of this pathway is via MKK3/6 (Kaiser et al., 2009).
Furthermore, MAP kinase signalling was over-represented in the regulated phos-
phorylation sites (table 5.4). Combined with the presence of MKK3/6 in the TPL-
2/ABIN-2/NFκB1 p105 triple complex interactome, MKK3/6 regulation by TPL-2
was worthy of further investigation.
MKK3 and MKK6
MKK3/6 are the canonical MAP 2-kinases for the p38 MAP kinase pathway (fig-
ure 6.1). They are known to be exclusively able to phosphorylate p38 isoforms
and do not show cross-talk with the other MAP kinase pathways (Cuenda and
Rousseau, 2007). MKK3 and MKK6 share about 80 % homology.
Deletion of both MKK3 and MKK6 results in embryonic lethality whereas dele-
tion of either alone is viable in mice, suggesting overlapping functionality and com-
pensation by the remaining isoform (Cuenda and Rousseau, 2007). Their actions
are not entirely redundant however, with differences in the importance of each iso-
form varying in a cell type and stimulus specific manner. For example, MKK6 was
found to be necessary for deletion of double positive thymocytes whereas MKK3
was not. Instead,Mkk3-/- CD4+ T cells were resistant to T cell death upon TCR ac-
tivation or cytokine removal, neither of which were affected by absence of MKK6
(Tanaka et al., 2002). There is also evidence that MKK3 and MKK6 activation
can be regulated separately in certain circumstances, as protein kinase R (PKR)
has been shown to activate MKK6, but not MKK3, in response to double-stranded
RNA stimulation (Silva et al., 2004).
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MKK4
In contrast to the single MKK3 or MKK6 “knock-outs”, constitutive deletion of
MKK4 in mice is embryonic lethal (Abell et al., 2005). MKK4 shares roughly 50
% identity with MKK3 and about 60 % identity with MKK6. MKK4 and MKK7 are
the canonical MAP 2-kinases for the JNK MAP kinase pathway. However, in vitro
studies suggested that MKK4 could also contribute to p38 MAP kinase activation
(Dérijard et al., 1995; Doza et al., 1995; Lin et al., 1995). Analyses of MKK4-
deficient murine embryonic fibroblasts (MEFs) have subsequently demonstrated
that MKK4 contributes to the activation of p38α by ultraviolet light but not TNFα in
whole cells (Brancho et al., 2003).
Figure 6.1: p38 MAPK pathways.
The four p38 isoforms show different patterns of activation by MKK3, MKK4 and
MKK6. Unlike the other isoforms, p38α can be activated by MKK4. All four p38
isoforms can be activated by MKK6, whilst MKK3 activates all except p38β. MAP
2-kinase - MAP kinase pairing shows cell type and stimulus specificity.
6.1.1 Validation of MKK3/6 phosphorylation as an ERK1/2-independent,
TPL-2 regulated site
The phosphorylated residues from MKK3/6 found in this study were compared
with those listed in the Uniprot (Consortium, 2015, accessed 8/5/15) and Phos-
phoSitePlus® databases (www.phosphosite.org, Hornbeck et al., 2012, accessed
8/5/15). This study found three phosphorylated sites in MKK3 of which one, S7,
was previously unknown (figure 6.2). For the site responsible for activation of
MKK3/6 kinase activity it was not possible to determine whether the identified
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peptide came from MKK3 (S218) or MKK6 (S207). Only this site was found to be
changing upon perturbation of the system, supporting the assumption that it is a
change in phosphorylation status and not protein level. Immunoblotting confirmed
this phosphorylation was dependent on TPL-2 kinase activity, because it was ab-
sent in Map3k8D270A/D270A cells, and independent of ERK1/2 activity, because it
was not affected by treatment of wild type cells with a MEK1/2 inhibitor (figure 6.3).
Furthermore, it was shown to be dependent on NFκB1 p105 phosphorylation us-
ing the Nfκb1SSAA/SSAA and Nfκb1SSAA/SSAAMap3k8D270A/D270A mutants.
Figure 6.2: Known MKK3 and MKK6 phosphorylation sites.
Sites highlighted in red are the activating residues. Sites shown in bold were iden-
tified in this study, of which those in italics were newly identified. * indicates sites
found to be regulated by TPL-2. The MKK6 D domain, which mediates binding to
the MAPK substrate, and DVD domain, which mediates MAP3K binding, are pre-
dicted by similarity. Information was collated from Uniprot and PhosphoSitePlus®
databases (Consortium, 2015, accessed 8/5/15; www.phosphosite.org, Hornbeck
et al., 2012, accessed 8/5/15).
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Figure 6.3: MKK3/6 activation loop phosphorylation is regulated by TPL-2.
A: Lysates from SILAC-labelled BMDM, stimulated with 100 ng/ml LPS for 15
mins, were compared by mass spectrometry. The MKK3 (Map2k3) and/or
MKK6 activation loop phosphopeptide (S218/S207 respectively) is highlighted.
Graph axes show Log2 ratio comparing wild type with Map3k8D270A/D270A BMDM;
x-axis shows the label reversal experiment of the y-axis. B: wild type, and
Map3k8D270A/D270A BMDM were left untreated or treated with PD0325901 and
100 ng/ml LPS for the indicated times. C: wild type, Nfκb1SSAA/SSAA and
Nfκb1SSAA/SSAAMap3k8D270A/D270A BMDMwere left untreated or stimulated with 100
ng/ml LPS for the indicated times. Cells were lysed, proteins separated by gel
electrophoresis and transferred to PVDF membranes. The indicated antibodies
were used for immunoblotting. Immunoblots are representative of 3 independ-
ent experiments. WT = wild type BMDM, PD0325901 = MEK1/2 inhibitor treated
BMDM. D270A = TPL-2 kinase-inactive BMDM.
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6.2 Which MKK isoforms are regulated by TPL-2?
Due to sequence identity in their activation loop sequences, it was not possible
to distinguish between MKK3 and MKK6 activating site phosphorylations in the
phosphoproteomics data. These kinases are often co-regulated, however there
are reports of differential isoform activation (e.g. PKR activates MKK6 but not
MKK3 in response to double-stranded RNA stimulation), meaning the detected
phosphopeptides might have originated from both or just one of the two isoforms
(Silva et al., 2004; Zhang et al., 2007). Interrogation of the phosphoproteomics
data also indicated that the activating residues of MKK4 were not being regulated
by TPL-2 (figure 6.4). However, it is thought that TPL-2 can contribute to the reg-
ulation of JNK activation via MKK4 in fibroblasts following TNFα and IL-1β stim-
ulation, as well as p38 activation, presumably via MKK3 and MKK6, in dendritic
cells treated with LPS or CpG (Das et al., 2005; Kaiser et al., 2009). Therefore,
in order to understand more completely which isoforms were being regulated by
TPL-2, each isoform was immunoprecipitated individually and probed for activa-
tion loop phosphorylation by immunoblotting.
MKK3 and MKK6 separately immunoprecipitated from wild type BMDM
showed LPS-inducible phosphorylation of their activation loops, which was not
blocked by the presence of the MEK1/2 inhibitor, PD0325901. However, MKK3
and MKK6 phosphorylation was blocked by Map3k8D270A/D270A mutation. In con-
trast MKK4 showed LPS-inducible phosphorylation when immunoprecipitated
from wild type, PD0325901-treated wild type or Map3k8D270A/D270A BMDM (fig-
ure 6.5). These results demonstrated that TPL-2 catalytic activity regulated the
activation of both MKK3 and MKK6 after LPS stimulation. In contrast, TPL-2 cata-
lytic activity was dispensable for LPS activation of MKK4.
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Figure 6.4: MKK4 activating phosphorylations do not appear to be regulated
by TPL-2.
MKK4 (Map2k4) activation loop phosphopeptides (Ser255 and Thr259) are high-
lighted. Lysates from SILAC-labelled WT and Map3k8D270A/D270A BMDM, stimu-
lated with 100 ng/ml LPS were compared by mass spectrometry. Graph axes
show log2 ratio comparing wild type with TPL-2D270A BMDM; the x-axis shows the
label reversal mix of the y-axis. WT = wild type BMDM, D270A = TPL-2 kinase-
inactive BMDM.
Earlier research by the Ley laboratory established that TPL-2 activation of
MEK1/2 was dependent on IKK2 phosphorylation of its inhibitor, NFκB1 p105
(Babu et al., 2006b). To investigate whether this IKK2 regulated step was also
required for TPL-2-dependent phosphorylation of MKK3 and MKK6, each kinase
was immunoprecipitated from Nfκb1SSAA/SSAA BMDM, in which the IKK2 phos-
phorylation serines, 930 and 935, in the PEST region of NFκB1 p105 are mutated
to alanine. Nfκb1SSAA/SSAA mutation blocked LPS-induced phosphorylation of both
MKK3 and MKK6, while MKK4 phosphorylation was unaffected (figure 6.6). Con-
sistent with this, LPS-induced phosphorylation of MKK3 andMKK6, but not MKK4,
was blocked by pre-treatment of cells with a small molecule inhibitor of IKK2,
BI605906 (Clark et al., 2011). Together, these results indicated that TPL-2 regu-
lation of MKK3 and MKK6 phosphorylation was dependent on IKK2 activity and
NFκB1 p105 phosphorylation, similar to MEK1/2.
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Figure 6.5: Phosphorylation of MKK3 andMKK6, but not MKK4, is dependent
on TPL-2 kinase activity but not ERK1/2 activation.
MKK3, MKK4 and MKK6 were individually immunoprecipitated from wild type,
PD0325901-treated wild type and Map3k8D270A/D270A BMDM, left unstimulated or
stimulated with 100 ng/ml LPS for 15mins. Eluates (A) or whole cell lysates (B and
C) were separated by gel electrophoresis and transferred to PVDF membranes,
followed by immunoblotting with the indicated antibodies. Representative of three
independent experiments. WT = wild type BMDM, I = immunoprecipitation input,
PI = post-immunoprecipitation.
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Figure 6.6: Phosphorylation of MKK3 andMKK6, but not MKK4, is dependent
on IKK2 activity and NFκB1 p105 phosphorylation.
MKK3, MKK4 and MKK6 were individually immunoprecipitated from wild type,
Nfκb1SSAA/SSAA and Nfκb1SSAA/SSAAMap3k8D270A/D270A BMDM, left untreated or
treated with BI605906 and/or 100 ng/ml LPS for 15 mins. Eluates (A) or whole cell
lysates (B and C) were separated by gel electrophoresis and transferred to PVDF
membranes, followed by immunoblotting with the indicated antibodies. Repres-
entative of three independent experiments. WT = wild type BMDM, I = immuno-
precipitation input, PI = post-immunoprecipitation.
6.2.1 Can TPL-2 directly phosphorylate MKK3 and MKK6?
The experiments in the previous section clearly established that TPL-2 cata-
lytic activity controlled the phosphorylation of MKK3/6 in primary LPS-stimulated
macrophages. However, it was not clear whether this reflected the direct phos-
phorylation of MKK3 and MKK6 by TPL-2 or was mediated via an intermediate
downstream kinase. It is not possible to isolate soluble active TPL-2 without co-
expression with NFκB1 p105 and ABIN-2, as it is completely insoluble. M30-TPL-
230-397 is partially soluble and active, but can only be purified to approximately 40
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% (Jia et al., 2005). To circumvent these problems, in vitro kinase assays were
performed using highly purified recombinant TPL-2/ABIN-2/NFκB1 p105 complex
(Gantke et al., 2013), generated in the Ley laboratory. As earlier experiments
had demonstrated that TPL-2 phosphorylation of MEK1 is inhibited by the NFκB1
p105 death domain (DD) (Babu et al., 2006b), in vitro kinase assays were also
carried out using recombinant TPL-2/ABIN-2/NFκB1 p105ΔDD. Recombinant pur-
ified MKK6 protein was used as a substrate and phosphorylation on the activation
loop was monitored by immunoblotting. Purified MEK1 protein was included in
assays as a control.
These assays demonstrated that TPL-2/ABIN-2/NFκB1 p105 complex phos-
phorylated the activation loop of MKK6 (figure 6.7). In line with earlier experiments
using MEK1 as a substrate, the ability of TPL-2 to phosphorylate MKK6 was reg-
ulated by NFκB1 p105DD, and MKK6 phosphorylation was stronger with TPL-
2/ABIN-2/NFκB1 p105ΔDD than the wild type complex. It will be important to test
whether TPL-2-dependent regulation of MKK3 phosphorylation in LPS-stimulated
macrophages is also a result of direct MKK3 phosphorylation. This is very likely
because of the high degree of similarity between the two MKK isoforms. In addi-
tion, it will be necessary to determine whether endogenous TPL-2, immunoprecip-
itated from LPS-stimulated primary macrophage lysates, phosphorylates MKK3
and MKK6 in vitro.
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Figure 6.7: Complexed TPL-2 directly phosphorylates MKK6 in vitro.
Recombinant TPL-2/ABIN-2/NFκB1 p105 triple complex with or without the NFκB1
p105 death domain was incubated with either recombinant MKK6 or recombin-
ant MEK1 for 60 mins. Reaction mixtures were separated by gel electrophoresis
and transferred to PVDF membranes, before immunoblotting with the indicated
antibodies. Representative of 3 technical replicates. WT = wild type TPL-2/ABIN-
2/NFκB1 p105 complex, ΔDD = TPL-2/ABIN-2/NFκB1 p105ΔDD complex, Ctl =
control reaction on ice, KA = kinase reaction at room temperature.
6.3 What are the downstream targets of TPL-2/MKK3/6 sig-
nalling?
6.3.1 p38 isoforms
Four p38 isoforms exist, α, β, γ and δ. These can be separated broadly into two
groups based on homology, sensitivity to inhibitors and substrate specificity; α
and β, which share 75 % identity, and γ and δ, which are about 70 % identical
to each other but only about 60 % identical to α and β (Cuenda and Rousseau,
2007). The four isoforms have over 90% identity in the kinase domains (Coulthard
et al., 2009). At low concentrations, only p38α and p38β are sensitive to the
pyridinyl imidazole inhibitors, although others such as the allosteric inhibitor BIRB-
796 are capable of inhibiting all four isoforms (Zhang et al., 2007; González-Terán
et al., 2013). Expression patterns also vary between the different isoforms. Whilst
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p38α is ubiquitously high, p38β, p38γ and p38δ show more restricted expression
patterns with p38β most abundant in brain, p38γ in skeletal muscle, and p38δ in
endocrine glands (Tortorella et al., 2003; Risco and Cuenda, 2012).
Substrates and downstream functions
Some substrates are shared between all four p38 isoforms, such as transcrip-
tion factors like Elk-1 and Elk-4. There are also isoform specific substrates, such
as MAPKAP-K2 and MAPKAP-K3 that are phosphorylated by p38α/β, but not
p38γ/δ (Cuenda et al., 1997; Goedert et al., 1997). Several splice variants exist
for p38α in humans, including Exip, Mxi2 and CSBP1. Exip, which has a differ-
ent C-terminus and cannot be phosphorylated by classical p38 activating treat-
ments, has been reported to regulate NFκB signalling (Yagasaki et al., 2004).
Mxi2 also has an alternate C-terminus and reduced binding to, and subsequent
phosphorylation of, classical p38α substrates, but instead regulates nuclear im-
port of ERK1/2 (Casar et al., 2007). The third variant, CSBP1, differs at an internal
sequence of 25 amino acids; its role in signalling is not yet understood (Lee et al.,
1994).
Unique amongst the p38 MAP kinases, p38γ contains a PDZ binding do-
main which facilitates interaction with specific substrates. These include the cyto-
skeletal scaffold protein α1-syntrophin, which localises p38γ to the neuromuscu-
lar junction in skeletal muscle (Hasegawa et al., 1999). Although not contain-
ing a PDZ domain, p38δ has also been reported to regulate the cytoskeleton via
phosphorylation of stathmin (Parker et al., 1998). SAP97 function in cell adapt-
ation to osmotic stress is regulated by p38γ, independently of its kinase activ-
ity, by displacing interacting proteins such as PSF, a regulator of transcription
and pre-mRNA processing (Sabio et al., 2005, 2010). Another example of the
kinase-independent functions is the stabilisation of TPL-2 by p38γ/δ in macro-
phages (Risco et al., 2012). Although the substrate specificities of the different
p38 isoforms have not been systematically investigated, present knowledge in-
dicates differences in isoform substrate specificity and implies distinct functional
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roles. As the most widely expressed and extensively studied isoform, p38α has
been implicated in processes including mRNA stability, apoptosis, cell migration
and senescence (Cuadrado and Nebreda, 2010; Risco and Cuenda, 2012). The
strength and duration of signalling are thought to determine the final outcome,
with strong signalling in response to stress signals more likely to cause apoptosis
and weaker/shorter activation associated with homeostatic functions (Dolado and
Nebreda, 2008). It has been suggested that p38α is involved in pathologies ran-
ging from inflammatory/immunological disease to cancer and neurodegenerative
disease (Cuadrado and Nebreda, 2010). A chemical genetic approach, in which
either p38α or p38β were mutated to be resistant to most commonly used p38 in-
hibitors, showed that blockade of TLR-induced TNFα release and protection from
antibody-induced arthritis by these inhibitors is largely the result of p38α inhibition
(O’Keefe et al., 2007). This implies that p38β is largely dispensable for inflam-
matory signalling. p38δ is thought to be involved in cytoskeletal remodelling and
insulin secretion (Risco and Cuenda, 2012). p38γ and p38δ have jointly been
implicated in cancer, immune disorders such as rheumatoid arthritis and meta-
bolic disorders (Coulthard et al., 2009; Cuadrado and Nebreda, 2010). Biological
functions ascribed to p38γ include skeletal muscle differentiation and senescence,
although through a different mechanism to p38α (Risco and Cuenda, 2012).
Regulation of p38 activation
The major pathway of p38 activation involves phosphorylation by MAP 2-kinases
MKK3 and MKK6 on the threonine and tyrosine residues of the Thr-Gly-Tyr (TGY)
motif in the p38 activation loop (figure 6.1). Although MKK3/6 are the primary ac-
tivators of all p38 isoforms, MKK4 has also been shown to phosphorylate and ac-
tivate p38α in MEFs exposed to ultraviolet light (Brancho et al., 2003). Alternative
mechanisms of activation that do not require a MAP 2-kinase have also been pro-
posed for p38α. These include p38α interaction with TAB1, which promotes p38α
auto-phosphorylation and activation (Ge et al., 2002). In T cells activated through
the T cell receptor, p38α activation has been reported to involve phosphorylation
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of a non-canonical activating residue, Tyr323. This phosphorylation induces p38α
activity, possibly by altering the structural conformation, allowing phosphoryla-
tion of both the canonical activating TGY motif residues and substrates (Salvador
et al., 2005). However, these MAP 2-kinase-independent mechanisms have not
been confirmed in cells lacking MKK3, 4 and 6.
The mechanism by which p38 signalling is down-regulated is less well de-
scribed than its activation. De-phosphorylation of p38α by multiple phosphatases,
including protein serine/threonine phosphatases, protein tyrosine phosphatases
and dual-specificity phosphatases has been described (Cuadrado and Nebreda,
2010; Risco and Cuenda, 2012). The PDZ binding motif of p38γ allows it to inter-
act with and be dephosphorylated by the protein tyrosine phosphatase, PTPH1
(Risco and Cuenda, 2012). In contrast, p38α, which lacks a PDZ domain, is not
dephosphorylated by PTPH1.
Peregrin et al. (2006) also demonstrated a role for phosphorylation in the inac-
tivation of p38α. Phosphorylation of threonine 123 reduces the ability of p38α to
interact with both its MAP 2-kinase MKK6 and its substrates decreasing its ability
to transduce signals. It is unclear whether other p38 isoforms are subject to a
similar type of regulation.
6.3.2 Does TPL-2 control p38 MAPK pathway activation
MKK3 and MKK6 are considered to be the canonical MAP 2-kinases for the p38α
signalling pathway. However, my immunoblotting and phosphoproteomic data
showed that although TPL-2 catalytic activity was required for activation of MKK3
and MKK6 in LPS-stimulated macrophages, the phosphorylation of p38α was
TPL-2 independent (figure 6.8). Experiments in MEFs have previously shown
that MKK4 can activate p38α (Brancho et al., 2003). Together these results sug-
gest that LPS activation of p38α in macrophages is largely mediated via MKK4,
rather than MKK3/6.
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Figure 6.8: p38α phosphorylation is not regulated by TPL-2.
A: Lysates from SILAC-labelled BMDM, stimulated with 100 ng/ml LPS for
15 mins, were compared by mass spectrometry. The p38α activation loop
phosphopeptides (Thr180 and Tyr182) are highlighted. B: wild type and
Map3k8D270A/D270A BMDM were left untreated or treated with PD0325901 and/or
100 ng/ml LPS for the indicated times. C: wild type, Nfκb1SSAA/SSAA and
Nfκb1SSAA/SSAAMap3k8D270A/D270A BMDMwere left untreated or stimulated with 100
ng/ml LPS for the indicated times. Cells were lysed, proteins separated by gel
electrophoresis and transferred to PVDF membranes, followed by immunoblot-
ting with the indicated antibodies. Immunoblots are representative of 3 independ-
ent experiments. WT = wild type BMDM, PD0325901 = MEK1/2 inhibitor treated
BMDM, D270A = TPL-2 kinase-inactive BMDM.
Although the results of the current study clearly demonstrated TPL-2 regulated
the activation of MKK3 and MKK6 in LPS-stimulated macrophages, the biological
significance of this signalling pathway remained unclear. One possibility was the
TPL-2 specifically regulated the activation of p38 isoforms other than p38α. A sur-
prising link between TPL-2 signalling and p38γ and p38δ was recently reported
by the group of Dr. Ana Cuenda. Cells lacking expression of p38γ and p38δ were
found to be profoundly deficient in both TPL-2 and ABIN-2 protein, although levels
of mRNA encoding these proteins were not affected (Risco et al., 2012). The sta-
bility of TPL-2 and/or ABIN-2 therefore are regulated by p38γ/δ, and consequently
TPL-2 signalling is impaired in p38γ/δ-deficient cells. These results were remin-
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iscent of an earlier study showing that the stability of p38α was dependent on
the expression of one of its substrates, MK2 (Ronkina et al., 2007). This raised
the possibility that TPL-2 might function upstream of p38γ and p38δ, which are
specifically phosphorylated by MKK3 and MKK6.
Analysis of the phosphoproteomics data revealed that no p38γ/δ phosphoryla-
tion sites had been identified, likely due to their very low abundance in BMDM
(Risco et al., 2012). Therefore, immunoprecipitation was used to enrich p38γ and
p38δ consecutively from 15mgBMDMwhole cell lysate prior to immunoblotting for
activation loop phosphorylation. In wild type cells, phosphorylation of the activat-
ing residues of p38γ was clearly induced by stimulation with 100 ng/ml LPS for 30
minutes. However, LPS did not induce p38γ phosphorylation inMap3k8D270A/D270A
BMDM, showing that p38γ activation was regulated by TPL-2 catalytic activity (fig-
ure 6.9). Pre-treatment of wild type cells with a MEK1/2 inhibitor did not affect
LPS induction of p38γ phosphorylation, in agreement with earlier results showing
that MKK3/6 phosphorylation in LPS-stimulated macrophages was independent
of ERK1/2 signalling. Phosphorylation of p38δ could not be detected even after
immunoprecipitation. This may reflect the low levels of this kinase or be the result
of non-specific losses during the sequential immunoprecipitation methodology in
which p38γ was isolated before p38δ.
To investigate indirectly whether TPL-2 regulated p38δ activation, the phos-
phorylation of a reported p38δ downstream target, eEF2 Thr56, was assessed by
immunoblotting. p38δ phosphorylates eEF2K at Ser359 which results in eEF2K
inactivation. This in turn prevents phosphorylation of eEF2 at the inhibitory site
T56 and results in a reduction in its phosphorylation when p38δ is active (Knebel
et al., 2001; González-Terán et al., 2013). Reduced phosphorylation at Thr56 al-
lows eEF2 to catalyse extension of nascent proteins at the ribosome (Ryazanov
et al., 1988; Carlberg et al., 1990). In line with this, wild type BMDM phosphoryla-
tion of eEF2 was clearly reduced by LPS stimulation. However, this reduction
was substantially blunted in Map3k8D270A/D270A BMDM (figure 6.10). p38γ is not
able to activate this pathway (Knebel et al., 2001; Cohen and Knebel, 2006) giving
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support to the hypothesis that TPL-2 is necessary for activation of p38δ as well as
p38γ. The reduction was also partially abrogated in wild type cells treated with the
MEK1/2 inhibitor, suggesting the ERK1/2 MAP kinase pathway also contributes
to this response, although this could alternatively be due to off-target effects of
the inhibitor.
Figure 6.9: Phosphorylation of p38γ activation loop residues is dependent
on TPL-2 kinase activity.
p38γ was immunoprecipitated from lysates of unstimulated or LPS-stimulated wild
type, PD0325901-treated wild type or Map3k8D270A/D270A BMDM. Eluates (upper
panel) or whole cell lysates (lower panel) were separated by gel electrophoresis
and transferred to PVDF membranes, followed by immunoblotting with the indic-
ated antibodies. Representative of 3 independent experiments, each using 6 wild
type and 3 Map3k8D270A/D270A mice. WT = wild type, IP = immunoprecipitation, I
= immunoprecipitation input, PIγ = post-immunoprecipitation of p38γ, PIδ = post-
immunoprecipitation of p38δ.
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Figure 6.10: Phosphorylation of eEF2, a downstream target of p38γ/δ, is
altered by disruption of the TPL-2 pathway.
A: wild type andMap3k8D270A/D270A were left untreated or treated with PD0325901
and/or 100 ng/ml LPS for 15 mins. B: wild type, Nfκb1SSAA/SSAA and
Nfκb1SSAA/SSAAMap3k8D270A/D270A were left unstimulated or stimulated with 100
ng/ml LPS for 15 mins. Cell were lysed, proteins separated by gel electrophoresis
and transferred to PVDF membranes. The indicated antibodies were used for im-
munoblotting. Representative of 3 independent experiments. WT = wild type
BMDM, D270A = TPL-2 kinase-inactive BMDM.
6.4 TPL-2 protein levels and ERK1/2 phosphorylation are nor-
mal in Mapk12Y185F/Y185F/Mapk13-/- BMDM
The laboratory of our collaborator, Dr. Ana Cuenda, generated a
Mapk12Y185F/Y185F/Mapk13-/- mouse strain that expresses catalytically inact-
ive p38γ and no p38δ. Generation of BMDM from these mice demonstrated
that expression of kinase-inactive p38γ allowed normal expression of TPL-2
protein in BMDM and rescued LPS-induced activation of ERK1/2 (figure 6.11).
These results suggested that p38γ functioned as a scaffold to stabilise TPL-2
and indicated that p38γ catalytic activity was not required for TPL-2-dependent
activation of MEK1/2 and subsequent activation of ERK1/2. Cells from these
mice will be useful in future experiments for investigating the specific functions of
the TPL-2/MKK3/6/p38γ/δ signalling pathway identified by this study.
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Figure 6.11: Mapk12Y185F/Y185F/Mapk13-/- BMDM have normal levels of TPL-2
and phosphorylation of ERK1/2 activation loop residues upon LPS stimula-
tion.
BMDM generated from wild type or Mapk12Y185F/Y185F/Mapk13-/- mice were left
unstimulated or stimulated with 100 ng/ml LPS for 15 mins. Cells were lysed,
proteins separated by gel electrophoresis and transferred to PVDF membranes.
The indicated antibodies were used for immunoblotting. Shown are replicates
from parallel cultures of three different mice. WT = wild type BMDM, p38γ/δ =
kinase-inactive p38γ/p38δ deficient BMDM.
6.5 Summary
The current study has validated MKK3/6 activation loop residues, identified
by SILAC/mass spectrometry, as TPL-2-dependent, ERK1/2-independent phos-
phorylations by immunoblotting in unlabelled BMDM plus/minus LPS stimulation.
It was subsequently shown, using immunoprecipitation-immunoblotting, that TPL-
2 phosphorylates MKK3 and MKK6, but not MKK4, on their activating residues.
Using small molecule inhibitors, this was found to be independent of ERK1/2
kinase activity but dependent on IKK2 kinase activity. The phosphorylation of
MKK3 and MKK6 is also dependent on NFκB1 p105 phosphorylation by IKK2, as
shown using NFκB1 p105 macrophages. TPL-2 phosphorylation of MKK6 was
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found to be direct using recombinant TPL-2 in an in vitro kinase assay. How-
ever, it will be necessary to confirm that this phosphorylation is the result of TPL-2
activity using the specific inhibitor, C34 (Green et al., 2007), as well as repeat-
ing these experiments using kinase-inactive MKK6 that was not available at the
time of this study. Furthermore, proof that endogenous TPL-2 can also directly
phosphorylate MKK6 by doing immunoprecipitation-kinase assays from LPS stim-
ulated wild type and TPL-2 kinase dead BMDM will be vital. It has subsequently
been shown that TPL-2-dependent MKK3/6 phosphorylation results in the phos-
phorylation of p38γ. In order to show that p38δ regulation is the same as p38γ
it will be necessary to repeat the immunoprecipitations of p38δ from fresh lys-
ates. We have, however, provided indirect evidence for the activation of p38δ by
showing defective dephosphorylation of eEF2, a downstream target of p38δ that
associates with the TPL-2/ABIN-2/NFκB1 p105 complex in HEK293 cells (Ley
laboratory, unpublished data), in the absence of TPL-2 kinase activity.
Although it has not been formally investigated here, it is likely that, given the
proven ability of MKK4 to regulate p38α phosphorylation, the p38α pathway is
activated through MKK4 in LPS stimulated macrophages independently of TPL-
2. This would need to be tested using a macrophage specific MKK4 knock-out
because the full knock out has an embryonic lethal phenotype (Abell et al., 2005).
Published targets of p38γ/δ give some indication of what TPL-2 could be reg-
ulating though this novel pathway. All four p38 isoforms are known to activate
the transcription factors Elk1, Elk3 (SAP2) and Elk4 (SAP1) (Goedert et al., 1997;
O’Callaghan et al., 2014) which belong to the SRF-TCF family of transcription
factors, members of which were suggested as regulators of TPL-2-dependent,
ERK1/2-independent genes by transcription factor enrichment analysis follow-
ing RNA sequencing (Ley laboratory, unpublished data). Control of p38γ/δ may
also provide the mechanism by which TPL-2 regulates TNFα. A recent study by
González-Terán et al. (2013) found that absence of p38γ/δ in macrophages was
protective against an LPS and D-galactosamine-induced murine model of liver
disease. This protection was mediated by a reduction in TNFα production which
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was shown to result from a block in eEF2-dependent translation of TNFα mRNA.
This is a striking parallel with the phenotype of Map3k8D270A/D270A macrophages
which seem to have fairly normal levels of TNFα mRNA but produce very little
TNFα protein. Alternatively, p38γ could regulate TACE-dependent TNFα cleav-
age through its substrate, SAP97, which can interact with the cytoplasmic tail of
TACE (Levine, 2008).
With the newly available p38γ/δ knock-in/knock-out mice it will be interesting
to test more fully how BMDM from these mice compare to those from the TPL-2
kinase dead. As well as ELISAs for production of TNFα and other key cytokines,
this could include RNA sequencing to identify genes overlapping with the TPL-2
transcriptome recently generated in the Ley laboratory (unpublished data). A large
proportion of TPL-2 regulated genes (51 out of 94 genes) were shown to be inde-
pendent of ERK1/2 and these, or a proportion thereof, could be regulated instead
by p38γ/δ. By identifying the link between TPL-2 and p38γ/δ it will now be pos-
sible to use the p38γ/δ knock-in/knock-out mice to understand more completely
how TPL-2 regulates innate immune responses.
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7 Discussion
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7.1 Impact
In this study, BMDM have been SILAC labelled and used to generate an unbiased
phosphoproteomics dataset of sites present in LPS stimulated cells. By making
pairwise comparisons between different genetic and chemical perturbations, it has
been possible to determine which phosphosites were regulated in vivo by endo-
genous TPL-2 independent of ERK1/2 signalling. This allowed identification of the
activation loop residue of MKK3 andMKK6 as TPL-2 substrates in LPS-stimulated
BMDM, which was confirmed by immunoblotting with phospho-specific antibod-
ies. Furthermore, TPL-2 was shown to be required for phosphorylation of the
MKK3/6 substrate p38γ. These data define a novel TPL-2/MKK3/6/p38γ MAP
kinase pathway that is activated in LPS-stimulated macrophages. Interestingly,
TPL-2 suppression of the HGF/c-Met pathway in intestinal myofibroblasts is medi-
ated independently of any effects on ERK1/2 and p38α activation (Koliaraki et al.,
2012). It is possible that TPL-2 regulates this pathway via activation of p38γ. It
will be important in future studies to determine whether TPL-2 also regulates the
activation of p38δ in LPS-stimulated macrophages and whether TPL-2 regulates
p38γ/δ activation after stimulation with other TLR ligands and in other cell types.
Although relatively few substrates of p38γ/δ are known, they could shed light
on how TPL-2 regulates its ERK1/2-independent functions. Known p38γ sub-
strates include SAP97 (Risco and Cuenda, 2012), which interacts with the cyto-
plasmic tail of TACE (Levine, 2008) and could explain how TPL-2 regulates re-
lease of TNFα. Proteins regulated by p38δ include eEF2K and its substrate eEF2
(Risco and Cuenda, 2012). eEF2 phosphorylation was shown in the current study
to be regulated by TPL-2 kinase activity, and eEF2 was previously found to as-
sociate with the TPL-2/ABIN-2/NFκB1 p105 triple complex in HEK392 cells (Ley
laboratory, unpublished data). eEF2 promotes translation (Ryazanov et al., 1988),
indicating another level, in addition to transcriptional and post-translational modi-
fication levels, at which TPL-2 may control cell function. González-Terán et al.
(2013) have shown that eEF2 is important for the translation of TNFα mRNA,
providing an alternative possible link between TPL-2 and TNFα production.
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The results of this study may explain seemingly conflicting results in mutant
mice. Deletion of either MKK3 or MKK6 was protective in antibody transfer models
of arthritis, however, deletion of p38α in myeloid cells was not (Guma et al., 2012).
The results of the current study suggest that the reason for this discrepancy may
be that MKK3/6 are controlling p38γ/δ in this model rather than p38α. Currently
most p38 inhibitors do not block p38γ/δ and there are no specific inhibitors for
these isoforms, therefore TPL-2 inhibitors may prove an effective way to block
p38γ/δ activation until specific inhibitors become available.
In spite of the limited knowledge of p38γ/δ substrates, some studies have
demonstrated their role in models of inflammatory conditions. For example, Cri-
ado et al. (2014) found that mice deficient in both p38γ and p38δ were protec-
ted from collagen-induced arthritis. Similarly, p38γ/δ-deficient mice were pro-
tected from an inflammation-associated colon cancer model induced by azoxy-
methane and dextran sodium sulphate (del Reino et al., 2014). These mice
had reduced recruitment of neutrophils and macrophages as well as lower levels
of pro-inflammatory cytokines and chemokines than the wild type. The cur-
rent study has indicated that p38γ may contribute to immune functions of TPL-
2 and the autoimmune and inflammatory diseases in which TPL-2 is implicated
(e.g. IBD). Therefore, direct comparison of the effects of Map3k8D270A/D270A and
Mapk12Y185F/Y185F/Mapk13-/- in disease models will be important to determine
whether the effects of TPL-2 in inflammation are mediated via p38γ/δ.
None of the published substrates of TPL-2 were found to be regulated in the
current study, except for NFκB1 p105. This could be the result of differences in the
cell type and/or stimulus used. For example, PLCβ3 was found to be a TPL-2 tar-
get in fibroblasts stimulated through G-protein coupled receptors (Hatziapostolou
et al., 2011) and the signalling could be substantially different in the TLR-activated
macrophages tested in this study. Alternatively these phosphorylations may have
been artefacts of the non-physiological methods used by many of the studies.
This study identified a major limitation with the SILAC methodology as both
K0R0 and K8R10 SILAC labelling altered the activation of ERK1/2 in response
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to LPS stimulation in Nfκb1SSAA/SSAA macrophages. This did not appear to be
dependent on the presence of carbon/nitrogen/hydrogen isotopes in the amino
acids, but may have been due to dialysis of the FCS or LCCM used. Changes
in MAP kinase pathways were not evident for all genotypes, so it is possible
that only certain genotypes are affected. However, as all genotypes experi-
ence the same culture conditions it seems likely that other signalling pathways
may also be affected compared to unlabelled cells. Therefore, SILAC labelling
could have impacted the phosphorylations which were identified as TPL-2 regu-
lated in this study, hence the need for independent validation of each phosphos-
ite. To enable future MS-based phosphoproteomics studies of Nfκb1SSAA/SSAA
and Nfκb1SSAA/SSAA Map3k8D270A/D270A macrophages alternative methods will be
needed such as in vitro labelling after cell lysis using iTRAQ (Wiese et al., 2007).
In spite of these problems, the ability to SILAC label BMDM will be valuable
in combination with other studies. For example, in studies with an analogue-
sensitive TPL-2 mutant being developed by the Ley laboratory, SILAC labelling
will help to reduce false-positives (Shah et al., 1997; Carlson et al., 2011). A
SILAC-labelled cell lysate incubated with the analogue-sensitive TPL-2 would be
compared with an unlabelled lysate incubated without the mutant kinase, allowing
any background use of the ATP analogue by other kinases to be removed from
the results. It would also be interesting to develop analogue-sensitive mutants of
p38γ and p38δ as there is currently very little known about what these p38 iso-
forms do. None of the TPL-2-dependent phosphorylations identified in this study
are known p38γ/δ substrates, however, using analogue-sensitive p38γ/δ isoforms
to identify their substrates on a large scale may change this.
This study also identified over 200 ERK1/2 regulated proteins. A large pro-
portion of these were suggested to be involved in gene expression and RNA pro-
cessing, including translation, key processes for activation of macrophages. Other
highly represented protein categories were components of the cytoskeleton and
regulators of small GTPases. Such proteins contribute to actin rearrangement, an
important process in the phagocytic and chemotactic functions of activated mac-
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rophages during the innate immune response. This suggests that ERK1/2 may
play a role in regulating these processes in pathogen clearance.
7.2 Future work
Further characterisation of MKK3/6 as TPL-2 substrates, including determination
of Michaelis-Menten parameters (Km, Vmax and Kcat), will allow a detailed com-
parison with MEK1/2 which could indicate how these two pathways might be co-
ordinately regulated by TPL-2 in cells and whether there might be competition
for TPL-2 phosphorylation between MEK1/2 and MKK3/6. Further studies will be
necessary to show that regulation of MKK3/6 phosphorylation by TPL-2 is de-
pendent, not only on NFκB1 p105 phosphorylation by IKK2 as has been shown
here, but also on TPL-2 release from the triple complex. It will also be interest-
ing to determine whether 14-3-3 binding to the TPL-2 C-terminus is required for
phosphorylation of MKK3/6, similar to MEK1/2 (Ben-Addi et al., 2014).
In addition to further biochemical characterisation, it will be important to under-
stand how the TPL-2/MKK3/6/p38γ/δ pathway contributes to macrophage func-
tions in innate immune responses. Whether p38γ/δ control TNFα production will
need to be tested in Mapk12Y185F/Y185F/Mapk13-/- macrophages. As shown in the
current study, theMapk12Y185F/Y185F/Mapk13-/- mutation does not affect TPL-2 sig-
nalling via ERK1/2 but selectively blocks p38γ/δ signalling, enabling specific in-
vestigation of this pathway in TNFα production. If there is an effect on TNFα
production, further experiments, such as retroviral replacement of p38γ or p38δ
in p38γ/δ-deficient cells, will be needed to determine which isoform is responsible.
Similarly, it will be necessary to determine by RNA sequencing experiments, using
Mapk12Y185F/Y185F/Mapk13-/- macrophages, whether p38γ/δ control the ERK1/2-
independent fraction of TPL-2 regulated genes identified by RNA sequencing
(Ley laboratory, unpublished data). In particular, transcription factors from the
SRF-TCF family can be activated by both p38γ and p38δ (Goedert et al., 1997;
O’Callaghan et al., 2014) and were suggested as regulators of TPL-2-dependent,
ERK1/2-independent genes by transcription factor enrichment analysis.
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As the list of TPL-2-dependent, ERK1/2-independent sites is not extensive it
would be feasible to take a medium throughput approach to investigate whether
these sites are important in TPL-2 regulated innate immune functions. Knock-
down of targets using genome-wide perturbation methods like RNA interference
(RNAi) has historically been more challenging in macrophages than in other cell
types like fibroblasts because of highly sensitive induction of non-specific immune
responses to both dsRNA and transfection reagents (Judge et al., 2005; Cekaite
et al., 2007; Lacaze et al., 2009). Recently, a protocol for achieving this using
small interfering RNA (siRNA) in the RAW264.7 and THP1 macrophage cell lines
was published by Li et al. (2015). By testing hundreds of transfection conditions,
the authors identified combinations of siRNA and transfection lipids that resulted
in minimal induction of type I interferons while maintaining efficient target gene
silencing. Their optimised transfection system would be useful for conducting a
secondary siRNA screen of themost interesting phosphorylated proteins identified
in the current study. Readouts which could be applied in this secondary screen to
assess similarity of each “knock-down” to the effects ofMap3k8D270A/D270A mutation
include cytokine release using a multiplexed assay such as Luminex® (Life Tech-
nologies, USA). Furthermore, GO analysis of TPL-2 regulated phosphoproteins in
the current study has suggested that TPL-2 may regulate cell movement, the actin
cytoskeleton, intracellular transport and steroid metabolism. It will be interesting
to determine the importance of TPL-2 signalling in regulating these processes by
determining the effects of Map3k8D270A/D270A mutation in LPS-stimulated macro-
phages. If these experiments are positive, the role of specific TPL-2 regulated
phospho-proteins could be determined by siRNA knockdown.
Proteins identified by the secondary screen as relevant to macrophage func-
tion could then be mutated at the TPL-2 phosphorylation site in an alternative
system already established in the Ley laboratory to show that the phosphorylation
is important. Using the Hoxb8 oncogene under control of the oestrogen receptor,
primarymyeloid progenitors can be immortalised then differentiated with cytokines
to produce macrophages (Wang et al., 2006). As these cells can be maintained
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indefinitely, CRISPR (clustered regularly interspaced palindromic repeats) could
be used to create point mutations in the genes of interest (Cong et al., 2013; Mali
et al., 2013) and then the determined read-outs used to test if the phosphoryla-
tion is functional. CRISPR uses a guide RNA to target a DNA endonuclease to a
corresponding gene sequence, where it introduces a double-strand break. By in-
troducing a template DNA strand, non-homologous end joining can be harnessed
to introduce a mutation when repairing the break (Shalem et al., 2015).
Proteins found to be phosphorylated in a TPL-2-dependent manner will be
tested as substrates in in vitro kinase assays using immunoprecipitated wild type
or kinase-inactive TPL-2 to establish whether they are direct TPL-2 substrates or
if an intermediate kinase is required. Finally, validated proteins could be mutated
in mice to allow a more detailed investigation of their physiological relevance in
immune responses and autoimmune or inflammatory diseases.
The importance of ERK1/2-regulated phosphoproteins in different aspects of
macrophage function could also be validated and investigated using the approach
outlined above, in combination with MEK1/2 inhibitors. As this study sugges-
ted that ERK1/2 regulated proteins linked to cytoskeletal rearrangement, macro-
phage functions like phagocytosis, migration and chemotaxis could be tested us-
ing MEK1/2 inhibitors to identify which processes involving ERK1/2 activity. This
would provide the read-out with which to interpret the siRNA and CRISPR screens
as well as suggesting a mechanism through which TPL-2/ERK1/2 signalling could
contribute to macrophage function in the innate immune response.
The SILAC/MS experiments identified very few transcription factors that were
regulated by TPL-2 so it is difficult to assess directly how TPL-2 signalling might
regulate gene expression. To focus the investigation on transcription factors,
which are generally of low abundance, it will be necessary to repeat the phosphop-
roteomic comparisons with a greater degree of fractionation prior to LC-MS/MS
analysis. This could be achieved by bulk purification of nuclei prior to lysis. This
might introduce quantification errors but would mean that only nuclear proteins
will be analysed. Alternatively, more fractions could be collected during strong
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cation exchange, which would significantly increase the time necessary for phos-
phopeptide enrichment and analysis. If one of these approaches works, it should
be possible to determine which transcription factors are phosphorylated in a TPL-
2 dependent fashion, and whether these are controlled via ERK1/2-dependent or
-independent pathways. This is particularly interesting as RNA sequencing exper-
iments carried out by the Ley laboratory have demonstrated that TPL-2 signalling
regulates gene expression in LPS stimulated macrophages via ERK1/2 and non-
ERK1/2 pathways (unpublished data). Such experiments would significantly in-
crease our understanding of how TPL-2 regulates innate immune responses.
As well as determining the biological relevance of novel TPL-2 substrates in
BMDM, it will be important to confirm these in ex vivo macrophage populations
like peritoneal macrophages after intra-peritoneal injection of LPS. It would also
be interesting to extend this to establish how many novel substrates are com-
mon to other cell types or whether TPL-2 signalling is heavily dependent on the
cell context. For example, could the novel TPL-2/MKK3/6/p38γ/δ pathway found
here control the ERK1/2-independent, TPL-2-mediated regulation of IL-1β in bone
marrow-derived dendritic cells described by Mielke et al. (2009)? In the same
way, whether these substrates are involved in TPL-2-dependent responses to
other ligands such as TNFα and IL-1. To facilitate such experiments it would be
necessary to generate phospho-specific antibodies against the TPL-2 target sites
so that phosphorylation can easily be monitored across different conditions.
Since only LPS-stimulated samples were analysed, it is not possible to estab-
lish whether TPL-2-dependent phosphorylations detected were present in unstim-
ulated cells. However, earlier data from the Ley laboratory has demonstrated TPL-
2 in macrophages has very little activity towards MEK1 without LPS stimulation,
making this unlikely. Nevertheless, this will be important to determine this directly
by MS analysis of unstimulated BMDM. An extension of this will be to determ-
ine whether TPL-2 regulates other substrates at earlier or later time points before
degradation, as this study has looked at only one stimulation time-point. Cross-
referencing the phosphorylated targets from phosphoproteomics experiments us-
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ing different time-points may make it clearer which pathways are being activated
by tracing them from upstream components to downstream ones through the time-
course.
7.3 Concluding remarks
This study has extended our understanding of TPL-2 signalling which will lead to a
clearer picture of how TPL-2 controls the biological outcomes that contribute to in-
nate immune responses. Furthermore, this dataset will augment future studies of
TPL-2 signalling, such as the search for upstream regulators, as new information
gives context to a larger proportion of the list of regulated proteins.
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Appendices
A MAP kinase activation in SILAC-labelled BMDM
lysates for phosphoproteomics.
203
204
205
206
B Total protein levels of TPL-2 dependent phos-
phorylations.
Ratios have not been inverted for one of each label reversal pair, as they have for
the presented phosphoproteomics data.
207
C TPL-2/ERK1/2 regulated phosphosites identified
by phosphoproteomics.
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